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Abstract 
RSK is a family of four Ser/Thr protein kinases activated by ERK1/2 signaling. 
RSK has been found to be misregulated in a variety of cancers, including breast and 
prostate. More recently, RSK1 and RSK2 have been shown to promote metastasis in 
vivo. Currently, no targeted therapies to inhibit metastasis are available. Our laboratory 
has described the first potent and selective small molecule of RSK, SL0101. We found 
that this compound is not suitable for in vivo studies, therefore we set out to develop 
and validate new analogues based on the SL0101 pharmacophore. Here, we report a 
series of modifications improving the in vivo properties of SL0101. 
We characterize the mode of inhibition of RSK by SL0101. We find that this 
molecule acts as an allosteric non-competitive inhibitor of RSK. We postulate that this 
unusual mode of inhibition of RSK accounts for a remarkable selectivity of SL0101 for 
this kinase. We identify a number of modifications to the parent molecule that increase 
its in vitro affinity and stability in cell-based assays. We characterize new analogues that 
maintain the selectivity of the inhibitor for RSK. In addition, we discover that SL0101 is 
an isoform-selective inhibitor of RSK1/2 and not RSK3/4. The importance of these 
findings is highlighted by the fact that RSK1/2 serve tumor-promoting functions, while 
RSK3/4 are thought to be tumor suppressors. Therefore, SL0101 displays a desired 
isoform-selectivity as a potential novel therapeutic strategy to treat cancers. 
Isoform-specific functions of RSK are not very well understood. Here, we 
describe development of a biotin labeling-mediated proteomic screen to identify novel 
RSK1 interacting partners. We find that a portion of RSK1 interacts with intracellular 
membranes, while RSK2 does not. We identify potential novel RSK1-binding partners 
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among the proteins of the endoplasmic reticulum and mitochondrial membranes. 
Therefore, we postulate that RSK1 may be involved in regulation of protein synthesis 
and energy homeostasis. 
Finally, we uncover a novel function of RSK1/2 in stimulating mitochondrial 
oxidative phosphorylation in breast cancer cells. We find that this function of RSK1/2 is 
specific to transformed cells. Therefore, we postulate that RSK1 can be involved in the 
metabolic transformation of breast cancer cells. Blocking this function by means of small 
molecules we develop could constitute a novel therapeutic strategy to target alterations 
in metabolism of cancer cells. 
Given the emerging roles of RSK1/2 in promoting metastasis, we envision that 
RSK inhibitors could constitute a novel class of drugs targeting this aspect of cancers. 
Our studies open new avenues of investigation of RSK-mediated cellular processes and 
their role in various disease states. 
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Chapter 1 
Introduction: Overview of RSK inhibitors 
 
1.1. Kinases as drug targets 
 Protein kinases represent one of the most important classes of molecular targets 
used in treatment of human diseases. The therapeutic potential of targeting kinases is 
based on three main observations. First, with the human kinome comprising 
approximately 520 kinases, almost every cellular process is controlled through a 
mechanism involving transduction of the phosphorylation signal (Manning et al., 2002, 
Zhang et al., 2009). Therefore, kinase inhibition can allow for a modulation of diverse 
processes. Second, even though kinases share a high degree of similarity in the 
mechanism of ATP binding and phosphotransfer, highly selective small molecules with 
desired biological properties can be developed (Bain et al., 2007, Davies et al., 2000). 
Third, biological studies have revealed that selective kinase inhibitors against specific 
targets involved in the disease can often be well tolerated by normal cells, providing a 
potential window for the therapeutic intervention (Zhang et al., 2009). In recent decades, 
29 small-molecule kinase inhibitors have been approved for clinical use, the majority of 
them in oncological disorders (Fabbro, 2015). Approximately 130 further kinase 
inhibitors are reported to currently be in phase I-III clinical trials (Fabbro, 2015). Some of 
the approved molecules have proven very successful in therapy. An excellent example 
of such success is imatinib, an inhibitor of the oncogenic fusion kinase Bcr-Abl in the 
treatment of chronic myelogenous leukemia (CML) (O'Brien et al., 2003, Druker et al., 
2 
 
2006). In addition to cancer, kinase inhibitors have found use in diverse disorders, 
including immunological, neurological, metabolic and infectious diseases (Zhang et al., 
2009). Even beyond the novel therapeutic potential, selective small molecule kinase 
inhibitors remain an invaluable tool for studying basic biological processes regulated by 
kinases. Therefore, there is an ongoing effort to develop new molecules against known 
kinase targets, as well as to identify novel kinases amenable for therapeutic 
intervention. 
1.2. Kinase domain structure  
 Several decades of extensive research in the area of structural biology have 
allowed us to understand the basic structure and mechanism of action of protein 
kinases (Cowan-Jacob et al., 2014). Protein kinases can be divided into two major 
groups, depending on the selectivity for the substrate amino acid. Kinases can 
phosphorylate Ser and Thr residue within their target, or a Tyr residue (Manning et al., 
2002). Despite differences in certain regulatory motifs between these two classes of 
enzymes, they share the same overall domain structure. A kinase domain consists of a 
small N-lobe formed mostly from -sheets, and a larger C-lobe comprising mostly -
helices (fig. 1). The two lobes are connected via a short hinge region. The groove 
formed between the two lobes of the kinase forms the binding site for the ATP molecule, 
which is the source of the phosphate group. The ATP molecule binds to the kinase 
through the hydrogen bonds between the adenine ring of ATP and amino acid residues 
within the hinge region of the kinase. The N-lobe contains a glycine-rich loop, which is 
involved in the proper positioning of the -phosphate for the phosphotransfer. Another 
part of the N-lobe interacting with the phosphates is the C-helix, which contains a Glu 
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residue that forms a salt-bridge with the Lys residue of the active site. The C-helix is a 
dynamic regulatory element of the kinase, and is often referred to as the signal 
integration motif (Johnson et al., 2001). The distance between the C-helix and the 
activation loop in the C-lobe is an essential determinant of the ability of the kinase to 
catalyze phosphotransfer, and therefore it defines the open and closed conformations of 
the enzyme (Narayana et al., 1997). 
 The C-lobe of the kinase contains the activation loop that is linked via a salt 
bridge to the aforementioned C-helix. The activation loop can undergo substantial 
conformational changes, which regulates the activity of the kinase. There is a wide 
diversity of conformations found among inactive states of kinases, and in some inactive 
kinases the activation loop is disordered. However, upon activation, almost all kinases 
attain a very highly conserved structure of the activation loop (Kornev et al., 2006). This 
activation is triggered by the phosphorylation of a regulatory Thr of Ser residue within 
the loop. The activation loop starts with a conserved sequence of three amino acids, 
Asp-Phe-Gly, hence it is referred to as the DFG motif. This motif coordinates the Mg2+ 
ion positioned close to the phosphate section of ATP, and this metal ion is essential for 
the cleavage of the phosphate bond. In many kinases in the inactive conformation the 
Phe residue within the DFG motif is occluding the site typically occupied by the ATP 
molecule, a conformation referred to as “DFG-out”. In these kinases, phosphorylation of 
the activation loop causes a rearrangement of this segment that switches the orientation 
of Phe residue, moving it away from the ATP site. Therefore, it now becomes the “DFG-
in” conformation. In some kinases, however, as in the case of Src and CDK2,
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Figure 1. Protein kinase domain structure.  
A) Linear representation of the protein kinase secondary structures. Blue arrows 
represent -strands, green cylinders represent -helices, and red lines represent 
functionally relevant loops. The N-lobe consists mostly of -strands and includes the 
glycine-rich loop and an C-helix. The C-lobe is mostly composed of -helices and 
includes the catalytic loop and the activation loop segment. The catalytic loop 
includes the catalytically active amino acid triad, HRD. The activation segment starts 
with the DFG amino acid triad and ends with the APE amino acid triad. 
B) Tertiary structure of ATP bound to the active conformation of the kinase. Blue blocks 
represent core domains of the N- and C-lobe. Teal circle represents C-helix within 
the N-lobe. Orange line represents activation loop, and within it red amino acid 
residues represent the DFG motif. Green line represents the catalytic loop and within 
it green amino acids represent the HRD motif. Dark blue line represents the hinge 
region between the two lobes. Gray loop represents the kinase substrate peptide. 
Lys residue within the C-helix forms a salt bridge with Glu residue within the core of 
the N-lobe, and coordinates the triphosphate chain of ATP. Phe residue in the DFG 
motif moves away from the ATP-site to allow ATP binding. Phosphorylated residue 
in the activation loop interacts electrostatically with Arg residue within the HRD motif. 
His residue from the HRD motif catalyses -phosphate bond cleavage in the ATP 
molecule. 
5
 
6 
 
the inactive conformation of the kinase still represents the DFG-out arrangement, and 
the activation of the kinase is mostly driven by the changes in the C-helix position. 
Whereas the DFG-in conformation will always indicate inactive kinase, the DFG-out 
conformation is not the only determinant of the activation state.  
 The activation loop ends with another triad of conserved residues, the APE motif. 
This motif is thought to assist in substrate recognition of the kinase. The binding of the 
substrate is performed by the P+1 loop, which binds the amino acid directly downstream 
from the phosphorylated residue of the substrate, hence the P+1 name. The 
phosphotransfer reaction is catalyzed by the residues contained in the catalytic loop of 
the C-lobe. The catalytic core of this segment is a sequence of three amino acid 
residues, the HRD motif. Within this motif, the Asp residue is a base acceptor for the 
proton transfer. The arginine residue coordinates with the phoshorylated residue in the 
activation loop to stabilize the active conformation. The presence of phosphorylated 
Ser/Thr residue is conserved among all kinases, however the exact interactions 
between this residue and the HRD motif differ between Ser/Thr and Tyr kinases (Krupa 
et al., 2004).  
1.3. Modes of kinase inhibition 
 All kinases share a very conserved active site responsible for ATP binding and 
phosphotransfer. Therefore, small molecule inhibitors designed to bind to this site are 
likely to be able to inhibit a very wide range of kinases. In an effort to overcome this 
issue, early studies aimed at identifying sequence-specific features of the ATP-binding 
sites that could confer ligand binding specificity.  
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Figure 2. Structural diversity of kinase inhibitors 
A) Mode of binding of the ATP molecule to the hinge region of the kinase. R indicates 
the position of the gatekeeper residue. Dashed lines represent hydrogen bonds. 
B) Mode of binding of a type 1 inhibitor. A represents hydrogen bond acceptor and D 
represents hydrogen bond donor in the inhibitor molecule. HYD represents the 
hydrophobic core of the molecule. Type 1 inhibitor utilizes similar hydrogen bonds as 
ATP in binding to the hinge region of the kinase. 
C) Mode of binding of a type 1.5 inhibitor. A represents hydrogen bond acceptor and D 
represents hydrogen bond donor in the inhibitor molecule. HYD represents the 
hydrophobic core of the molecule. Type 1.5 inhibitor utilizes similar hydrogen bonds 
as ATP in binding to the hinge region of the kinase, but also interacts with the 
peptide bond within the DFG motif in “DFG-in” conformation and a conserved Glu 
residue. 
D) Mode of binding of a type 2 inhibitor. A represents hydrogen bond acceptor and D 
represents hydrogen bond donor in the inhibitor molecule. HYD represents the 
hydrophobic parts of the molecule. Type 2 inhibitor binds to the kinase in the “DFG-
out” conformation, which exposes new hydrophobic pocket behind the DFG motif.  
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 Through these studies the gatekeeper residue was identified (constituent “R” in 
fig. 2A). This amino acid side chain is typically located in the vicinity of the adenine-
binding site and regulates the access of the small molecule to a hydrophobic pocket 
extending away from the hinge region of the kinase (Liu et al., 1999). It has been 
observed that 77% of all kinases in human kinome have a relatively large gatekeeper 
residue, such as leucine, methionine and phenylalanine, which effectively block the 
access of small molecules to the hydrophobic pocket (Taylor and Kornev, 2011). 
However, in 21% of all kinases, the gatekeeper residue is a small amino acid such as 
threonine and valine, which allows design of small molecules that would engage the 
hydrophobic pocket. The small gatekeeper is most frequently found in the tyrosine 
kinases and was first utilized in developing the Src kinase inhibitors (Liu et al., 1999). 
The selectivity of Gleevec, the inhibitor oncogenic kinase BCR-Abl, also relies on the 
presence of the threonine gatekeeper residue in the Abl kinase domain (Buchdunger et 
al., 2000). The rationale behind utilizing the gatekeeper residue for the drug design 
relies on creating a small molecule that would only fit in the hydrophobic pocket of the 
target kinase. Therefore, even though the ATP binding pocket of all kinases are very 
similar, the presence of both the gatekeeper and the hydrophobic pocket allow to 
rationalize highly specific small molecule inhibitors of kinases. 
 Based on the mode of inhibitor binding to the kinase, the small molecules can be 
classified into three general categories. Type I inhibitors will bind to the same site as the 
ATP molecule, acting as ATP mimetics (fig. 2B). A common feature of all type I 
inhibitors is the fact that they bind to the “DFG-in” conformation of the kinase. In the 
majority of cases this arrangement represents the active form of the kinase.  
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 This bias can be explained by the fact that in most in vitro studies to identify new 
kinase inhibitors, the kinase molecules are fully activated. Therefore, such studies favor 
identification of molecules that will strongly interact with the active kinase conformation. 
In addition, many kinase inhibitors have been designed to mimic the size and shape of 
the ATP molecule. Such inhibitors will typically consist of a heterocyclic ring system 
occupying the adenine-binding site in the kinase groove (Zhang et al., 2009). As 
mentioned above, the selectivity of type I inhibitors often relies on the properties of the 
gatekeeper residue and the size and shape of the hydrophobic back pocket. Classic 
examples of type I inhibitors include gefitnib and erlotinib, the inhibitors of the epidermal 
growth factor receptor (EGFR) (Fabbro, 2015). In addition to the hydrophobic back 
pocket, selective type I inhibitors can employ more distant surfaces of the kinase for 
binding, such as the peptide-binding site. Examples of such molecules are 
bivalent/bitopic inhibitors (Hill et al., 2012) and macrocycles (Tao et al., 2007).  
 As mentioned above, in some kinases the DFG-in conformation is not sufficient 
to determine the activation state of the kinase. The inhibitors that utilize this property are 
classified as type 1.5 (fig. 2C). An example of such inhibitor is another inhibitor of 
EGFR, lapatinib. In the case of lapatinib, the molecule binds to a conformation in which 
the C-helix is pushed away from the activation loop (Wood et al., 2004). Therefore, even 
though the kinase is in the DFG-in fold, it is not active.  
 The second general class of inhibitors binds to the inactive DFG-out 
conformation of the kinase. Since these inhibitors are still binding to the same site as 
the ATP molecule, they still act as ATP-competitive inhibitors. The switch between the 
active DFG-in and inactive DFG-out conformation exposes an additional hydrophobic 
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pocket adjacent to the ATP site, which becomes engaged by the inhibitor molecule 
(fig. 2D). This interaction stabilizes the kinase in the inactive conformation (Cowan-
Jacob et al., 2014). The examples of type 2 inhibitors include the inhibitors of PDGFR, 
KIT and Abl, imatinib and nilotinib (Fabbro, 2015).  
 The third main class of inhibitors represents those molecules that do not bind to 
the hinge region of the kinase. Since these compounds do not bind to the same site as 
ATP, in general they do not act as ATP-competitive inhibitors. Instead, binding of ATP 
can occur even when the inhibitor is bound to the kinase. Such inhibitors will therefore 
be classified as non-competitive inhibitors. The binding surface for the inhibitor is called 
the allosteric site, therefore type 3 inhibitors can also be referred to as allosteric 
inhibitors. This type of inhibitors tends to exhibit the highest degree of selectivity, 
because they rely on a very specific feature of the target kinase that does not have to 
be conserved in other enzymes. The modes of binding of allosteric inhibitors vary 
greatly between the representatives of this class of molecules, each exhibiting a unique 
set of properties. The best-characterized example of an allosteric kinase inhibitor is CI-
1040, an inhibitor of MEK1/2. This compound occupies a site adjacent to the ATP-
binding groove of MEK, but the surfaces involved in binding of the two molecules do not 
overlap (Ohren et al., 2004). Special cases of type 3 inhibitors are those that bind to an 
allosteric site, but the binding induces the DFG-out conformation of the kinase. In such 
case the Phe residue of the DFG motif forms a steric hindrance to the binding of ATP. 
Therefore, such inhibitors will act as functional ATP-competitors. The examples of such 
compounds include the inhibitors of insulin-like growth factor-1 receptor (IGF-1R) 
(Heinrich et al., 2010), FAK (Tomita et al., 2013) and p38 (Over et al., 2013). Allosteric 
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inhibition can also occur through the interactions of the molecule with the substrate-
binding surface of the kinase, like in the case of thioqinazolinones, the CHK1 inhibitors 
(Converso et al., 2009). Finally, allosteric inhibitors can bind to regulatory sites of the 
kinase that are far removed from the ATP binding site, like in the case of Abl inhibitors 
binding to the myristate pocket of the kinase (Adrian et al., 2006). 
1.4. MAPK pathway as a drug target 
 RAS-MAPK pathway has long been recognized as a very important pro-survival 
and pro-growth pathway that is often activated in cancer (Sebolt-Leopold and Herrera, 
2004). More than 30% of all human cancers harbor mutations within this pathway, 
mostly leading to gain of function and hyperactivation of the pathway (Hoshino et al., 
1999). In addition, RAS-MAPK has also been investigated in the context of inflammatory 
diseases, cardiac hypertrophy and pain (Stanton et al., 2003, Hofman, 2004, Ji, 2004). 
Therefore, there has been a lot of interest in developing means of targeting this 
pathway, both in basic research and in clinical studies (Zhang et al., 2009). However, 
early studies revealed that inhibiting RAS/MAPK pathway could prove too toxic to 
normal proliferating cells, such as the gut and skin epithelia (Sebolt-Leopold and 
Herrera, 2004). Additional caveat to targeting the RAS-MAPK pathway lies in the 
number of feedback loops regulating the activity of the pathway that could overcome the 
inhibition. Therefore, targeting the downstream effectors of the RAS-MAPK pathway has 
emerged as a potential new way of blocking the pro-proliferative and pro-survival 
signaling of the RAS-MAPK axis. Since each downstream effector of the RAS-MAPK 
pathway regulates only a subset of all MAPK-regulated proteins, targeting these 
individual effectors would in principle decrease the likelihood of engaging the feedback 
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loops (Eisinger-Mathason et al., 2010). RSK is one of these downstream effectors that 
have been proposed as a target for RAS-MAPK signaling intervention.  
1.5. RSK family of kinases 
 RSK is a family of four Ser/Thr protein kinases activated by the ERK1/2 pathway 
in response to growth factors, cytokines and neurotransmitters (Bonni et al., 1999, Bhatt 
and Ferrell, 1999). The four isoforms share very high degree of sequence similarity and 
are expressed as products of separate genes (Anjum and Blenis, 2008). RSK is unusual 
among other kinases in that it possesses two fully functional kinase domains (Fisher 
and Blenis, 1996) (fig. 3A). The only other dual kinases are two close relatives of RSK, 
the mitogen and stress regulated kinases 1 and 2 (MSK1/2). Despite very similar 
structures, MSK kinases appear to have very different biological functions (Arthur, 
2008). MSK is predominantly activated by p38 MAPK family of kinases, and to a much 
lesser extent by ERK1 (Pierrat et al., 1998). The C-terminal kinase domain (CTKD) of 
RSK belongs to the calcium/calmodulin dependent protein kinase superfamily (CaMK), 
while the N-terminal kinase domain (NTKD) is a member of the superfamily 
encompassing protein kinases A, G and C (AGC). The sequences of the kinase 
domains of RSK are >80% conserved between the isoforms, while the N- and C-
terminal extension and the linker between the kinase domains share less homology 
(Romeo et al., 2012). The linker region contains multiple regulatory sequences that are 
important for RSK interaction with other proteins, and activation of the protein. It is 
unclear why RSK and MSK evolved to have two functional kinase domains within one 
protein. It is thought that the complexity of RSK protein structure allows it to integrate 
signaling downstream of ERK1/2 with high fidelity in response to additional stimuli from 
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other pathways (Romeo et al., 2012). This notion is based on complex mode of 
activation of RSK kinases. 
1.5.1. RSK activation cascade 
 The C-terminal tail of RSK contains an ERK1/2 docking site (Smith et al., 1999). 
Interaction of RSK with ERK1/2 through that motif is required for the activation of the 
kinase in response to mitogens. In the inactive state, ERK and RSK form a complex 
(Roux et al., 2003). When ERK1/2 is activated, it phosphorylates Thr577 residue within 
the CTKD of RSK, as well as two residues within the linker region, Thr365 and Ser369. 
Active ERK then dissociates from RSK and does not form a complex until is inactivated 
again. The mechanism of dissociation of the RSK-ERK complex involves RSK 
autophosphorylation of Ser737 in a close proximity of the ERK-binding site. Therefore, 
the re-assembly of the complex between the inactive kinases requires phosphatase 
action, however the identity of this phosphatase remains elusive. Phosphorylation of 
Thr577 mediated by ERK allows for the activation of the CTKD of RSK. The only known 
function of the CTKD is to autophosphorylate Ser386 residue in a hydrophobic motif 
within the linker of RSK (Frodin et al., 2000). This phosphorylation provides a docking 
site for PDK1, which phosphorylates Ser227 within the activation loop of the NTKD 
(fig. 3A) (Jensen et al., 1999). It has been suggested that in certain cellular contexts, 
additional kinases can phosphorylate Ser386, allowing for the activation of the NTKD in 
the absence of the CTKD-mediated stimulus. However, this alternative activation of the 
NTKD has only been reported in the context of dendritic cells (DC) and macrophages 
(Cohen et al., 2007, Zaru et al., 2007). In these cells, Toll-like receptor signaling 
triggered by lipopolysaccharide (LPS) signals through p38 to activate kinases MK2/3 
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that will phosphorylate Ser386 (Zaru et al., 2015). It is unknown whether the CTKD-
independent activation of RSK is unique to the immune cells, or whether it can occur in 
other cell types, and what stimuli could activate this alternative pathway. It is important 
to note that Toll-like receptors are expressed by multiple cell types, including fibroblasts 
and epithelial and endothelial cells (Broz and Monack, 2013).  
 Regardless of the pathway leading to the phosphorylation of Ser386 in the linker 
region of RSK, the signal is always further propagated by PDK1, as there is no evidence 
of any other kinases phosphorylating Ser227 of RSK (Frodin et al., 2000). Therefore, it 
appears that even though there could be several pathways activating the Ser386, this 
signal requires PDK1 involvement in transferring the stimulus leading to the activation of 
the NTKD. Consistently, massive overexpression of PDK1 is sufficient to activate RSK 
in the absence of ERK activation (Jensen et al., 1999). PDK1 is also involved in the 
activation of Akt downstream of the PI3 kinase, and this activation requires PDK1 and 
Akt to colocalize at the plasma membrane (Alessi et al., 1997, Stokoe et al., 1997). 
However, unlike Akt, RSK is activated by PDK1 independent of the ability of PDK1 to 
interact with the cell membrane (McManus et al., 2004). Consistent with this notion, 
inhibition of the PI3 kinase does not reduce the activation of RSK, but completely blocks 
Akt activation (Moritz et al., 2010, Degen et al., 2013, De Mesquita et al., 2001). 
Therefore, although PDK1 is involved in the regulation of both RSK and Akt, it does not 
serve as a node integrating the ERK and PI3K pathway signals to stimulate RSK.   
 It is important to note, however, that although PDK1 is required for full activation 
of RSK1-3, RSK4 appears to have high basal activity that is independent of PDK1 
(Dummler et al., 2005). That constitutive activity of RSK4 is associated with its 
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phosphorylation at conserved residues analogous to other members of RSK family, 
including the PDK1 docking site, but even in the complete absence of PDK1 Ser227 
within the NTKD of RSK4 is still phosphorylated. The kinase phosphorylating Ser227 of 
RSK4 in the absence of PDK1 has never been identified, and it was proposed to be 
performed by RSK4 CTKD itself (Dummler et al., 2005). The phosphorylation of Ser227 
induces changes in the conformation of the activation loop. These changes involve 
stabilization of the C-helix in the ATP-binding pocket of the kinase, allowing for the 
optimal positioning of the amino acid residues involved in the phosphotransfer (Taylor 
and Kornev, 2011, Hauge et al., 2007). Interestingly, phosphorylation of Ser227 itself 
was found to account for only 10% of the maximal activity of the kinase (Frodin et al., 
2002). The remaining 90% of activity is accomplished by the interactions of 
phosphorylated hydrophobic motif in the linker with the phosphate-binding site within the 
ATP-binding groove of the NTKD (Biondi et al., 2001). Therefore, Ser386 is responsible 
for both recruiting PDK1 to phosphorylate Ser227, and for increasing the activity of the 
NTKD through conformational change.  
1.5.2. RSK knockout studies 
 Mutations in the RSK2 gene were shown to be associated with the Coffin-Lowry 
Syndrome (CLS), a form of X-linked mental retardation and dysmorphism (Temtamy et 
al., 1975, Jacquot et al., 1998). A wide spectrum of mutations in the RSK2 gene was 
observed in patients with CLS, but a common feature of all these alterations was a loss 
of RSK2 kinase activity (Pereira et al., 2010). Patients with CLS display short body 
stature, delayed bone age, delayed closure of fontanelles, osteopenia and digital 
dysmorphism. The skeletal abnormalities observed in CLS are also recapitulated in the 
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genetic RSK2 knockout mouse model. In addition to phenocopying the symptoms of 
CLS, RSK2 knockout mice display a number of other abnormalities, including insulin 
resistance, lipodystrophy and increased glycogen synthesis (El-Haschimi et al., 2003, 
Dufresne et al., 2001). RSK1/2/3 triple knockout animal has also been characterized to 
reproduce the cranioskeletal abnormalities observed in the RSK2 single knockout mice 
(Laugel-Haushalter et al., 2014). In addition to RSK2 knockout mice, loss of RSK2 has 
also been reported to cause skeletal abnormalities and cardiac hypertrophy in the zebra 
fish model (Lara et al., 2013). However, the knockout models of the three remaining 
isoforms individually have never been described. Therefore, the functions of individual 
members of the RSK family in development are still not very well understood.  
1.5.3. RSK expression patterns  
 RSK1-3 appear to be ubiquitously expressed in all human tissues, although the 
relative expression levels of each isoform vary between cell types (Zeniou et al., 2002, 
Moller et al., 1994, Wu et al., 2009). On the mRNA level, RSK1 appears to be more 
abundant in the lung, kidney, pancreas, bone marrow and T cells, whereas RSK2 
seems to be more highly expressed in T cells, skeletal muscle, heart, pancreas, lymph 
nodes and the prostate, compared to other tissues. RSK3 mRNA is most highly 
expressed in the lung, brain, skeletal muscle, heart, pancreas, spinal cord and retina. 
RSK4 mRNA is found at much lower levels compared to the other 3 RSK isoforms, and 
its levels seem to vary much less between the tissues (Kohn et al., 2003, Dummler et 
al., 2005, Wu et al., 2009). However, RSK4 was found to produce multiple splice 
variants of highly variable lengths, complicating our understanding of the expression 
patterns of this protein (Sun et al., 2013).  
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Figure 3. Complex biology of the RSK family of kinases. 
A) RSK displays a modular structure with two fully functional kinase domains, as 
well as a linker and the C- and N-terminal extensions. In basal state ERK1/2 
remains bound to the C-terminus of RSK. Upon ERK1/2 activation, this kinase 
phosphorylates residue Thr577 in the activation loop of the C-terminal kinase 
domain (CTKD), as well as two residues in the linker, Thr365 and Ser369. 
Activated CTKD phosphorylates Ser386 in the hydrophobic motif o the linker, 
which recruits the kinase PDK1. PDK1 phosphorylates Ser227 in the activation 
loop of the N-terminal kinase domain (NTKD), which leads to activation of the 
kinase. NTKD phosphorylates downstream targets of RSK. 
B) RSK1 and RSK2 phosphorylate diverse groups of substrates to reglate protein 
synthesis and gene expression programs. 
C) RSK kinases have been implicated in a variety of mechanisms regulating cellular 
nutrient uptake and energy homeostasis. 
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 Variable expression patterns and co-expression of multiple isoforms of RSK in 
tissues have long been proposed as the evidence of isoform-specific functions of RSK 
(Lara et al., 2013). However, teasing apart these isoform-specific functions has proven 
notoriously difficult. Many of the studies that reported the functions of RSK in specific 
cellular contexts have not investigated which isoform was responsible for the observed 
phenotypes. In many cases it is also unclear if the specified isoform is the only RSK that 
can perform a given function and what is the degree of redundancy between the 
isoforms. Despite all these limitations, with the history of over 20 years of studies, we 
can begin to observe common themes and tendencies of certain isoforms to be more 
likely to perform a specific function. In the following sections, such common themes will 
be proposed. 
1.5.4. RSK substrate recognition 
 To better understand what are the potential phosphorylation targets of the RSK 
family of kinases, the consensus phosphorylation motif of these proteins has been 
characterized by several groups. It was found that RSK preferentially phosphorylates 
in vitro Ser and Thr residues contained within a consensus motif RxRxx(S/T) or 
RRx(S/T), where Arg can also be Lys (Leighton et al., 1995, Galan et al., 2014, Stokoe 
et al., 1993). Interestingly, the same consensus motif has also been found to be 
phosphorylated by other kinases of the AGC superfamily, including Akt and S6K1 
(Leighton et al., 1995, Stokoe et al., 1993). All these studies used in vitro 
phosphorylation of peptide libraries to map the phosphorylation sites, and the kinase 
used in these studies was either RSK1 or it was not specified which isoform was used. 
However, since S6K1 kinase domain shares 56% identity with RSK1 NTKD, and all four 
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RSK isoforms are >90% identical in their NTKD sequence, it is very likely that all these 
isoforms will phosphorylate the same consensus motif. Indeed, an analysis of all RSK 
substrates reported to date has confirmed that these substrates share the RxRxxS or 
RRxS motifs (Smadja-Lamere et al., 2013). Intriguingly, only 3 out of 47 reported RSK 
substrates are phosphorylated on Thr residue, but the basis for such selectivity remains 
unknown.  
 Since multiple AGC kinases can potentially phosphorylate the same motif, 
additional levels of regulation are required for the appropriate substrate choice. In case 
of RSK, substrate selectivity has been proposed to be achieved by specific interactions 
of substrates with the PDZ-binding motif in the extreme C-terminus of RSK (Romeo et 
al., 2012). This motif has been shown to be important in the regulation of RSK2-
dependent synaptic functions in the rat brain (Thomas et al., 2005). However, the PDZ 
ligand sequence of RSK is not conserved in Drosophila and in Caenorhabditis elegans. 
In addition, all four isoforms of RSK possess this PDZ ligand motif in their sequences. 
Finally, many of known RSK substrates do not contain the PDZ motif. These 
observations suggest that the PDZ ligand motif is responsible for regulating 
phosphorylation of a small subset of RSK2-substrates, and it is not the only factor 
regulating substrate specificity of RSK.  
 A potential mechanism contributing to the substrate-specificity of RSK isoforms 
could involve differential localization of these proteins to various cellular compartments. 
When inactive, all 4 RSK isoforms were found to predominantly localize to the 
cytoplasm (Chen et al., 1992, Zhao et al., 1995, Eisinger-Mathason et al., 2008). 
However, several pieces of evidence suggest that upon activation, RSK isoforms can 
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change their sub-cellular distribution. First, Active RSK1 was suggested to transiently 
localize to the plasma membrane, and then translocate to the nucleus (Richards et al., 
2001). However, the study used an overexpression of avian RSK1, and the localization 
of the endogenous RSK1 still remains controversial. One study using RSK1-specific 
antibody in immunohistochemistry found that in brain tissue sections RSK1 localizes to 
the perinuclear region in cells and is not found in the nuclei (Heffron and Mandell, 
2005). The authors of this study suggested that the perinuclear region enriched in RSK1 
staining could represent the Golgi apparatus. However, multiple other sub-cellular 
compartments, including mitochondria, endosomes and lysosomes are also known to 
accumulate in the perinuclear region in multiple cell types.  
 RSK1 and RSK2 have also been suggested to associate in the cytoplasm with 
polysomes, the actively translating ribosomes (Angenstein et al., 1998). Inactive RSK2 
was found to be cytoplasmic and to translocate into the nucleus upon mitogen activation 
(Eisinger-Mathason et al., 2008). In addition, this study found that RSK2 localized to 
cytoplasmic protein-mRNA aggregates called stress granules. Nuclear localization of 
RSK seems to require its phosphorylation and activation, however the lack of isoform-
specific antibodies of phospho-RSK has impeded the identification of specific isoforms 
capable of nuclear localization.  
 Of all the isoforms, only RSK3 has a putative nuclear accumulation signal (NLS), 
and was found to localize to the nucleus using RSK3-specific antibody (Zhao et al., 
2003). Nuclear localization of RSK3 is supported by the staining pattern observed in the 
immunohistochemistry of multiple tissues reported in the Human Protein Atlas (Uhlen et 
al., 2015). Sub-cellular distribution of RSK4 was only investigated once, and in this 
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study it was found to be predominantly cytoplamic (Romeo et al., 2012, Dummler et al., 
2005). The authors of this study also found RSK4 to be consitutively active, suggesting 
that activation of this protein does not lead to its nuclear accumulation.  
 Taken these observations together, differential sub-cellular localization of RSK 
isoforms remains a potential factor contributing to the substrate specificity of RSK family 
members. However futher studies are required to elucidate the exact distribution of 
isoforms, as well as the underlying mechanisms of targeting RSK proteins to different 
cellular compartments. 
 The fact that several kinases share the same substrate recognition motif further 
supports the hypothesis that additional, yet undiscovered factors, regulate the substrate 
specificity of RSK. Furthermore, the same phophorylation sites could be modified by 
other kinases in addition to RSK. Indeed, the studies of small-molecule inhibitors of 
MEK and PI3K, the upstream activators of RSK and Akt, respectively, showed a 
significant overlap between the phosphorylation targets of these kinases in the context 
of gastric and lung cancer cell lines (Moritz et al., 2010). Excellent examples of such 
overlapping targets are CREB, TSC2 and ribosomal S6 protein (rps6). These 
observations further complicate the understanding of the exact signals mediated by 
RSK. With these caveats in mind, the following sections of this chapter will summarize 
the current state of knowledge on the functions of RSK in various cellular processes. 
1.5.5. RSK regulation of translation 
 RSK was originally discovered to phosphorylate rps6 in vitro (Erikson and Maller, 
1986). However, later studies indicated that in somatic cells this phosphorylation was 
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predominantly mediated by p70 S6 kinases (S6K1 and S6K2) (Blenis et al., 1991). In 
addition, inhibition of S6K1/2 signaling by blocking its upstream activator, mTOR, using 
rapamycin, showed complete loss of insulin-stimulated rps6 phosphorylation, further 
suggesting major role of S6K1/2 in phosphorylating S6 protein (Chung et al., 1992). 
Finally, cells derived form S6K1/2 double knockout mice showed almost complete loss 
of rps6 phosphorylation (Pende et al., 2004). However, the same S6K1/2 double 
knockout cells still displayed very low levels of phosphorylation of rps6 that were still 
dependent on MAPK activation, suggesting residual role of RSK in phosphorylating this 
target in vivo. That role of RSK in phosphorylating rps6 in addition to S6K1/2 was further 
supported by studies using silencing of RSK1/2 in serum-stimulated HEK293 and HeLa 
cells (Roux et al., 2007). This study revealed that out of four phosphorylation sites within 
rps6, two were exclusively phosphorylated by S6K1 (Ser240 and Ser244), while the 
other two sites were phosphorylated by both RSK1/2 and S6K1 (Ser235/236). 
Ser235/236 phosphorylation enables rps6 protein interaction with the 7-
methylguanosine cap complex, which promotes cap-dependent translation and 
polysome assembly (Roux et al., 2007). Therefore, RSK1/2 appears to regulate global 
protein translation in response to mitogenic stimulation, and it does so in cooperation 
with S6K1 through co-regulation of rps6. This notion is supported by the finding that 
both RSK1 and RSK2 associate with actively translating ribosomes (Angenstein et al., 
1998).  
 In addition to phosphorylating rps6, RSK has been reported to regulate multiple 
other proteins involved in controlling global protein translation. For example, RSK1 was 
shown to phosphorylate kinase eEF2K (Wang et al., 2001b, Das et al., 2010). The only 
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known substrate of this kinase is eukaryotic elongation factor-2 (eEF2) (Kaul et al., 
2011). RSK1-mediated phosphorylation of eEF2K inactivates this kinase, which leads to 
a decrease in the phosphorylation of eEF2. De-phosphorylation of eEF2 enables it to 
promote the elongation step of translation. Therefore, active RSK1 stimulates protein 
translation through maintaining the de-phosphorylated state of eEF2. Both studies of the 
role of RSK in regulating eEF2 phosphorylation have used the dominant negative (DN) 
mutant of RSK1 to show that loss of RSK1 activity is sufficient to block eEF2K function. 
These results suggested that it is RSK1, and not other RSK isoforms, that 
phosphorylates eEF2K. It is possible that the DN mutant of RSK1 would interfere with 
the activities of other RSK isoforms, and the two studies did not assess changes in 
pS380 or pS227 of RSK upon DN-RSK1 expression. Therefore, it remains a theoretical 
possibility that one of the other RSK isoforms of RSK is also involved in the regulation of 
eEF2.  
 RSK1 has also been reported to phosphorylate the eukaryotic translation 
initiation factor-4B (eIF4B) in three independent studies (Shahbazian et al., 2006, 
Degen et al., 2013, Kroczynska et al., 2009, Kuang et al., 2011). These studies used 
silencing and knock-down of RSK1, as well as expression of DN-RSK1 mutant, to show 
that loss of the activity of this kinase was sufficient to abrogate eIF4B phosphorylation. 
RSK1-mediated phosphorylation of this protein was shown to increases eIF4B 
interaction with the eukaryotic translation initiation factor 3 (eIF3), which stimulated cap-
dependent translation. While several studies showed the ability of RSK1 to 
phosphorylate eIF4B, RSK2 knock-down did not change the phospho-eIF4B levels, 
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suggesting that eIF4B is a specific target of RSK1, and not of other RSK family 
members (Kroczynska et al., 2009).  
 The connection between RSK activity and eIF4B has also been reported in the 
context of the lytic replication of the Kaposi Sarcoma-associated Herpesvirus (KHSV). 
The authors of the study reported that RSK activation in the Kaposi sarcoma cell line 
was triggered by the expression of the KHSV-derived protein ORF45, which led to an 
increase in the phospho-eIF4B levels (Kuang et al., 2011). This increase in eIF4B could 
be reversed by silencing of both RSK1 and RSK2 simultaneously, and was increased by 
over-expression of both wild-type and consitutively-active RSK2, but not by an over-
expression of the kinase-dead version of RSK2. However, it was not determined 
whether silencing of individual isoforms alone was sufficient to block the 
phosphorylation of eIF4B. In addition, the effects of the ectopic expression of RSK2 on 
the activity of RSK1, were not assessed. Therefore, it remains unknown if RSK2 can 
phosphorylate eIF4B. Despite these shortcomings, it is important to note that this study 
provided additional evidence for the role of RSK in regulating eIF4B phosphorylation in 
various cellular contexts. It also implicated RSK in stimulating the replicative potential of 
the KHSV virus, suggesting that RSK could also play a role in viral infections. 
 Finally, another mechanism by which RSK was shown to regulate cap-dependent 
translation is through the phosphorylation of 4E-BP1 (Kroczynska et al., 2011). 4E-BP1 
can be phosphorylated by S6K1 in response to insulin stimulation, and this 
phosphorylation is completely rapamycin-sensitive (Wang et al., 2005). However, 
stimulation of a human adenocarcinoma cell line, as well as a retinal pigment epithelial 
cell line and immortalized mouse embryonic fibroblasts, with interferon-lambda (IFN-) 
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was shown to induce phosphorylation of 4E-BP1 that was partially inhibited by both 
rapamycin and the MEK inhibitor UO126 (Kroczynska et al., 2011). In these cells, 
inactive RSK1 was associated with a repressive complex of 4E-BP1 and eIF4E, and 
IFN-triggered activation of this kinase caused both phosphorylation of 4E-BP1 and 
release of eIF4E. Although rapamycin treatment partially reduced the phosphorylation of 
4E-BP1, it was not sufficient to dissociate RSK1 from 4E-BP1 and release the inhibition 
of eIF4E. Therefore, in the context of IFN- in both normal epithelial and cancer cell 
lines, RSK1 was shown to integrate the ERK1/2 input with signals downstream of 
mTOR to ultimately stimulate the cap-dependent translation through 4E-BP1/eIF4E 
complex. It is also worth mentioning that this manuscript corroborated the previous 
findings that eIF4B was a target of RSK1 (Kroczynska et al., 2009, Kroczynska et al., 
2011). Interestingly, IFN-is an important cytokine produced by multiple cell types in 
response to viral infections (Kotenko et al., 2003). Therefore, the studies of RSK1 in the 
context of eIF4B and 4E-BP1 have also suggested its involvement in viral infection. 
Consistent with this hypothesis, a recent study has demonstrated that RSK1 
phosphorylates SKAR in response to another cytokine, interferon-alpha (INF-) 
(Kroczynska et al., 2014). This phosphorylation facilitates interaction of SKAR with 
eIF4G, resulting in an increase in cap-dependent translation. 
 Early studies have also implicated RSK in phosphorylation of the glycogen 
synthase kinase-3(GSK3) both in vitro in cell-based assays (Sutherland et al., 1993, 
Stambolic and Woodgett, 1994, Torres et al., 1999, Eldar-Finkelman et al., 1995). 
GSK3 phosphorylates and thereby inactivates the eukaryotic translation initiation 
factor-2B (eIF2B) (Wang et al., 2002). Therefore, active RSK could increase the activity 
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of eIF2B to drive translation. As these studies were performed before the complexity of 
RSK family became appreciated, it is very difficult to determine which isoforms were 
investigated in this context. For example, one report by the Cohen group mentions 
using RSK2 in vitro (Sutherland et al., 1993), while the same group later states that 
RSK1 was used in this study (Stambolic and Woodgett, 1994). The sequences of used 
contructs were not included in the manuscripts, making it impossible to independently 
identify the isoforms. It is important to note, that GSK3 is regulated by multiple other 
kinases, including PKA, Akt and S6K1/2 (Cross et al., 1995, Fang et al., 2000). As a 
result, it is still unknown to what extent RSK contributes to the regulation of protein 
translation by GSK3. The regulation of GSK3 by RSK could heavily depend on the 
cell type and the activating stimulus, just like in the case of 4E-BP1. For example, in rat 
cerebellar granule neurons potassium triggers phosphorylation of GSK3 that is 
completely independent of MEK-ERK-RSK activation (Song et al., 2010).  
 As mentioned above, multiple examples demonstrated that RSK can share its 
substrates with the elements of the mTOR pathway. This pathway itself has been 
extensively studied in the context of global protein synthesis (Mayer and Grummt, 
2006). For example, mTOR activates transcription of RNA polymerases I and III, which 
are responsible for the synthesis of ribosomal RNA. In addition, mTOR drives 
expression of RNA polymerase II, which is responsible for the expression of ribosomal 
proteins. Finally, mTOR activates S6K1/2, which cooperates with RSK1 to phosphoylate 
and activate rps6, eIF4B and 4E-BP1. Adding to the complexity of the regulation of 
protein translation by both mTOR through S6K1/2 and ERK1/2 through RSK, a crosstalk 
between these two pathways has also been discovered. RSK1 was revealed to be the 
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protein mediating this crosstalk, and it was shown to perform this function through at 
least two meachinsms. First, it was shown to phosphorylate the protein protein tuberous 
sclerosis complex-2 (TSC2) (Roux et al., 2004). This phosphorylation leads to a release 
of TSC2-mediated inhibition of the upstream activator of mTOR, Rheb (Inoki et al., 
2003). Second, RSK has been shown to phosphorylate another component of the 
mTOR pathway, the mTORC1 component Raptor (Carriere et al., 2008a). In the case of 
Raptor, RSK1 was shown to phosphorylate it in vitro, but in cell based assays a dual 
silencing of RSK1/2 and inhibition of all 4 isoforms of RSK was used. As a result, it is 
still not clear which isoform of RSK phosphorylates Raptor in intact cells. Taken these 
observations together, RSK1, and potentially other RSK isoforms as well, could regulate 
global protein translation through promoting mTOR-mediated ribosome biogenesis and 
cap-dependent translation.  
 In addition to functions in stimulating ribosome biogenesis and translational 
activity, RSK was shown to participate in stabilizing mRNA molecules. Under certain 
stress conditions that reduce or block protein translation cells will sequester nascent 
mRNA molecules into cytoplasmic RNA-protein aggregates called stress granules 
(Kedersha et al., 2002, Kedersha et al., 2005). The function of stress granules is to 
protect mRNA molecules from degradation such that when the block in translation is 
alleviated cells can rapidly restore synthesis of necessary proteins. In addition to 
mRNA, stress granules contain multiple proteins, including the T-cell restricted 
intracellular antigen-1 (TIA1), poly(A)-binding protein-1 (PABP1), RasGAP SH3-domain-
binding protein-1 (SH3BP1), elongation factors 2 and 3 (eIF2, eIF3) and 40S ribosomal 
components (Kedersha et al., 1999, Kedersha et al., 2000, Kedersha et al., 2005, 
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Kedersha et al., 2002, Tourriere et al., 2003). Intriguingly, RSK2 was found to regulate 
formation and be recruited to newly formed stress granules upon induction of oxidative 
stress in breast epithelial cells (Eisinger-Mathason et al., 2008). RSK2 was found to 
regulate stress granule formation through its interactions with TIA1. This ability to 
stimulate stress granule assembly was dependent on RSK2 kinase activity, as both 
RSK small-molecule inhibition and RSK2 kinase-dead mutant prevented stress granule 
formation. This study also found that RSK2-dependent assembly of stress granules 
promotes cell survival in response to oxidative stress. Finally, while silencing RSK2 
prevented formation of the stress granules, loss of RSK1 expression did not have the 
same effect. 
 In summary, RSK has been shown to activate protein translation through a 
variety of mechanisms (fig. 3B). In the majority of studies RSK1 was suggested as a 
predominant isoform responsible for the effects. Some of the downstream targets of 
RSK1 in this context are shared by S6K1/2 and mTOR. These two kinases themselves 
can be regulated by RSK1 through the inhibitory phosphorylation of TSC2. Therefore, 
RSK appears to stimulate translation in partial co-operation with the mTOR pathway. 
The role of RSK in this context could be to serve as an integrator of Ras-MAPK and 
PI3K-mTOR inputs leading to changes of protein translation. Regulation of global 
protein translation by RSK highlights the importance of this family of kinases in 
promoting cell growth and prolifertation. Interestingly, global protein translation has 
been proposed to act as a potential driver of transformation and drug resistance in 
various tumor types (Larsson et al., 2007, Lim et al., 2013b, Meric-Bernstam et al., 
2012, Pervin et al., 2008). Consistent with the potential role of RSK1-dependent 
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translation in the context of cancer, a recent report has demonstrated that over-
expression of RSK1 conferred resistance of MCF-7 breast cancer cell line to the 
inhibition of the PI3 kinase pathway (Serra et al., 2013). This aquired resistance was 
associated with a rescue in a phosphorylation of rps6. Furthermore, blocking RSK 
activity sensitized multiple cell lines to the inhibitors of the PI3K-Akt pathway. 
Intriguingly, an overexpression screen of kinases conferring resistance to PI3K 
inhibitors performed in this study also identified RSK3 and RSK4 as potential proteins 
involved in the resistance to PI3K inhibitors. Over-expression of each of these two 
kinases was sufficient to partially rescue both phospho-rps6 and phospho-eIF4B levels 
in cells treated with PI3K inhibitors, suggesting that RSK3/4 could also regulate protein 
translation (Serra et al., 2013). Since the study did not assess the effects of RSK3/4 
expression on S6K1/2 phosphostatus, it remains unclear whether these two isoforms of 
RSK act to directly phosphorylate the components of the cap-dependent translation, or 
to re-activate S6K1/2 kinases, for example through the RSK-TSC2-mTOR crosstalk. It 
also remains unclear whether the role of RSK3 and RSK4 in regulating protein 
translation is limited to breast cencer cell lines and what is their contribution to this 
process relative to RSK1. 
1.5.6. RSK regulation of transcription 
 Among the plethora of cellular functions regulated by ERK1/2, changes in gene 
expression have long been of great interest. Since RSK is almost excusively activated 
by ERK1/2 in most cell types and is thought to be a major downstream effector of this 
pathway, this family of kinases has also been studied in the context of transcriptional 
regulation. Indeed, one study performed in MDCK cell line demonsrated a critical role of 
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RSK as a downstream mediator of ERK1/2-dependent gene transcription (Doehn et al., 
2009). The study revealed that out of 1089 ERK-regulated genes, 288 were under the 
control of RSK. This regulation of a range of targets involved several mechanisms, and 
53 of the 288 RSK-mediated effects appeared to involve the transcription factor FRA1. 
FRA1 was shown to be regulated by RSK, either through mRNA expression or on a 
post-transcriptional level, depending on the cell type. Interestingly, ~25% of the genes 
regulated by RSK are involved in motility and invasiveness, suggesting the role of RSK 
in regulating this cellular property. It is important to note that the study used a small-
molecule inhibitor RSK1,2,4 for gene expression analysis, therefore it did not determine 
which isoform was responsible for the observed changes in transcription. In trems of 
genes associated with motility, silencing of RSK1 and RSK2 individually caused non-
overlapping changes in some, but not all targets identified through gene expression 
analysis, suggesting that multiple RSK isoforms play roles in regulating pro-motile and 
pro-invasive phenotypes downstream of ERK1/2. 
 A close relative of the transcription factor FRA1, c-Fos, has also been proposed 
to be regulated by RSK. RSK was shown to directly phosphorylate c-Fos, which leads to 
both protein stabilization and activation of its transcriptional activity (Chen et al., 1993, 
Chen et al., 1996). These studies did not specify which RSK isoform was responsible 
for the observed effects. In addition, RSK was proposed to be involved in the regulation 
of mitogen-stimulated expression of c-Fos. One potential mechanism of c-Fos 
regulation by RSK is through phosphorylation and activation of the Elk1/SRF (serum 
response factor) complex (Bruning et al., 2000, Rivera et al., 1993). This study was 
perfomed in embryonic fibroblast lines derived from RSK2 knock-out mice, suggesting 
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that this particular isoform was responsible for the observed effects on c-Fos 
expression. Another mechanism of c-Fos regulation by RSK was proposed to involve 
the cAMP-response-element-binding protein (CREB) (Ginty et al., 1994),(Xing et al., 
1996). CREB phosphorylation and c-fos transcription were found to be severely 
decreased in a fibroblast cell line drived from a Coffin-Lowry syndrome patient with a 
frameshift mutation in the RPS6KA3 gene resulting in expression of a RSK2 mutant 
lacking the entire C-terminal half of the protein (De Cesare et al., 1998). Importantly, 
this loss in CREB phosphorylation and c-Fos expression was observed only in cells 
stimulated with EGF, but not in cells treated with full serum or UV radiation, suggesting 
that other kinases can also phosphorylate and activate CREB. Indeed, MSK1/2 was 
also shown to phosphorylate CREB in mouse embryonic fibroblasts, resulting in 
changes in c-Fos expression, in the context of UV irradiation and serum stimulation, but 
in the case of EGF treatment (Wiggin et al., 2002). Therefore, c-Fos expression through 
CREB appears to be regulated by RSK2 and MSK1/2 in the stimulus-dependent 
manner. In summary, RSK2 has been shown to regulate c-Fos through several 
mechanisms, both directly and indirectly through Elk1/SRF and CREB. The 
physiological significance of this regulation is highlighted by the fact that in RSK2-
knock-out mice c-Fos overexpression failed to induce ostesarcomas (David et al., 
2005).  
 RSK has been studied in the context of another CREB family member, activating 
transcription factor-4 (ATF4). RSK2 was found to physically interact with in the nucleus 
and directly phosphorylate ATF4, which leads to an increase in the transcriptional 
activity of ATF4 (Yang et al., 2004). The function of ATF4 is to promote osteoblast 
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differentiation and function, which is essential for the maintenance of proper bone 
density. RSK2 knockout and ATF4 knockout mice share the same defects in bone 
morphology, supporting the role of this interaction between RSK2 and ATF4. The 
function of RSK2 in regulating this important transcription factor in osteoblast 
differentiation could help explain skeletal abnormalities in patients with Coffin-Lowry 
syndrome (Temtamy et al., 1975). 
 RSK has also been shown to phosphorylate Ser167 within the activation 
function-1 (AF1) domain of the estrogen receptor- (ER) (Joel et al., 1998, Yamnik 
and Holz, 2010). This phosporylation leads to mitogen-dependent activation of 
transcription of ER target genes independently of the stimulation by the receptor 
ligand, estrogenJoel et al used in-gel kinase assay of the N-terminal part of ER to find 
that RSK1 was capable of phosphorylating this protein. However, the other RSK 
isoforms were not evaluated in this study. Yamnik et al silenced RSK1 and RSK2 
simultaneously to reduce ER phosphorylation on Ser167 in response to potent 
mitogen phorbol myristate acetate (PMA), but not in response to insulin. Therefore, 
these two studies together suggested that RSK1 and/or RSK2 can phosphorylate ER, 
but it remains unknown which isoform performs this function in intact cells and in vivo. 
Interestingly, RSK2 was also shown to regulate transcriptional activity of ER through 
the allsoteric modulation of the hormone-binding domain (HBD) (Clarkl et al., 2001). 
This regulation was shown to be mediated by RSK2 binding to the HBD of the receptor, 
which induced a conformational change leading to the activation of the transcriptional 
activity. This effect could be blocked by anti-estrogens, like 4-hydroxytamoxifen, which 
disrupted this interaction and prevented allosteric activation of ER by RSK2. Potential 
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role of RSK-mediated phosphorylation of ER-Ser167 was supported by the 
observations that in breast cancer tissue samples this phosphorylation was strongly 
correlated with active RSK, and the presence of ER-phosphoSer167 predicted better 
responses of patients to anti-estrogen therapy (Jiang et al., 2007). 
 RSK has been proposed to regulate another important transcription factor, c-
Myc. For example, inhibition of RSK1-4 has been shown to decrease Myc levels in 
squamous cell carcinoma cell lines (Degen et al., 2013). Additionally, RSK has been 
shown to phosphorylate a negative regulator of c-Myc, mitotic arrest-deficient protein 1 
(Mad1) (Zhu et al., 2008). The function of Mad1 is to compete with an essential 
transcriptional co-activator of Myc, Max (Rottmann and Luscher, 2006). When 
phosphorylated by RSK, Mad1 was sent to proteosomal degradation, which enabled 
Myc-Max interaction (Zhu et al., 2008). The study used RSK1 to demonstrate Mad1 
phosphorylation in vitro, and silencing of both RSK1 and RSK2 in cell-based assays, 
therefore it remains unknown which isoform was responsible for the effects.  
 Recent studies have also indicated the role of RSK in regulating the stability of 
the GLI2 transcription factor (Liu et al., 2014). This transcription factor is constitutively 
cleaved by the proteasome in a phosphorylation-dependent manner, which blocks its 
ability to stimulate transcription of target genes (Pan et al., 2009, Bhatia et al., 2006). 
Activation of the Hedgehog (HH) signaling pathway represses phosphorylation of GLI2 
and allows for its stabilization and transcriptional activation. Among the kinases that 
phosphorylate GLI2 to stimulate its proteasomal processing is GSK3 (Jia et al., 2005). 
RSK2 has been fond to stabilize GLI2 by repressing GSK activity, leading to an 
increase in the expression of GLI2 target genes, including anti-apoptotic protein BCL2, 
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the constitutively active HH transcription factor GLI1 and pro-tumorigenic cell-cycle 
control protein cyclin D1 (Liu et al., 2014). The implications of the study are two-fold. 
First, it provided further evidence that in certain cellular contexts GSK3 is a 
physiologically relevant substrate of RSK. Second, RSK was shown to cooperate with 
the HH signals to stimulate activity of transcription factors with critical functions in 
regulating development and normal tissue homeostasis in multiple organs, including 
breast epithelium (Lee et al., 2013, Vokes et al., 2007, Vokes et al., 2008, Lee et al., 
2010, Chandramouli et al., 2013). Interestingly, RSK activity has been shown to 
participate in cell fate determination in mammary epithelial cells, which is consistent with 
its potential role in modulating the HH signaling network (Pasic et al., 2011). In addition, 
RSK2 was also shown to drive cyclin D1 expression in transformed mammary epithelial 
cells (Eisinger-Mathason et al., 2008). Deregulation of the HH pathway has been 
observed in various pathological processes, including cellular transformation (Harrison 
et al., 2014, Wellbrock et al., 2015, Schnidar et al., 2009, Thiyagarajan et al., 2007), 
suggesting that RSK activation could contribute to tumorigenesis through its ability to 
stabilize and activete GLI transcription factors. 
 Another transcription factor important in development that was found to be under 
the control of RSK is GATA4 (Li et al., 2012b). This transcription factor is a critical 
regulator of heart development and homeostasis, and its overactivation is associated 
with cardiac hypertrophy (Yamak et al., 2014, Stefanovic et al., 2014, Molkentin and 
Olson, 1997, Molkentin et al., 1997, Liang et al., 2001a). RSK2 overexpression was 
found to increase phosphorylation of GATA4, which stimulated its ability to bind to target 
gene promoters and drive their transcription (Li et al., 2012b). The authors of this study 
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also showed that this mechanism was responsible for the cardiac hypertrophy induced 
by phenylephrine, as the effects of this 1-adrenergic receptor agonist could be 
completely blocked by small-molecule inhibition of RSK. Interestingly, GATA4 has also 
been shown to be modified by other kinases as well, including those downstream of the 
PI3K-Akt pathway (Yanazume et al., 2002, Chandrasekar et al., 2005, Morisco et al., 
2001, Liang et al., 2001b), suggesting that RSK could function as a fidelity factor 
contributing to the integration of multiple upstream signals to drive specific gene 
expression program in the heart. 
 As mentioned before, RSK has been shown to be activated by immune 
cytokines, suggesting its potential role in the inflammatory response. Therefore, this 
family of kinases has also been investigated in the context of the transcriptional 
program associated with inflammation. Indeed, RSK1 was shown to phosphorylate 
endogenous inhibitors of the transcription factor NF-B, IB and IkB(Schouten et al., 
1997, Xu et al., 2006). This phosporylation led to the degradation of the two proteins, 
releasing NF-B from inhibition (Ghoda et al., 1997). In addition to sending inhibitors of 
NF-B for degradation, RSK1 has also been shown to directly phosphorylate NF-B 
component p65 (RelA) (Zhang et al., 2005, Bohuslav et al., 2004). This RSK1-mediated 
phosphorylation disrupted the interaction of p65 with its negative regulators, allowing its 
activation independent of the presence of IB. Interestingly, in this study RSK activation 
leading to phosphorylation of p65 was due to p53-mediated activation of the upstream 
activator of ERK, MEK1. Therefore, activation of p65 by RSK did not occur in response 
to mitogens, however it still involved the classical upstream activator of RSK, ERK. The 
ability of p53 to activate MEK1 independent of growth factors has previously been 
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reported (Ryan et al., 2000). It highlights the possibility that RSK can be activated by 
other pathways than the growth factors, such as DNA damage that will activate p53, as 
long as ERK becomes activated in the process.  
 It has been noted that many of the nuclear proteins that are phosphorylated and 
regulated by RSK have been shown to interact with the transcriptional co-activator 
CREB-binding protein (CBP). The proteins interacting and being regulated by CBP 
include CREB, c-Fos, ER and NF-B (Kwok et al., 1994, Chrivia et al., 1993, Bannister 
and Kouzarides, 1995, Papoutsopoulou and Janknecht, 2000, Goel and Janknecht, 
2004, Chakravarti et al., 1996, Hanstein et al., 1996, Huang et al., 2007). Based on its 
ability to interact with these proteins, CBP was proposed to be a transcriptional co-
regulator of two major groups of targets: those activated by cAMP through CREB and 
those activated by mitogen signaling (Arias et al., 1994, Cardinaux et al., 2000). Growth 
factors such as insulin were shown to inhibit activation of cAMP-responsive genes, 
presumably through interfering with CBP interaction with CREB (Quinn, 1994). 
Interestingly, activated RSK has been found to interact with CBP in the nucleus, and 
this interaction led to an increase in C/EBP ability to drive expression of mitogen-
stimulated genes (Nakajima et al., 1996). In addition, the formation of the CBP-RSK 
complex suppressed the ability of CBP to stimulate expression of cAMP-responsive 
genes. Therefore, it appears that RSK is a factor responsible for mediating the mitogen-
dependent suppression of CREB-CBP function (Wang et al., 2003). As a result, RSK 
can help fine-tune the global gene expression program in response to growth factors. 
Interestingly, the ability of RSK to regulate CBP function appeared to be independent of 
the phosphotransferase activity of RSK, as the kinase-dead mutant of RSK still 
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interacted with CBP and had the same effects on CBP function as the wild-type RSK 
(Wang et al., 2003). All these studies investigating the connection between RSK and 
CBP used avian RSK1 over-expression, or RSK1-specific antibody in nuclear extracts. 
Therefore, it is unclear whether RSK1 is the only isoform interacting with CBP. In 
addition, while RSK2 localization to the nucleus has previously been described in 
multiple cell types, the ability of RSK1 to translocate to the nucleus is much less 
supported in the literature. Finally, CBP was proposed to help RSK mediate its effects 
on various transcription factors, but the majority of these effects were observed in the 
context of RSK2, and not RSK1. As a result, the true identity of the RSK isoform 
interacting with CBP in the nucleus is still debatable. Despite this caveat, CBP remains 
an important target of RSK that offers the potential explanation of how this kinase can 
regulate a wide array of transcription factors.  
 In summary, multiple transpription factors and transcriptional co-regulators have 
been found to be the substrates of RSK kinases (fig. 3B). Although the distinction 
between RSK isoform-specific functions in the context of gene expression is less clean-
cut than in the case of global protein synthesis, the emerging trend suggests a more 
prominent role of RSK2. This general observation is particularily evident when resident 
nuclear proteins, such as ER, c-Fos, ATF4 and GATA4, are concerned. Consistent 
with such compartmentalization of RSK functions, the inhibitors of NF-kB transcription 
factor, which exert their effects in the cytoplasm, were found to be regulated by RSK1. 
Compared to RSK1/2, the functions of the remaining two RSK isoforms are almost 
completely unknown. It is surprising, given the proposed nuclear locaization of RSK3. 
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 Several proteins that are phosphorylated by RSK have also been shown to be 
controlled by other kinases, in particular those in the PI3K-Akt pathway. These 
observations suggest that, while being an important downstream mediator of the Ras-
MAPK pathway, it exerts many of its functions in cooperation with other signaling 
pathways. It is conceivable that such collaboration between different networks allows for 
integration of the signals and the choice of an appropriate biological effect in the context 
of the entire signaling landscape. Therefore, even though RSK is almost exclusively 
activated by ERK1/2, the physiological outcome of RSK signaling will be impacted by 
other signaling pathways as well. The common theme among all the transctiptional 
responses stimulated by RSK signaling is to promote survival, proliferation and 
differentiation of various cell types.  
1.5.7. RSK and cell cycle 
 As summarized in pervious sections, RSK functions in transcription and 
translation are often associated with accelerated cellular proliferation (fig. 3B). 
Additional factors, such as direct influence of RSK on the cell cyce machinery, could 
contribute to the observed increases in proliferation. Indeed, several studies have 
demonstrated that RSK could participate in the regulation of cell cycle progression, 
through a variety of mechanisms. One very important cell cycle protein under the control 
of RSK is cyclin D1 (Eisinger-Mathason et al., 2008). Cyclin D1 expression was shown 
to be regulated on the transcriptional level by RSK2, but not RSK1. Although the exact 
mechanism of this regulation was not determined, it was suggested to be independent 
of CREB and c-Fos. Instead, the proposed pathway involved ER, as the promoter of 
cyclin D1 is known to contain estrogen-response elements (EREs) and its expression 
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has been shown to be stimulated by estrogen (Basu and Rowan, 2005). Therefore, 
cyclin D1 appears to be transcriptionally regulated by ER. As mentioned above, RSK 
has been shown to interact with ER, which leads to its activation, both in 
phosphorylation-dependent and independent manner (Joel et al., 1998, Clarkl et al., 
2001). Furthermore, in addition to ERa, cyclin D1 levels could be regulated by RSK2 
through its ability to stabilize and transcriptionally activate the transcription factor GLI2 
(Liu et al., 2014). 
 Another cell-cycle regulator under the control of RSK is the inhibitor of the cyclin-
dependent kinase-2 (CDK2), p27kip1 (Fujita et al., 2003, Larreaa et al., 2009). p27kip1 is 
regulated by RSK through two mechanisms. This protein is phosphorylated by RSK1, 
which creates a recognition site for 14-3-3 protein binding to p27kip1 (Fujita et al., 2003). 
14-3-3 protein sequesters p27kip1 to the cytoplasm, away from the CDK2-cyclin E 
complex, which is localized to the nucleus. p27kip1 localization to the cytoplasm releases 
CDK2-cyclin E from inhibition and allows cell entry into S phase. RSK1 by itself also 
forms a complex with p27kip1 in the cytoplasm, further contributing to cytoplasmic 
localization of p27kip1 (Larreaa et al., 2009). Interestingly, RSK1-mediated 
phosphorylation of p27 plays an additional role in regulating p27kip1 function as a 
regulator of cell motility and cytoskeleton organization. When phosphorylated by RSK1 
and localized to the cytoplasm, p27kip interacts with RhoA (Larreaa et al., 2009). p27kip1 
binding to this GTPase leads to inhibition of RhoA activation of ROCK1, and a 
subsequent increase in cell motility (Besson et al., 2004). Therefore, interactions of 
RSK1 with p27kip result in both increase in cell entry to S phase and an increase in 
motility.  
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 RSK2 has been proposed to regulate the spindle assembly checkpoint at the 
onset of mitosis. It has been observed that inhibition of RSK leads to a loss of 
localization of Mad1 and Mad2 at the kinetochore (Vigneron et al., 2010). Interestingly, 
Mad1 has also been shown to be regulated by RSK in the context of Myc activity in the 
G1/S phase of the cell cycle (Zhu et al., 2008). In addition to the regulation of mitosis, 
RSK1 has been shown to regulate activation of meiosis in Xenopus (Schmitt and 
Nebreda, 2002). RSK1 phosphorylates the kinase myelin transcription factor-1 (Myt1), 
which is a negative regulator of p34cdc2 (Palmer et al., 1998). Inactivation of Myt1 by 
RSK-mediated phosphorylation leads to a release of the inhibition of p34cdc2 and allows 
cell entry into M phase. In addition to Myt1, RSK phosphorylates and activates another 
regulator of p34cdc2, Cdc25C (Wang et al., 2010, Wu et al., 2014). Interestingly, RSK1 
seems to be a negative regulator of oocyte maturation, through activation of the 
metaphase II arrest. RSK1 phosphorylates two regulators of anaphase-promoting 
complex (APC), kinase Bub1 and early mitotic inhibitor-2 (Emi2) (Schwab et al., 2001, 
Nishiyama et al., 2007). When phosphorylated by RSK1, these two proteins inactivate 
APC, leading to a block in cell cycle progression. Despite being well characterized in 
frog oocytes, however, RSK does not seem to play a role in regulating meiosis in mouse 
oocytes (Dumont et al., 2005). Therefore, RSK function in regulation of meiosis in other 
organisms than frog remains controversial. 
 Increased proliferation rates induced by mitogenic signaling exert a significant 
stress on the DNA, which promotes DNA damage and replication checkpoints (Bartkova 
et al., 2005, Gorgoulis et al., 2005). One of the proteins involved in cell cycle regulation 
in this context is Chek1 (Zhao and Piwnica-Worms, 2001). RSK has been shown to 
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phosphorylate Chek1 in response to serum stimulation in hTERT-immortalized retinal 
pigment epithelial cells, as well as HeLa and U2OS cancer cell lines, as well as mediate 
constitutive Chek1 phosphorylation in Raf-mutant melanoma cell lines (Li et al., 2012a, 
Ray-David et al., 2013). Overexpression of each RSK isoform was could induce Chk1 
phosphorylation in HEK293, HeLa and U2OS cell lines, but RSK1 had the strongest 
effect (Ray-David et al., 2013). In addition, silencing of RSK1 alone was sufficient to 
reduce Chk1 phosphorylation to the same extent as RSK1/2 double silencing, and RSK 
inhibition with both SL0101 and BI-D1870. Although both studies found the same effects 
of RSK on Chk1 phosphorylation upon serum stimulation, they demonstrated the 
opposite effects on G2/M block. Therefore, it remained unclear whether the function of 
RSK was to induce the block in cell cycle following DNA damage, or to promote 
bypassing this checkpoint.  
 The possibility that RSK acts to promote the G2/M checkpoint was supported by 
the observations that RSK2 knock-out mouse embryonic fibroblasts and fibroblasts 
derived from CLS patients failed to arrest in G2/M phase in response to genotoxic 
stress (Lim et al., 2013a). Re-introduction of RSK2 in theses cells was sufficient to 
restore ATM and p53 phosphorylation, and proper activation of the DNA-damage 
checkpoint.  
 The hypothesis that RSK promoted bypassing of the G2/M checkpoint was 
supported by a study in which RSK inhibition and silencing of RSK1/2 in prostate cancer 
cell lines, PC3 and LnCaP, caused stalling in the G2/M transition (Chen et al., 2013). 
However, the authors of this study did not investigate the changes in Chk1 
phosphorylation. Instead, a new mechanism was proposed, in which RSK 
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phosphorylated the protein meiotic recombination-11 (Mre11), which resulted in 
suppressed ability of ATM to bind to damaged DNA and activate damage response. 
Furthermore, RSK was shown to drive entry into mitosis in PC3 cells through direct 
phosphorylation of Cdc25 (Wu et al., 2014). In the context of Chk1 phosphorylation, 
previous studies have showed that this modification caused re-distribution of Chk1 into 
the cytoplasm and failure to activate the G2/M checkpoint (Puc et al., 2005, King et al., 
2004). Therefore, it appeared that both opposing models of RSK regulation of DNA-
damage checkpoint are supported by experimental evidence. This conflict could be 
reconciled by the fact that inhibition of RSK caused G2/M block in cells with high basal 
activity of ERK and constitutive phosphorylation of Chk1, while loss of RSK activity 
resulted in the block in G2/M phase transition in cells with basal low ERK activity that 
becomes induced by genotoxic stress or serum stimulation. Such observations suggest 
an interesting model in which a function of RSK in normal homeostasis is to promote 
DNA-damage checkpoint to allow cells to repair the lesions, while in the state of chronic 
ERK activation RSK allows cells to proliferate despite DNA damage.   
 Taken all this information together, RSK can drive cell cycle progression by 
phosphorylating specific cell cycle regulators, in addition to the transcriptionally 
regulated processes. Such ability to post-translationally impact cell cycle machinery 
would enable RSK to elicit its effects in a more acute way, in addition to a long-term 
alterations of cellular phenotype. Therefore, RSK could represent a signaling 
component allowing for rapid adaptation of the cell cycle to the changes in cellular 
environment, in particular in the context of mitogenic stimulation. The functions of RSK 
in cell cycle regulation seem to involve both RSK1 and RSK2, and could potentially 
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include RSK3 and RSK4 as well. However, it appears that all isoforms may contribute to 
cell cycle regulation in non-overlapping ways, as loss of individual RSK proteins is 
sufficient to induce changes in cell cycle progression. Therefore, RSK family could act in 
coordination, rather than in redundancy in the context of cell cycle regulation. 
1.5.8. RSK and apoptosis 
 RSK has been found to inhibit apoptosis through phosphorylation of specific 
targets. For example, in hepatic stellate cells treated with transforming growth factor-
alpha (TGF), or a hepatotoxin CCl4, RSK phosphorylates the protein CCAAT/enhancer 
binding protein  (C/EBP) (Buck et al., 1999, Buck et al., 2001). The phosphorylation 
of this protein enables it to interact with caspases 1 and 8. This interaction prevents 
activation of these caspases and blocks the propagation of the death signal. 
Interestingly, C/EBP-RSK1 interplay has also been recently reported in lung epithelium 
(Lin et al., 2014). In this study thrombin induced phosphorylation of C/EBP by RSK1, 
which led to association of C/EBP with the promoter region of interleukin-8 (IL8) and 
an increase in expression and secretion of this chemokine by lung epithelium. IL8 has 
been shown to stimulate pro-survival and pro-proliferation signaling in multiple cancers 
(Waugh and Wilson, 2008). Therefore, the function of RSK1 in phopshorylating C/EBP 
is not limited to the inhibition of apoptotic cascade through caspases 1 and 8, but can 
also stimulate cell survival through changes in cellular microenvironment.  
 RSK has been shown to phosphorylate Bad, the pro-apoptotic BH3-only protein 
found in the outer mitochondrial membrane (Bonni et al., 1999, Shimamura et al., 2000). 
Phosphorylation of Bad enhances its interaction with the cytosolic 14-3-3 proteins, 
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which sequesters Bad away from the mitochondrial membrane and prevents 
incorporation of Bad into the mitochondrial permeability transition pore. As a result, 
sequestering Bad into the cytoplasm prevents opening of the pore and release of 
cytochrome C from the intramembrane space. This prevents cytochrome C-mediated 
activation of the apoptotic cascade. The studies of BAD phosphorylation by RSK used 
overexpression to show that both isoforms were capable of modifying this protein, 
however it remains to be determined which RSK is a physiological kinase for BAD.  
 Another pro-apoptotic protein that has been found to be negatively regulated by 
RSK is the protein Bcl-2 interacting mediator of cell death (Bim) (Dehan et al., 2009). 
Endogenous RSK1 was demonstrated to interact with and phosphorylate Bim, and 
inhibition of RSK as well as silencing of RSK1/2 prevented this phosphorylation. The 
function of this post-translational modification was to induce proteasomal degradation of 
Bim, thereby decreasing the cellular levels of this strong inducer of apoptosis. RSK was 
also shown to phosphorylate and thereby inactivate the pro-apoptotic death associated 
protein kinase (DAPK) (Anjum et al., 2005). Similarily to BAD, in this study both RSK1 
and RSK2 were shown to increase phosphorylation of DAPK when over-expressed, and 
silencing of RSK1/2 decreased this modification of DAPK. Finally, another mechanism 
through which RSK could inhibit apoptosis is through phosphorylation of Apaf-1. This 
modification was shown to facilitate Apaf-1 binding to 14-3-3 and decrease Apaf-1 
interactions with cytochrome c, which prevented apoptosome formation (Kim et al., 
2012). As in previous cases, the study used consitutively active RSK1 and RSK2 
overexpression, as well as RSK1/2 double silencing in the experiments, therefore it 
47 
 
remains unknown which isoform is physiologically responsible for Apaf-1 
phosphorylation.  
 In summary, RSK has been shown to phosphorylate and thereby regulate 
several proteins involved in the induction of apoptosis. The function of RSK in this 
context is to inhibit cell death. While both RSK1 and RSk2 were suggested to mediate 
the anti-apoptotic signals downstream of ERK1/2, the relative contributions of these two 
isoforms remain unknown. Furthermore, the role of RSK3/4 in the context of apoptosis 
remains almost completely unexplored. 
1.5.9. RSK and cell migration and adhesion 
 The ability of RSK to regulate cell motility was first proposed based on the 
observation that RSK could phosphorylate the actin-cytoskeleton associated protein 
filamin-A (Woo et al., 2004). RSK-mediated phosphorylation of filamin A resulted in an 
increase in membrane ruffling, which is a hallmark of a migratory cell phenotype 
(Vadlamudi et al., 2002b, Vadlamudi et al., 2002a). Silencing of RSK1 and RSK2 
individually had similar effects on filamin A phosphorylation, suggesting that both 
isoforms are involved. Another piece of evidence showing the ability of RSK to promote 
cell motility comes from the observations that RSK1 could phosphorylate Src homology-
3 domain containing protein-2 (SH3P2) (Tanimura et al., 2011). This protein was 
identified through a cDNA overexpression screen of novel regulators of motility and was 
proposed to act as a negative regulator of motility. RSK1 was shown to phosphorylate 
and thereby inactivate SH3P2, leading to an increase in migration and invasion of 
multiple cancer cell lines. Silencing of RSK1 alone was sufficient to reduce cell invasion, 
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while silencing of RSK2 had no effect on invasiveness in these studies, suggesting a 
predominant role of RSK1 in stimulating motility. The mechanism of SH3P2 action as a 
suppressor of motility was not elucidated in this report.  
 In addition to phosphorylating and regulating specific regulators of motility, RSK 
has also been found to control pro-migratory gene expression programs. The role of 
RSK as an important regulator of cell motility was further supported by the study 
mentioned in section 1.5.6. In this study both RSK1 and RSK2 were found to promote a 
broad pro-migratory gene expression program in both normal and transformed cells. 
This ability of RSK to promote pro-migratory phenotype was found in a wide range of 
cell types, including kidney, colon, breast, prostate and thyroid (Doehn et al., 2009). The 
gene program triggered by RSK encompassed a variety of targets, including integrins 
and matrix remodeling enzymes, and was at least in part mediated through the FRA1 
transcription factor. Interestingly, FRA1 has independently been shown to be an 
important regulator of motility in multiple cell types (Kustikova et al., 1998, Sayan et al., 
2012).  
 Another high-throughput study screened genes whose knockdown promoted 
motility and invasiveness in non-transformed breast epithelial cell line MCF10A. As a 
result of this screen, 31 genes were identified. Interestingly, knocking down each of 
these genes was associated with an activation of (Smolen et al., 2010). The pro-
migratory phenotype induced by knocking down each of the 31 genes could be blocked 
by small molecule inhibition of RSK and by silencing RSK1. Interestingly, loss of RSK1 
was not as effective in blocking cell migration as pharmacological inhibition, suggesting 
that other isoforms of RSK can also be involved in regulating the pro-migratory 
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phenotype of these cells. These observations are consistent with the findings that RSK2 
can also promote invasiveness of multiple cell types (Doehn et al., 2009). 
 While the majority of studies have suggested both RSK1 and RSK2 to promote 
migration and invasion, a high-throughput siRNA screen done in non-small cell lung 
cancer (NSCLC) cell line A549 identified RSK1 as a negative regulator of invasion, 
while RSK2 and RSK4 promoted motility in these cells (Lara et al., 2011). These 
observations suggest that the function of RSK in promoting motility could depend on cell 
type. Finally, this study highlighted the necessity to further investigate the functions of 
RSK3 and RSK4 in the context of migration. 
1.5.10. RSK and cellular energy homeostasis 
 In addition to cellular functions summarized above, the phenotypes observed in 
RSK2 knockout mice have suggested that RSK family of kinases could also play a role 
in regulating energy homeostasis. Indeed, some of the proteins described in the 
sections above are known to also be involved in these cellular processes. For example, 
GSK3 has been extensively studied in the context of glucose and glycogen 
metabolism (McCubrey et al., 2014). mTOR is known to be involved in amino acid 
sensing (Jewell and Guan, 2013, Jewell et al., 2013), as well as regulation of glycolysis 
through its role as a modulator of the hypoxia inducible factor-1 alpha (HIF-1) (Sun et 
al., 2011, Duvel et al., 2010). Finally, RSK is known to regulate Bad, which resides in 
the mitochondrial membrane (Shimamura et al., 2000, Bonni et al., 1999). In addition to 
promoting apoptosis, Bad has been suggested to regulate mitochondrial energy 
production through various mechanisms (Danial, 2008, Gimenez-Cassina and Danial, 
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2015). Therefore, RSK could regulate cellular energy metabolism through its 
interactions with many proteins with known functions in energy homeostasis (fig. 3C). 
 In addition to the substrates mentioned above, RSK1 has been proposed to 
regulate the liver kinase-B1 (Lkb1), also known as serine/threonine kinase-11 (STK11), 
by phosphorylating it on residue Ser341 (Sapkota et al., 2001). Lkb1 phosphorylates 
AMPK, which is a master sensor of the cellular energetic state (Shackelford and Shaw, 
2009). Therefore, Lkb1 participates in regulating a broad range of cellular processes 
involved in nutrient signaling. Interestingly, while the study mentioned above showed 
that in addition to RSK1, the same site on Lkb1 was phosphorylated by PKA, the 
individual kinases mediated the phosphorylation of Lkb1 in response to different stimuli. 
The activator of adenylate cyclase, forskolin, induced Lkb1 phosphorylation through 
PKA, but not through RSK. In EGF-stimulated cells RSK was the only kinase mediating 
the phosphorylation of Lkb1, as inhibition of mTOR or PKA, or knock-down of MSK1/2, 
did not affect the ability of this growth factor to induce Lkb1 phosphorylation. However, 
the study did not evaluate whether phosphorylation of Lkb1 was associated with any 
changes in cellular metabolism. The only identified function of this phosphorylation was 
to prevent the anti-proliferative effect of Lkb1 overexpression in a cancer cell line that 
does not normally express Lkb1. Other studies have shown that phosphorylation of 
Lkb1 on Ser341 does not alter its ability to associate with the plasma membrane or 
phosphorylate AMPK (Fogarty and Hardie, 2009, Houde et al., 2014). Therefore, it 
remains unknown whether RSK1-mediated phosphorylation of Lkb1 results in changes 
in cellular metabolism. 
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 RSK1 has been found to phosphorylate the protein Akt substrate of 160 kDa 
(AS160) (Geraghty et al., 2007). AS160 is Rab GTPase-activating protein (RabGAP) 
whose role is to inhibit membrane localization of the glucose transporter GLUT4 (Kane 
et al., 2002). Upon stimulation with various growth factors, including insulin and EGF, 
the GAP activity of AS160 is reduced, leading to GLUT4 translocation to the plasma 
membrane and a subsequent increase in cellular glucose uptake. Phosphorylation of 
AS160 by RSK1 was shown to promote the association of AS160 with the cytoplasmic 
14-3-3 protein, which interferes with AS160 GAP activity. Therefore, RSK1 was shown 
to be the kinase mediating the growth factor-induced signal leading to inactivation of 
AS160. As a result, RSK1 was shown to potentiate glucose uptake in cells stimulated 
with insulin and EGF. It is important to note, however, that many cell types express 
multiple glucose transporters, and of those GLUT1-3 are constitutively localized to the 
plasma membrane. Therefore, insulin-stimulated GLUT4 translocation to the plasma 
membrane is not the only mechanism by which cells regulate glucose uptake. The role 
of RSK1 in changing the glucose uptake into cells will therefore depend on the activities 
of insulin-independent glucose transporters. 
 Taken all these observations together, both RSK1 and RSK2 were implicated in 
regulation of cellular energy and nutrient metabolism in a variety of cell types (fig. 3C). 
However, the exact involvement of RSK in promoting energy production in cells remains 
poorly understood. It is also unclear whether the proposed mechanisms of RSK 
regulation of cellular energy production and nutrient utilization are unique to the 
investigated cell types, or can be extended to other biological contexts. Given the 
increasing numbers of reported RSK phosphorylation targets with known functions in 
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cellular energy homeostasis, and the expanding literature implicating known RSK-
dependent pathways in this new context, futher studies of RSK involvement in the 
cellular energy production are warranted.  
1.5.11. RSK substrates in the heart and brain 
  RSK has been extensively studied in the context of cardiac and neuronal 
biology. Interestingly, whereas in a majority of studies RSK mediates pro-survival and 
pro-proliferation signals, in heart and neuronal injury RSK activity is associated with cell 
death. RSK activity could promote cell death in these tissues through several potential 
mechanisms. For example, RSK was identified as a potential regulator of the sodium-
proton exchanger NHE1 (Takahashi et al., 1999, Cuello et al., 2007, Roberts et al., 
2005). NHE1 was shown to be activated upon cardiac and neuronal ischemia 
reperfusion injury, which leads to cellular sodium accumulation (Karmazyn, 1988, 
Kintner et al., 2004, Luo et al., 2005). Increased sodium triggers calcium influx into the 
cell, which is a signal for apoptosis. Phosphorylation of NHE1 by RSK was also shown 
to activate this channel, which contributes to the cellular ion imbalance following 
ischemia-reperfusion (Takahashi et al., 1999). Blocking RSK activity following ischemia-
reperfusion increased survival of cardiomyocytes and neurons, suggesting a protective 
potential of RSK inhibition following myocardial and cerebral ischemic insult (Maekawa 
et al., 2006, Manhas et al., 2010). It remains unclear whether the function of RSK in 
regulating cellular pH and ion homeostasis is limited to cardiomyocytes and neurons, 
and which RSK isoform is responsible for these effects. It is important to note, however, 
that NHE1 is ubiquitously expressed and seems to be a major channel for 
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sodium/proton exchange in multiple cell types (Fuster and Alexander, 2014). Therefore, 
the role of RSK in regulating cellular pH could extend to other cell types.  
 In addition to NHE1, the kinase ERK5 was proposed to be a target of RSK in the 
heart (Le et al., 2012). The study was conducted in the context of a diabetic mouse 
model. The authors of the study show that following myocardial infarction RSK binds to 
and phosphorylates ERK5. This interaction prevents ERK5 from binding to the ubiquitin 
ligase CHIP. As a result, the ubiquitin ligase activity of CHIP is decreased. The function 
of CHIP is to mediate the proteosomal degradation of the inducible cAMP repressor 
(ICER). Following myocardial infarction ICER acts to increase expression of pro-
apoptotic proteins. As a result, RSK interaction with ERK5 leads to the stabilization of 
ICER, and an increase in apoptosis. The ERK5-RSK interaction and phosphorylation of 
NHE1 by RSK together provide evidence for RSK involvement in ischemia-reperfusion 
injury. In this context, RSK activity increases apoptosis of cardiac tissue following 
ischemic insult. Therefore, RSK inhibition has been proposed to constitute a potential 
therapeutic strategy to limit tissue damage following cardiac infarction (Avkiran et al., 
2008). 
 
1.5.12. RSK in the context of cancer 
 As described above, RSK has been shown to mediate a variety of pro-growth 
and pro-survival signals downstream of the Ras-MAPK pathway. Therefore, there has 
been a lot of interest in studying the role of RSK in promoting tumorigenesis. Ectopic 
expression of RSK2 was shown to increase proliferation and anchorage-independent 
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transformation in epidermal growth factor (EGF) and phorbol ester (TPA) stimulated 
mouse embryonic fibroblasts (Cho et al., 2007). RSK1 and RSK2 have also been shown 
to be overexpressed in a portion of breast and prostate cancer patients (Smith et al., 
2005, Clark et al., 2005). RSK2 is thought to mediate the FGFR3-dependent 
transformation of haematopoietic cells (Kang et al., 2007b, Kang et al., 2007a). RSK 
inhibition has been recently shown to block proliferation and induce apoptosis in both 
multiple myeloma cell lines and patient-derived myeloma cell cultures (Shimura et al., 
2012). Another study found that FGFR1-transformed mammary epithelial cells rely on 
RSK activity for survival and anchorage-independent growth (Xian et al., 2009). Knock-
down of RSK1 and RSK2 together was shown to reduce tumor growth in BRAF-mutant 
melanomas (Romeo et al., 2013). RSK2 knock-down inhibited osteosarcoma 
development, and this effect was mediated through the regulation of ATF4 transcription 
factor (David et al., 2005). Taken these results together, RSK has been shown to 
promote survival and proliferation in multiple types of cancer. 
 In a phosphoproteomic study designed to identify novel substrates in melanomas 
RSK has been recently found to phosphorylate the putative tumor suppressor 
programmed cell death protein-4 (PDCD4) (Galan et al., 2014). Phosphorylation of 
PDCD4 promoted its binding to 14-3-3 protein, leading to the proteasomal degradation 
of PDCD4. The role of PDCD4 as a tumor suppressor is not limited to melanoma, as 
this protein has also been implicated in inhibiting tumorigenesis in multiple other tumor 
types, including lung, colon and breast cancer and glioma (Lankat-Buttgereit and Goke, 
2009). Therefore, RSK could regulate tumorigenesis through PDCD4 in other tumor 
types as well. In addition, in the cells of hematopoietic origin, but not in the mouse 
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embryonic fibroblasts, PDCD4 has been reported to be a substrate of RSK1 
(Kroczynska et al., 2012). The analysis of the putative RSK phosphorylation site done 
by the Galan et al revealed a similarity between this motif and the reported 14-3-3 
binding peptide (Gardino and Yaffe, 2011). Therefore, the authors used a separate 
screen to identify proteins binding to 14-3-3. Interestingly, out of 274 potential 14-3-3-
interacting partners, 54 were also identified as potential RSK phosphorylation targets 
(Galan et al., 2014). These observations suggested that phosphorylation-induced 
binding of the target protein to 14-3-3 could be a common mechanism of regulation of 
this protein activity by RSK. Importantly, this 14-3-3 mediated modulation of RSK 
targets has been demonstrated before, in such proteins as AS160, p27kip and Bad 
(Geraghty et al., 2007, Fujita et al., 2003, Bonni et al., 1999).  
 RSK has been shown to regulate an important transcription factor in breast 
cancer, Y-box protein-1 (YB-1) (Stratford et al., 2008). Phosphorylation of YB-1 by 
RSK1/2 stimulates its nuclear localization and subsequent transcriptional activity, which 
drives expression of a variety of genes involved in transformation, including EGFR, 
HER2 and c-Myc (Sakura et al., 1988, Kolluri and Kinniburgh, 1991, Stratford et al., 
2007). Therefore, blocking RSK1/2 activity could reduce breast cancer proliferation and 
survival through the inhibition of YB-1 activity. This observation was confirmed in a 
subsequent study, highlighting the role of RSK in tumor maintenance and proliferation in 
aggressive breast cancer (Stratford et al., 2012). Although these studies were 
performed in the context of an aggressive subtype of breast cancer, YB-1 has also been 
implicated in the transformation in other tumor types, including prostate, lung and colon 
cancers, as well as in osteocarcinomas, sarcomas and glioblastomas (Wu et al., 2006, 
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Gimenez-Bonafe et al., 2004, Oda et al., 1998, Gu et al., 2001, Shibahara et al., 2001, 
Shibao et al., 1999, Oda et al., 2003, Faury et al., 2007). Therefore, regulation of YB-1 
by RSK could prove relevant in multiple tumor types beyond breast cancer.  
 Consistent with multiple studies implicating RSK in regulation of cell motility, 
RSK2 was found to promote metastasis in head and neck squamous cell carcinoma 
(HNSCC) (Kang et al., 2010). In patients with HNSCC high expression of RSK2 
correlated with increased metastasis, and RSK2 knock-down in a mouse xenograft of 
human HNSCC reduced metastatic potential. Interestingly, RSK1 did not play a role in 
HNSCC metastasis. These results provide further evidence for isoform specific actions 
of RSK1 and RSK2 in regulating cell motility and invasiveness in various cell types.  
 Whereas RSK1 and RSK2 have been shown to mediate pro-survival and pro-
proliferation signaling in the context of multiple cancers, non-transformed cells appear to 
not rely on RSK signaling for their survival. For example, the proliferation of the breast 
cancer cell line MCF7 is reduced by RSK inhibition, while the non-transformed breast 
epithelial cell line MCF10A is not sensitive to RSK inhibition (Clark et al., 2005), 
chapters 3-6 and 8). In addition, RSK2 is dispensable for normal haematopoiesis (Lin et 
al., 2008), but essential for survival and proliferation in a subtype of myeloid leukemias 
(Elf et al., 2011). Therefore, targeting RSK1 and RSK2 in cancer therapy could 
potentially lead to less side-effects than therapies affecting normal cell function. 
 The functions of RSK3 and RSK4 in the context of cancer are much less 
understood. Recent studies have suggested that RSK3 and RSK4 may act as putative 
tumor suppressors. RSK3 was found to be down-regulated in ovarian cancer, and re-
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expression of RSK3 in ovarian cancer cell lines was shown to induce cell cycle arrest 
and apoptosis (Bignone et al., 2007). However, the mechanism of tumor suppression 
induced by RSK3 in ovarian cancer remains unknown. RSK4 expression was found to 
be reduced in colon and renal tumors (Richards et al., 2001). In addition, low expression 
of RSK4 in colorectal tumors was found to be correlated with poor outcome (Cai et al., 
2014). Overexpression of RSK4 in breast cancer cells was shown to induce growth 
arrest and apoptosis (Thakur et al., 2008). As with RSK3, the mechanism of tumors 
suppression by RSK4 remains elusive, but was suggested to involve p53-mediated 
growth arrest and induction of senescence (Lopez-Vicente et al., 2009). In contrast to 
these suggested functions of RSK3 and RSK4 as putative tumor suppressors, these two 
kinases have also been recently identified as potential promoters of resistance to PI3K 
inhibitors in breast cancer (Serra et al., 2013). These findings highlight the importance 
of further studies of RSK3/4 functions.  
 In order to better understand the biology of RSK, as well as explore the 
possibility of targeting this family of kinases in therapy, there has been an ongoing effort 
to identify novel small molecule inhibitors. The following section will summarize the 
advances in this field. 
1.6. RSK inhibitors 
 As discussed in section 1.5., RSK proteins consist of two fully functional kinase 
domains. Therefore, each molecule of RSK possesses two ATP-binding grooves that 
could potentially be targeted by kinase inhibitors. The inhibitors of both the NTKD and 
CTKD of RSK have been characterized.  
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1.6.1. Inhibitors of the N-terminal kinase domain 
1.6.1.1. SL0101  
 The first small-molecule inhibitor of RSK was discovered by our laboratory by 
screening the collection of botanical extracts of plants of rare genera (Clark et al., 
2005). The screen was performed in vitro against the full-length active RSK2 kinase. 
The read-out of the screen was the ability to inhibit phosphorylation of a peptide 
containing the estrogen receptor-alpha (ER) Ser167 sequence, which is a 
physiological target of RSK (Joel et al., 1998).  
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Figure 4. Structural diversity of the inhibitors of RSK NTKD 
A) Chemical structure of the RSK inhibitor SL0101. SL0101 is a glycosylated flavonoid, 
in which the rhamnose sugar residue is acetylated at two positions. 
B) Chemical structure of the RSK inhibitor BI-D1870. 
C) Chemical structure of the RSK inhibitor BIX 02565. BIX 02565 was developed in a 
series of indole inhibitors of RSK. 
D) Chemical structure of the RSK inhibitor compound 15. Compound 15 was generated 
as a derivative of BIX 02565 with decreased ability to interfere with adrenergic 
receptors. 
E) Chemical structure of the RSK inhibitor LJH685. 
F) Chemical structure of the RSK inhibitor LJI308. Compounds LJH685 and LJI308 
belong to the same family of compounds and display very similar biological and 
chemical properties. 
G) Summary table of the in vitro and cell-based efficacies of the RSK inhibitors.  
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Remarkably, out of ~10,000 extractstested only one showed the ability to inhibit RSK2 
in vitro. This extract was derived from Forsteronia refracta, a tropical forest plant with no 
known medicinal properties. On further investigation the extract was found to contain 
three compounds of very similar chemical structure that showed efficacy against RSK2 
in vitro (Xu et al., 2006). The compounds represented the same chemical backbone, 
consisting of a kaempferol flavonoid part linked via the glycosydic bond to an unusual 
deoxyhexose sugar, L-rhamnose. The difference between the three compounds lay in 
the acetylation state of the hydroxyl groups of the sugar moiety. The most active of the 
three compounds, possessing acetate residues in positions 3” and 4” of rhamnose, 
showed the in vitro IC50 of 89 nM, and was subsequently chosen for further studies. 
This compound was called SL0101 (fig. 4A). 
 SL0101 has been shown to inhibit RSK1 and RSK2, with a trend towards a 
higher efficacy against RSK1 (Bain et al., 2007, Smith et al., 2005). However, the 
efficacy of SL0101 against RSK3 and RSK4 has not been investigated. We have 
recently found that, unexpectedly, this inhibitor does not affect the in vitro activity of 
RSK3 and RSK4 (chapter 2). This result was unanticipated as there is no clear 
indication within the amino acid sequences of RSK isoforms that would suggest the 
differential ability of SL0101 to bind to and inhibit these kinases. SL0101 has been 
consistently found to be remarkably specific for RSK (Bain et al., 2007, Doehn et al., 
2009). Out of ~80 kinases tested, the only off-target kinases significantly inhibited by 
SL0101 were Aurora B, PIM1 and PIM3 (Bain et al., 2007). Importantly, SL0101 did not 
inhibit the most closely related kinases to RSK, MSK1/2 and p70S6K (Smith et al., 
2005).  
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 The original report on SL0101 properties described the inhibitor to act as an ATP 
competitor (Smith et al., 2005). The ATP-binding site of RSK NTKD represents a typical 
sequence found in all members of the AGC kinase superfamily, which suggests that if 
SL0101 utilized typical features of this binding site, it would also inhibit other kinases as 
well, as in the case of relatively non-selective kinase inhibitors staurosporin and H89 
(Tamaoki et al., 1986, Ikuta et al., 2007, Davies et al., 2000, Bain et al., 2003, Lochner 
and Moolman, 2006). In contrast to these two non-specific kinase inhibitors, however, 
SL0101 is remarkably specific for RSK1/2. Therefore, a more detailed study of SL0101 
interaction with RSK NTKD was warranted. The crystal structure of RSK NTKD bound 
to SL0101 showed the inhibitor bound at a site partially overlapping with the ATP-
binding groove between the two lobes of the kinase domain (Utepbergenov et al., 
2012). Surprisingly, however, the binding of the inhibitor was associated with a dramatic 
rearrangement of the entire N-lobe of the kinase. Due to the steric hindrances between 
individual secondary structures of RSK, this structural rearrangement was very unlikely 
to occur via a simple rotation of one lobe with respect to the rest of the kinase domain. 
Instead, it would require a partial unfolding and re-folding of the kinase domain. 
Therefore, the analysis of the crystal structure of RSK2 NTKD bound to SL0101 strongly 
suggests that this compound is an allosteric inhibitor of RSK. We have explored this 
possibility by performing an enzyme inhibition kinetics study and provide evidence in 
support of the function of SL0101 as an allosteric inhibitor of RSK (chapter 2). Allosteric 
regulation of RSK activity by SL0101 could explain the remarkable selectivity of this 
inhibitor for RSK and highlights the potential for further development of this small 
molecule. We have published a number of studies exploring the properties of SL0101 
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pharmacophore and demonstrate a promising platform amenable to chemical 
modifications (chapters 3-6).  
 The initial study of the effects of SL0101 on proliferation of breast cancer and 
normal breast epithelial cell lines revealed an ability of this compound to specifically 
inhibit the proliferation of cancer cells, without affecting the non-transformed cells (Smith 
et al., 2005). This differential ability to inhibit transformed breast epithelial cells was 
found to correlate well with the selectivity of small molecules towards RSK, highlighting 
the role of these kinases in promoting growth and survival of breast cancer cells (Smith 
et al., 2005; chapters 3-6). The concentrations of SL0101 required to elicit growth 
inhibition and decreases in downstream markers of RSK activity in cell lines are several-
fold higher than the IC50 of SL0101 against RSK2 in vitro. These observations could 
suggest a limited permeability of the inhibitor. In addition, other proteins present in the 
cells could affect the ability of the kinase to bind to SL0101, effectively increasing the 
IC50 value in cell-based assays. SL0101 could be decomposed in the cell-based 
assays, decreasing the apparent concentration of the inhibitor. Importantly, removal of 
two acetates in the sugar moiety of the inhibitor drastically increases the in vitro IC50 of 
SL0101, but this compound can still inhibit RSK in vitro (Smith et al., 2005). Another 
potential product of decomposition of SL0101, kaempferol, is also known to be a 
relatively weak inhibitor of multiple kinases (Calderon-Montano et al., 2011). Consistent 
with the possibility that SL0101 can be decomposed by cellular enzymes, SL0101 has a 
very short half-life in vivo (chapter 3). The sub-optimal properties of SL0101 in biological 
systems have led to limited applicability of this compound in studies of RSK functions. 
However, we have shown that SL0101 is amenable to modifications that can improve 
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on these properties (chapters 3-5 and appendix). Therefore, we continue to develop 
analogs of SL0101 with improved cell-based and in vivo properties. 
1.6.1.2. BI-D1870 
 A distinct pharmacophore that was shown to inhibit RSK was identified through a 
kinase selectivity screen of the derivatives of the Src family inhibitor PD180970 (Kraker 
et al., 2000). The compound was named BI-D1870 (fig. 4B) (Sapkota et al., 2007). 
Interestingly, various modifications to the initial Src inhibitor have produced selective 
inhibitors of diverse kinases (Zhang et al., 2009), including PD173074, an inhibitor of 
FGFR1, FGFR3 and FGFR4 (Mohammadi et al., 1998), and BI-2356, an inhibitor of 
Polo-like kinases (Lenart et al., 2007). The initial study of BI-D1870 demonstrated the 
compound to inhibit all four isoforms of RSK in the low nanomolar range, from RSK4 
IC50 of 15 nM to RSK1 IC50 of 30 nM at 100 M ATP. The ability of BI-D1870 to inhibit 
RSK1/2 in vitro depended on the ATP concentration, which the authors of the study 
used as the evidence of this compound being an ATP-competitive inhibitor, however 
this possibility was not formally tested. It is possible that inhibition involves both ATP-
competitive and non-competitive modes. To fully understand how the inhibitor binds to 
its target, enzyme kinetic analysis in the presence of various ATP and inhibitor 
concentrations should be performed (Cornish-Bowden, 1974, Dixon, 1953). When used 
in the HEK 293 cell line, BI-D1870 could inhibit RSK-mediated activation of GSK with an 
IC50 of 1 M, demonstrating that this compound is a very potent RSK inhibitor both 
in vitro and in cell-based assays. 
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 Although being relatively selective inhibitor of RSK1-4, BI-D1870 was shown to 
inhibit a number of off-target kinases (Sapkota et al., 2007, Bain et al., 2007). These off-
target kinases include PLK1, Aurora B, DYRK1a, CDK2-A, Lck, CK1, GSK3MELK, 
PIM3 and MST2. Importantly, the efficacies of BI-D1870 against RSK2 and off-target 
kinases PLK1 and Aurora B are very similar (Aronchik et al., 2014). In addition to in vitro 
kinase inhibition, BI-D1870 selectivity was also tested in cell-based assays using 
nucleotide acyl phosphate labeling (Edgar et al., 2014). In this method cells are 
incubated with the ATP analogue modified with a biotin group. This analogue will bind to 
the ATP sites of kinases and use a conserved Lys residue within this site to covalently 
attach the biotin tag to the kinase (Patricelli et al., 2007). The inhibitor will compete with 
the ATP-biotin label and decrease tagging of the kinase it binds to. As a result, 
comparing abundances of biotin-labeled kinases from cells treated with and without the 
inhibitor allows identification of those kinases that the inhibitor binds to (Patricelli et al., 
2007). When tested in bone marrow-derived dendritic cells (BMDC), BI-D1870 
significantly inhibited IRAK4, Slk, STK10 and STK4 kinases, in addition to RSK1-3 and 
PLK1 (Edgar et al., 2014). These kinases were not included in the in vitro inhibitor 
selectivity screens performed before. Interestingly, Slk, STK10 and STK4 are all 
members of the STE-20 like kinase family (Manning et al., 2002). Therefore, BI-D1870 
exhibits a considerable amount of off-target effects, and the results using this inhibitor 
should be interpreted with caution.  
 Thanks to a very high potency in vitro and in cell-based assays, BI-D1870 has 
been extensively used as a tool compound in the studies of RSK functions. For 
example, BI-D1870 was used in a study of the role of RSK1 as a negative regulator of 
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IRS-1 in myocytes and hepatocytes (Smadja-Lamere et al., 2013). This compound was 
also employed in a study investigating the cross-talk between RAS-MAPK and mTOR 
signaling induced by the mitogen PMA in multiple cell lines (Fonseca et al., 2011). BI-
D1870 was also used to validate the results of an RNAi screen that identified RSK as a 
critical regulator of epithelial cell migration and invasiveness (Smolen et al., 2010). 
Finally, BI-D1870 was used in a phosphoproteomics study to identify novel downstream 
targets of RSK in the context of melanoma (Galan et al., 2014). To our knowledge, 
however, BI-D1870 has never been used in animal studies, and its pharmacokinetic 
properties have never been assessed. 
1.6.1.3. BIX 02565 and other indole inhibitors 
 A third class of selective RSK inhibitors was identified through a high-throughput 
screen against RSK2 NTKD and is based on an indole pharmacophore (fig. 4C) (Boyer 
et al., 2012). Interestingly, some indole derivatives have previously been identified as 
inhibitors of MAPKAP-K2 (Goldberg et al., 2008). The design and testing of indole 
inhibitors or RSK described in the original study was assisted by the proprietary X-ray 
crystallography structures of RSK2 NTKD and by homology modeling to the structures 
of RSK1 and RSK3. Selected indole inhibitors were then tested for selectivity in vitro 
against a panel of 20 kinases and, in some cases, 227 kinases, based on the highest 
degree of cross-reactivity of the early analogs in the indole series (Kirrane et al., 2012). 
The study identified compound BIX 02565 that had very high affinity for RSK (IC50 of 1 
nM) and maintained relatively high selectivity, with in vitro IC50 below 1 M found in 10 
other kinases: LRRK2, PRKD1, PRKD2, PRKD3, RET, CLK1, CLK2, FGFR2, PDGFR 
and FLT3. Even though these ten kinases were also inhibited by BIX 02565 with IC50 
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value below 1 M, the difference in potency of the compound against RSK and off-
target kinases was between 16- and 1000-fold.  
 The properties of BIX 02565 in cell-based assays have not been very well 
investigated. The initial report only tested its ability to inhibit CREB phosphorylation, as 
the readout of RSK inhibition in cells. The IC50 of BIX 02565 was determined to be 20 
nM in this cell-based assay (Kirrane et al., 2012). Subsequently, BIX 02565 selectivity in 
cells was assessed in the study using nucleotide phosphate acyl labeling. This study 
compared cell-based selectivity of BIX 02565 in BMDC cells to that of BI-D1870. BIX 
02565 demonstrated almost complete specificity for RSK1-3 in the BMDC cells, IRAK4 
being the only other protein significantly affected by the inhibitor treatment (Edgar et al., 
2014). Additionally, BIX 02565 was shown to significantly reduce phosphorylation of 
RSK downstream targets BAD and filamin A in BMDC cells at concentrations above 1 
M. Therefore, BIX 02565 appears to be a potent and selective inhibitor of RSK in cell-
based assays. The described study is the only example in the literature of the use of 
BIX 02656 in cell-based assays. 
 BIX 02565 was developed as an indirect way of targeting the NHE1 activation in 
the treatment of cardiac ischemia-reperfusion injury (Boyer et al., 2012). Therefore, it 
was tested in vivo to assess potential cardiotoxicity (Fryer et al., 2012). This study was 
the only instance of the use of BIX 02565 in vivo. Interestingly, the inhibitor was found to 
induce a rapid and strong drop in both mean arterial pressure and heart rate when 
injected intravenously into rats. Of all the other RSK inhibitors, only SL0101 and fmk, 
the inhibitor of the C-terminal kinase domain of RSK, were also used in vivo (chapter 
3;(Li et al., 2013). Acute cardiotoxicity was not observed upon RSK inhibition in either of 
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these two studies. Therefore, BIX 02565-induced decrease in heart function was due to 
its off-target effects. BIX 02565 was found to inhibit multiple - and - adrenergic 
receptors as well as the imidazoline I2 receptor, with IC50 values between 0.052 and 
1.820 M. The authors of the study concluded that BIX 02565 exhibits intolerable 
cardiotoxicity in vivo that is independent of its kinase selectivity. Subsequently, 31 novel 
analogues of BIX 02565 were screened for their ability to inhibit RSK2 in vitro and in a 
cell-based assay, without significantly inhibiting 1A- and 2A- adrenergic receptor 
ligand binding in vitro (Fryer et al., 2012). As a result, an extremely potent inhibitor of 
RSK2, compound 15, was identified (fig. 4D). The RSK2 in vitro IC50 of compound 15 is 
0.2 nM, and the cell-based IC50 is 0.32 nM. Interestingly, among all 31 analogs, there 
was no correlation between RSK2 efficacy and the ability to inhibit adrenergic receptors, 
suggesting that distinct parts of the pharmacophore are responsible for affinities 
towards RSK and adrenergic receptors. The selectivity of compound 15 towards other 
kinases was not assessed. Since initial characterization, the use of compound 15 has 
not been reported in any other studies and its applicability for cell-based and in vivo 
studies of RSK remain to be determined. 
1.6.1.4. LJH685 and LJI308 
 A final class of RSK NTKD inhibitors has very recently been characterized 
(Aronchik et al., 2014). The series is based on the difluorophenyl pyridine 
pharmacophore, with the two representatives of this series being LJH685 and LJI308 
(fig. 4E-F). The two inhibitors have the in vitro IC50 of 4-13 nM against RSK1-3. These 
two compounds were not tested in an in vitro kinase assay against RSK4. However, 
KinomeScan kinase binding assay showed that LJH685 and LJI308 bound to all 4 
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isoforms of RSK. When interrogated against a panel of 442 kinases, in addition to RSK 
compounds LJH685 and LJI308 only bound to MEK4, S6K1 and HIP1-3. However, this 
assay was performed at 10 M inhibitor. When tested in vitro against S6K1, LJI308 
displayed IC50 of 0.8 M, which is 200-fold higher than that of RSK2. In addition, MEK4 
was inhibited by less than 50% at 10 M LJI308 and HIP1 activity was reduced by less 
than 50% by 1 M LJI308. Cell-based assays in COS-7 cell line showed that both 
LJH685 and LCI308 reduced phosphorylation of the downstream targets of RSK, YB-1 
and BAD, with the IC50 of 0.2-0.3 M. Therefore, both LJH685 and LJI308 appear to be 
very potent and selective inhibitors of all four RSK isoforms in vitro and in cell-based 
assays. When analyzed by X-ray crystallography, RSK2 NTKD (aa 53-359) bound to 
LJH685 showed an unusual conformation with Phe212 residue from the DFG motif bent 
outwards and away from the ATP-binding cleft, reminiscent of the DFG-out 
conformation of a kinase. The authors of this study hypothesized that this unusual 
conformation was responsible for the selectivity of LJH685. 
  The authors of the study describing the two difluorophenyl pyridine inhibitors 
have made a number of very interesting observations concerning the anti-proliferative 
effects of RSK inhibition. Multiple cancer cell lines with activating mutations in RAS-
MAPK pathway were relatively resistant to RSK inhibitors LJH685 and LJI308 in a 2D 
monolayer culture, despite robust decrease in the markers of RSK activity (Aronchik et 
al., 2014). However, the same cells grown in soft agar became extremely sensitive to 
RSK inhibition. For example, proliferation of aggressive breast cancer cell line MDA-
MB-231 was inhibited by 50% at 48 M compound when grown in attachment, but the 
IC50 of the compound dropped to 0.73 M in soft agar. Similarly, the IC50 of LJH685 in 
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the lung cancer cell line NCI-H358 was reduced from 66 M to 0.79 M by changing the 
growth conditions from attachment to soft agar. Therefore, cancer cell lines with 
activating mutations in the RAS-MAPK pathway rely very heavily on RSK activity for the 
survival and proliferation in 3D cultures, whereas RSK signaling is dispensable for the 
survival of these cell lines in monolayer. These results are consistent with the 
observations that upon transforming with FGFR1, the non-transformed breast epithelial 
cell line MCF10A, becomes sensitive to RSK inhibition for survival and proliferation 
(Xian et al., 2009). The study of LJH685 and LJI308 highlighted the unique role of RSK 
in regulating anchorage-independent growth of cancer cells that has not previously 
been appreciated. 
1.6.1.5. Summary of the NTKD-specific RSK inhibitors 
 Several diverse classes of RSK inhibitors have been described to date. The 
inhibitors vary in their in vitro affinity and cell-based efficacy against RSK isoforms 
(fig. 4G). Compounds BI-D1870 and SL0101 have been most extensively used in cell-
based studies of RSK signaling. Although BI-D1870 is a more potent inhibitor of RSK2 
in vitro, it is less selective for RSK than SL0101. On the other hand, SL0101 appears to 
be less potent in cell-based assays than BI-D1870, presumably due to limited cell 
permeability of the compound. SL0101 is very unstable in vivo, and therefore it was 
never used in animal studies, beyond the initial pharmacokinetic characterization 
(chapter 3). There are no reports of the use of BI-D1870 in vivo, but in the case of this 
inhibitor cell-based and in vivo stability have never been reported. Of all the other RSK 
inhibitors, only the indole RSK inhibitors were tested in vivo, and of those BIX 02565 
caused acute cardiotoxicity. BIX 02565 was used in one more study, whereas all the 
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other RSK NTKD inhibitors were never used beyond the studies describing initial report 
of discovery. 
 Of all the RSK NTKD inhibitors described to date, the majority appears to be 
ATP-competitive. SL0101 constitutes a notable exception, the kinetic data strongly 
suggesting that this compound is an allosteric inhibitor of RSK. In addition, SL0101 is 
the only isoform-specific inhibitor of RSK1/2 described to date, all the other inhibitors 
being equally potent against all four isoforms of RSK. Neither the kinetics nor the 
structural biology data for the majority of the other RSK inhibitors has been reported. 
The only other published structure of RSK NTKD bound to a selective inhibitor is that of 
the difluorophenyl pyridine LJH685. This structure showed an unusual conformation of 
RSK resembling the inactive DFG-out fold. However, the kinetic data for LJH685 is not 
available, therefore there is no clear evidence that this compound is an allosteric 
inhibitor of RSK. 
1.6.2. Inhibitors of the C-terminal kinase domain. 
 As discussed in section 1.3., the presence of a gatekeeper residue in the vicinity 
of the ATP-binding site of kinases is an important determinant of the selectivity of the 
kinase inhibitors. Small gatekeeper residue, like Thr or Val, enables design of inhibitors 
that would interact with the hydrophobic back pocket of the ATP groove. Interestingly, 
three out of four isoforms of RSK have a Thr gatekeeper residue in their CTKDs (Cohen 
et al., 2005). These isoforms are RSK1, RSK2 and RSK4 (fig. 5A). Therefore, the C-
terminal kinase domain of RSK was identified as a very promising candidate for the 
design of selective small molecule inhibitors (Cohen et al., 2005). 
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Figure 5. Covalent inhibitors of the C-terminal kinase domain of RSK. 
A) Sequence alignment of the hinge region of kinases with a reactive Cys residue, and 
the gatekeeper residue of these kinases. RSK1, RSK2 and RSK4 have a small 
gatekeeper residue, while RSK3 and two close relatives of RSK, MSK1 and MSK2, 
have a large gatekeeper residue. 
B) Chemical structure of the irreversible covalent inhibitors of RSK CTKD, fmk and 
cmk. The X atom in fmk is fluorine, while in cmk it is chlorine. 
C) Chemical structure of the reversible covalent inhibitor of the RSK CTKD, CN-NHiP. 
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 Among all 20 amino acids, cysteine has unique chemical properties that allow 
this residue to form covalent bonds with electrophilic molecules. This property has led to 
proposing that cysteine residues in the vicinity of the ATP-binding site could allow for a 
generation of an irreversible covalent kinase inhibitor (Cohen et al., 2005). This 
rationale was first tested in the design of covalent EGFR inhibitors (Fry et al., 1998). 
However, cysteine by itself does not confer the specificity of the kinase inhibitor, it only 
allows for a covalent bond formation. Rational kinase inhibitor design efforts have 
therefore focused on combining the cysteine reactivity with a method to confer the 
inhibitor specificity, such as the presence of a Thr gatekeeper. Interestingly, among all 
491 human kinases investigated, only RSK1, RSK2 and RSK4 have both the Thr 
gatekeeper residue and a Cys residue within a flexible glycine-rich loop (fig. 5A). 
Therefore, RSK has been identified as a very promising target for covalent inhibitor 
design (Cohen et al., 2005). The first study to employ this property has yielded 
identification of the first specific inhibitors of the RSK CTKD, called fmk and cmk (Cohen 
et al., 2005).  
1.6.2.1. Fmk and cmk 
 Fmk and cmk were designed based on the adenine scaffold. p-tolyl residue was 
added to employ the hydrophobic pocket behind the Thr gatekeeper. 
Chloromethylketone (fmk) and fluoromethylketone (cmk) represented the electrophilic 
component that was intended to react with the cysteine residue (fig.5B). This design 
approach resulted in the identification of remarkably specific and potent inhibitors, and 
due to a higher chemical stability fmk was further studied. This compound was shown to 
inhibit RSK2 with an IC50 of 15 nM at 100 M ATP, and this inhibitory activity was 
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completely dependent on the presence of the Cys residue in the kinase and 
chloromethylketone residue in the inhibitor. It is important to note, however, that the 
conventional in vitro IC50 measurements are of limited value in the case of covalent 
inhibitors (Singh et al., 2011). In a typical measurement of IC50, the binding of inhibitor 
to its target is determined at equilibrium. Unlike the non-covalent inhibitors, however, 
the binding reaction of the covalent inhibitor to its target continues until completion, and 
not equilibrium. Fmk inhibited the phosphorylation of Ser386 of RSK2, the only known 
substrate for the RSK CTKD, with an IC50 of 200 nM in cell-based assays (Vik and 
Ryder, 1997, Dalby et al., 1998). MSK1 has a Cys residue in the same position as 
RSK1/2, but the gatekeeper residue in MSK1 is Met. As a result, fmk does not inhibit 
MSK1 at all. However, mutating this gatekeeper to Thr is sufficient for MSK1 to become 
equally sensitive to fmk as RSK2. These results together prove evidence for the 
predicted mechanism for fmk potency and selectivity. Since fmk covalently binds to 
RSK, it was relatively easy to assess its ability to react with other proteins. When 
biotinylated fmk was incubated with cell lysate, only two proteins reacted with this 
compound and were subsequently affinity purified using streptavidin column. These two 
proteins were RSK1 and RSK2. The authors of the study did not provide explanation to 
the fact that even though RSK4 also possesses both the reactive Cys residue and the 
Thr gatekeeper residue, it was not identified in the screen of fmk-bound proteins. This 
experiment was performed in HEK 293T cells, which do express RSK4, albeit at very 
low levels (Uhlen et al., 2015, Sun et al., 2013). Fmk specificity has also been tested 
in vitro against a panel of ~80 kinases and was proven to be remarkably specific (Bain 
et al., 2007). This inhibitor only showed activity at 3 M concentration against Src, Lck 
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and to a lesser extent against S6K1. However, at a concentration that fully inhibited 
RSK2 in cell lines, fmk did not reverse the phenotypes induced by v-Src (Cohen et al., 
2005), further supporting the selectivity of fmk in cell-based systems. 
1.6.2.2. CN-NHiPr 
 Following the success of rational design of fmk, the unusual features of the RSK 
CTKD ATP-binding site were used in further studies of novel covalent inhibitors of RSK 
CTKD (Serafimova et al., 2012, Miller et al., 2013, London et al., 2014). CN-NHiPr, an 
fmk derivative intended to be a reversible covalent inhibitor (fig. 5C), maintained 
remarkable specificity for RSK1 in vitro, and in addition was proven to inhibit RSK4 
(Serafimova et al., 2012). Of the 442 kinases tested in vitro, CN-NHiPr at 1 M 
significantly inhibited 6 proteins, including MAP3K1, RIPK2, MEK5, STK16, RET and 
PDGFRB. This molecule was not tested against RSK2. Despite being a reversible 
inhibitor in vitro, however, this compound showed the same persistence of RSK 
inhibition in cell-based assays as fmk, suggesting that its half-life is longer than the 
turnover rate of the protein. The other two series of covalent inhibitors of RSK CTKD 
were designed using fragment-based screening design (Miller et al., 2013, London et 
al., 2014). In both cases however, the developed inhibitors were equally potent against 
MSK1/2 as RSK1/2. 
 
77 
 
Figure 6. Alternative mode of activation of the NTKD of RSK in the absence of CTKD 
activity. 
CTKD inhibitors fmk and cmk block CTKD-mediated autophosphorylation of the 
hydrophobic motif in the linker region of RSK. Alternative kinases, like MK2/3 in immune 
cells, can phosphorylate this residue, bypassing the CTKD inhibition. Phoshorylated 
hydrophobic motif recruits PDK1, which phosphorylates and activates NTKD of RSK.
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1.6.2.3. Biological significance of the inhibitors of RSK CTKD 
 The use of CTKD-specific inhibitors of RSK allowed for exploring the role of the 
autophosphorylation of Ser386, which is essential for the full activation of the NTKD. It 
has been observed that this residue could be phosphorylated in the absence of CTKD 
activity, but the identity of the kinase mediating this modification was unknown (Frodin 
et al., 2000, Chrestensen and Sturgill, 2002). The authors of one the study used a more 
cell-permeable propargylamine derivative of fmk (fmk-pa), which inhibited mitogen-
induced Ser386 phosphorylation in intact bone marrow-derived macrophages with an 
IC50 of 30 nM (Cohen et al., 2007). In the same cells stimulated with lipopolysaccharide 
(LPS), 1 M fmk-pa did not affect the phosphorylation levels of Ser386 at all. However, 
this effect seemed to be cell-type specific, as LPS did not rescue Ser386 
phosphorylation in fmk-pa-treated MA-MB-231 cell line. Consistent with the results of 
this study, RSK was later shown to be phosphorylated on Ser386 by MK2 and MK3 
downstream of p38 in dendritic cells (Zaru et al., 2007). One would expect RSK NTKD-
specific inhibitors to block RSK downstream signaling irrespective of the mode of the 
Ser386 activation. Therefore, these studies suggested that in certain cellular contexts 
CTKD-specific inhibitors could yield different results than inhibiting RSK using NTKD-
specific compounds.  
 The usefulness of fmk in inhibiting RSK downstream signaling has been proven 
by a number of studies. For example, fmk was used to demonstrate the role of RSK2 in 
mediating the transformation potential of FGFR3 in human myeloma cells (Kang et al., 
2007b). Fmk was also used to prove that RSK phosphorylates and activates the 
sarcolemmal sodium-proton exchanger NHE1 in response to alpha-1-adrenergic 
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stimulation in adult myocardium (Cuello et al., 2007). Finally, consistent with an 
emerging role of RSK in promoting metastasis, fmk was used in mouse xenograft 
studies of aggressive head and neck squamous cell carcinoma (HNSCC) (Li et al., 
2013). In these studies RSK inhibition by fmk caused a reduction in lymph node 
metastasis of the NHSCC cells, without affecting the size of the primary tumor. 
Therefore, RSK was shown to be an attractive therapeutic target for specifically 
inhibiting metastasis in HNSCC. 
 CTKD-specific inhibitors of RSK act to block the autophosphorylation-mediated 
activation of RSK (fig. 6). Therefore, these inhibitors will be the most effective when the 
basal activation status of the kinase is low. If RSK is active when CTKD inhibitor is 
introduced, the phosphorylation of Ser386 has to be removed, either by a phosphatase, 
or by turning over the whole protein. In contrast, the NTKD-specific inhibitors will block 
phosphorylation of the downstream targets of RSK even when the protein is fully 
activated. As a result, the temporal differences in the response to these two different 
classes of RSK inhibitors could be expected. In addition, as mentioned above, in certain 
cell contexts Ser386 of RSK can be phosphorylated by other kinases, which would 
bypass the effects of the CTKD-specific RSK inhibitor (fig. 6). 
1.7. Summary 
 Two decades of studies of the RSK family of kinases have allowed us to 
appreciate the complex biology of these proteins. RSK has emerged as a 
multifunctional downstream effector of the mitogenic signaling that is responsible for 
mediating a major fraction of all ERK1/2 functions. The processes regulated by RSK 
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ultimately aim at supporting cellular proliferation and survival. This goal is achieved by 
coordinated modulation of gene expression, protein synthesis, cell cycle and apoptosis. 
Multiple targets of RSK also receive inputs from the PI3K-Akt pathway, and the 
cooperation between these signals ultimately determines the biological outcome.  
 With the increasing number of studies investigating specific mechanisms 
regulated by the RSK family of kinases, we are now beginning to understand that these 
proteins could perform non-overlapping functions that appear to be isoform- and cell 
type-specific. The emerging patterns suggest that RSK2 functions could preferentially 
partition into the nucleus, while RSK1 could perform the majority of its roles in the 
cytoplasm. As a result, the former isoform would have a heavier impact on gene 
transcription, while the latter would support protein translation. Compared to RSK1/2, 
much less is known about the remaining two isoforms, therefore such predictions are 
very difficult to formulate with respect to RSK3/4. These differences in the involvement 
of RSK isoforms in already discovered mechanisms highlight the importance of 
developing methods to investigate the functions of individual RSK family members. In 
this context, RSK isoform-selective small molecule inhibitors could constitute an 
invaluable tool for future mechanistic studies of RSK isoform-specific biological 
functions. 
 The full understanding of the biological functions of RSK has also been limited by 
the paucity of in vivo studies using genetically engineered mouse models. In fact the 
only mouse models reported so far were a RSK2 knock-out and a RSK1/2/3 triple 
knock-out. As a consequence, the vast majority of the mechanistic data concerning the 
functions of RSK kinases were derived from studies performed in cell lines. It remains to 
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be determined whether these observations can be translated to meaningful biological 
effects in vivo. Small molecule inhibitors of the RSK kinases could offer a possibility to 
investigate the in vivo functions of RSK kinases in the absence of the genetically 
engineered models.  
 Being involved in critical processes regulating cellular proliferation and survival, 
RSK has been shown to play a role in various pathologies, including cancer. Therefore, 
it has been proposed to constitute a promising target for therapeutic intervention. To this 
end, several small molecule inhibitors of RSK have been discovered, however they 
display limited applicability in vivo. As a result, the therapeutic potential of RSK 
inhibition as a novel strategy to treat cancer in vivo remains almost completely 
unexplored. Therefore, there is a need to further develop inhibitors of RSK in order to 
identify clinically relevant lead compounds.  
 Taken all these factors together, there has been an ongoing effort to develop the 
small molecule inhibitors of RSK that could be used in vivo, as well as isoform-selective 
inhibitors of RSK. Here, we describe the properties of SL0101 as a very promising 
platform for further development of such clinically relevant RSK inhibitors. We 
demonstrate the complex interactions of this compound with its target, which contribute 
to our understanding of the basis for its efficacy and selectivity as a kinase inhibitor. We 
explore the biological space available to SL0101 derivatives and identify chemical 
modifications to the parent molecule that confer increased affinity for RSK in vitro, as 
well as its stability in cell-based systems. Finally, we identify a previously overlooked 
property of SL0101 as an isoform-selective inhibitor of RSK1/2 and not RSK3/4. These 
observations further highlight the usefulness of developing the analogs of this inhibitor, 
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both as tool compounds for the mechanistic studies of RSK1/2 isoforms, and as novel 
agents for investigating the therapeutic potential of inhibiting RSK in the treatment of 
various pathologies, including cancer. 
 We expand our studies beyond developing new RSK inhibitors to deepen our 
understanding of the biology of this family of kinases. We develop high-throughput 
proteomics approach to studying specific functions of RSK1 in intact cells and identify 
potential roles of this protein at an intersection of cellular energy homeostasis and 
protein synthesis. These results add to an increasing body of evidence in support of the 
potential role of RSK as a regulator of cellular energy and nutrient homeostasis (section 
1.5.10). Since this emerging novel function of the RSK family of kinases is still relatively 
understudied, we set out to further pursue this biological function of RSK. Our results 
show for the first time that inhibition of RSK1/2 does alter cellular energy and nutrient 
homeostasis, specifically through the suppression of mitochondrial oxidative 
phosphorylation downstream of multiple nutrients. Intriguingly, we discover a 
preferential dependency of transformed cell lines on RSK1/2 for maintaining their 
mitochondrial function. These observations add another element to an expanding 
repertoire of RSK functions in supporting cellular proliferation and survival, particularly 
in the context of cellular transformation. Finally, our novel findings highlighting the 
unique role of RSK1/2 in stimulating oxidative phosphorylation in transformed cells point 
to the potential of RSK inhibition as a novel strategy to specifically target energy 
homeostasis in cancer cells.  
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Chapter 2 
SL0101 is an allosteric inhibitor of RSK1 and RSK2. 
 
Summary 
A family of Ser/Thr protein kinases RSK has been shown to play important roles in 
regulation proliferation and motility in a variety of cancers. Therefore, RSK has been 
proposed as a potential novel therapeutic target in various malignancies. Of the four 
isoforms, RSK1 and RSK2 were shown to promote tumor growth and metastasis, while 
RSK3 and RSK4 are thought to be tumor suppressors. As a result, there is a need to 
develop isoform-specific inhibitors of RSK. SL0101 is a small-molecule inhibitor of RSK 
that was identified though a high-throughput screen of natural plant extracts. Previous 
studies have shown that this compound exhibits remarkable kinase selectivity. The 
analysis of the crystal structure the N-terminal kinase domain of RSK with SL0101 
revealed a unique conformation of the kinase bound to the inhibitor, suggesting that 
SL0101 is an allosteric inhibitor of RSK. Here, we provide evidence that SL0101 is a 
non-competitive inhibitor of RSK, and the binding of SL0101 induces a conformational 
change of the kinase. In addition, we show that SL0101 is a selective inhibitor of 
RSK1/2 and not RSK3/4. Therefore, this compound represents the first isoform-
selective, allosteric inhibitor of RSK1/2. 
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2.1. Introduction 
 Kinases represent the most promising class of potential targets for therapeutic 
intervention in a variety of disease states, including cancer (Fabbro, 2015). Among 
signaling cascades that have been most extensively pursued in cancer research is the 
mitogen-activated protein kinase (MAPK) cascade (Sebolt-Leopold and Herrera, 2004). 
MAPK pathway is reported to be deregulated in up to 30% of all cancers (Hoshino et al., 
1999). However, inhibition of the MAPK pathway could prove too toxic for normal 
proliferating cells (Sebolt-Leopold and Herrera, 2004). In addition, the pathway is 
involved in a number of feedback loops, which complicates the ability to predict cellular 
responses to its inhibition (Eisinger-Mathason et al., 2010). Therefore, we propose that 
downstream effectors of MAPK constitute potential drug targets for the inhibition of the 
MAPK pathway. One major downstream target of MAPK that has been extensively 
studied in the context of normal cell homeostasis and tumorigenesis is the family of p90 
ribosomal S6 kinases (RSK) ((Anjum and Blenis, 2008). 
 RSK is a family of four Ser/Thr protein kinases that are highly similar in terms of 
protein sequence, but appear to perform distinct functions in mammalian cells (Lara et 
al., 2013). RSK is unusual among other kinases in that it possesses two fully functional 
kinase domains within one polypeptide sequence (Anjum and Blenis, 2008). The C-
terminal kinase domain (CTKD) is involved in the autophosphorylation and activation 
cascade of the kinase, while the N-terminal kinase domain (NTKD) phosphorylates 
downstream targets of RSK (Bjorbaek et al., 1995). The NTKD belongs to the AGC 
(protein A, protein G and protein C) superfamily, while the CTKD is the member of the 
calcium-calmodulin dependent protein kinase (CaMK) superfamily (Anjum and Blenis, 
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2008). RSK is classically activated by ERK1/2 in response to various stimuli, including 
growth factors, hormones and neurotransmitters, and regulates various cellular 
processes promoting cell survival and proliferation (Anjum and Blenis, 2008). RSK1 and 
RSK2 were shown to be over-expressed in a variety of tumors, including breast and 
prostate (Smith et al., 2005, Clark et al., 2005), and appear to serve a variety of pro-
tumorigenic functions (Cho et al., 2007, Eisinger-Mathason et al., 2010, Kang et al., 
2007a, Romeo et al., 2013). RSK1/2 has been characterized as a major mediator of 
ERK1/2 signaling in promoting motility and invasiveness in melanoma (Doehn et al., 
2009). The study estimated that 20% of all ERK1/2 targets were co-regulated by 
RSK1/2, highlighting the central role of RSK as a downstream effector of the MAPK 
pathway in melanoma. In addition, blocking RSK by means of a covalent inhibitor was 
demonstrated to significantly inhibit the metastatic potential of the human head and 
neck squamous cell carcinoma in mouse xenografts (Li et al., 2013). Therefore, RSK 
emerges as a potential major therapeutic target for blocking both primary tumor growth 
and metastasis (Sulzmaier and Ramos, 2013).  
 The exact functions of individual RSK isoforms are not very well understood 
(Lara et al., 2013). Recent studies has suggested that, as opposed to established pro-
tumorigenic and pro-metastatic functions of RSK1/2, the remaining two isoforms act as 
putative tumor suppressors (Thakur et al., 2008, Cai et al., 2014, Bignone et al., 2007). 
Therefore, there is an ongoing effort to identify isoform-selective inhibitors of RSK for 
both biological and clinical studies (Nguyen, 2008). An ideal therapeutic agent would 
inhibit exclusively RSK1 or RSK2, or both these isoforms, without affecting the activities 
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of RSK3 and RSK4. Such inhibitor has not been characterized yet. However, not all 
reported RSK inhibitors were tested for their ability to inhibit all four isoforms of RSK. 
 SL0101 is an inhibitor of RSK that was derived from the plant extract of a tropical 
plant, Forsteronia refracta (Smith et al., 2005). Since initial discovery, it has been used 
as a tool compound in a number of studies of the functions of RSK (Nguyen, 2008). A 
major advantage of SL0101 over other RSK inhibitors is a remarkable selectivity of the 
compound for RSK (Bain et al., 2007). Of all kinases tested, only Aurora B, PIM1 and 
PIM3 appear to be potential off-target kinases inhibited by SL0101. However, the 
applicability of SL0101 in cell-based and in vivo studies has been limited by poor cell 
permeability and stability of the compound in biological systems (Smith et al., 2005; 
chapter 3). SL0101 has proven amenable to chemical modifications that improve on 
those properties, and it is continued to be developed as a potential novel RSK inhibitor 
in vivo (chapters 3-5 and appendix).  
 The selectivity of SL0101 is surprising, considering a relatively common structure 
of the molecule. SL0101 is a glycosylated flavonoid consisting of a kaempferol ring 
system and an unusual sugar, L-rhamnose (Smith et al., 2005). Kaempferol and many 
of its derivatives are non-selective inhibitors of kinases with relatively low affinity for 
multiple targets (Calderon-Montano et al., 2011). Interestingly, the X-ray diffraction 
crystal structure of SL0101 bound to the N-terminal kinase domain of RSK2 has 
recently been reported (Utepbergenov et al., 2012). This structure displayed a very 
unusual fold of the kinase bound to the inhibitor, opening a possibility that SL0101 is an 
allosteric inhibitor of RSK.  
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 Given the potential for developing novel kinase-selective inhibitors of RSK based 
on the SL0101 pharmacophore, and recent findings that SL0101 could owe its 
remarkable selectivity for RSK to its unusual mode of binding, we set out to better 
characterize the properties of this compound as a RSK inhibitor. We found that SL0101 
inhibits RSK through a non-competitive mode, and this inhibition involves a change in 
the conformation of the kinase. In addition, we find that SL0101 is a selective inhibitor of 
RSK1/2, and not RSK3/4. 
2.2. Materials and methods 
Reagents 
 SL0101 was synthesized by collaborators: George O’Doherty (Northeastern 
University, Boston MA), Michael Hilinski (University of Virginia, Charlottesville VA) or 
David Maloney (National Institutes of Health, Bethesda MD), according to a previously 
described synthetic route (Maloney and Hecht, 2005). BI-D1870 was purchased from 
Enzo Life Sciences (Farmingdale NY). Recombinant active RSK2, RSK3 and RSK4 
were purchased from Invitrogen (Carlsbad CA). Profection Calcium Phosphate 
Transfection kit was purchased from Promega (Madison WI). Primary antibodies used 
were mouse monoclonal anti-RSK2 (E-1), rabbit anti-RSK1 (C-21) and goat anti-RSK3 
(C-20) from Santa Cruz Biotechnology (Santa Cruz CA), mouse monoclonal anti-HA 
(Lymphocyte Culture Center, University of Virginia, Charlottesville VA) and rabbit anti-
ER-pSer167 (Smith et al., 2005). Secondary antibodies conjugated to horseradish 
peroxidase (HRP) were donkey anti-goat, donkey anti-rabbit and goat anti-mouse from 
Jackson Immunoresearch (West Grove PA). 
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Cell culture and treatment 
 BHK-21 cells were cultured as directed by American Type Culture Collection 
(ATCC). For protein expression, pKH3 plasmids containing RSK1-4 cDNA were 
transfected into cells using calcium phosphate method as described previously (Poteet-
Smith et al., 1999). 42 hours post-transfection cells were stimulated with 200 ng/mL 
EGF in fresh serum-containing medium for 15 min, followed by lysis on the plate using 
ice-cold lysis buffer (50 mM Tris, pH 8, at 4 °C, 150 mM NaCl, 1% Nonidet P-40, 0.5% 
Triton X-100, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1X Protease Inhibitor Cocktail, 
1 mM phenylmethylsulfonyl fluoride, 200 μM Na3VO4, 1 μM microcystin LR). The lysate 
was sheared by passing thrice through a 27G needle and snap-frozen in liquid nitrogen. 
Immunoprecipitation 
 Anti-HA antibody-conjugated magnetic beads were used for the 
immunoprecipitation of HA-tagged RSK proteins from BHK cell lysates. Briefly, 50 L of 
bead slurry for 15 cm confluent plate of BHK cells was washed twice with lysis buffer 
and incubated at 4C for 1 hour on a rotator. The beads were then washed 2 times with 
lysis buffer and 3 times with kinase assay buffer (5 mM -glycerophosphate, pH 7.4, 25 
mM HEPES, pH 7.4, 1.5 mM DTT, 30 mM MgCl2, 0.15 M NaCl). Immunoprecipitated 
protein was eluted with 250 mM HA peptide in kinase assay buffer by incubating 
overnight in a thermomixer at 4C. The protein amount in the elution was determined by 
Western Blotting against a loading control of recombinant RSK protein.  
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In vitro kinase activity assays 
 The assays of RSK activity were performed as described previously (Smith et al., 
2005). Briefly, 50 L of 5 nM kinase in kinase assay buffer with 1% bovine serum 
albumin (BSA)(Roche, France) was loaded into each well of a 96-well Maxisorp-treated 
polystyrene plate (Nunc, Denmark) coated with 1 g of the GST-ERSer167 peptide, 
sequence RRLASTND. 25 L of inhibitor at indicated concentration, or DMSO vehicle, 
was added to each well and incubated for 15 min or 120 min at room temperature. The 
reaction was initiated by addition of ATP in kinase assay buffer with 1% BSA at 
indicated concentrations. The reaction was allowed to proceed for 20 min, which is 
within the linear range of the assay (Smith et al., 2005). As a background control, 75 L 
of 500 mM EDTA pH 8.0 in water was added to the well before ATP. The reactions were 
terminated by addition of 500 mM EDTA pH 8.0 in water. After extensive washes of 
wells, rabbit antibody against phosphorylated Ser167 of ER was incubated for 30 min. 
Following extensive washes, the secondary donkey anti-rabbit antibody conjugated to 
horseradish peroxidase (HRP) was incubated for 30 min. The secondary antibody was 
removed, the plate was washed and Enhanced Luminescence Reagent (Perkin-Elmer, 
Boston MA) was used to measure HRP activity, according to manufacturer’s protocol. 
Half-inhibitory concentration of the compound (IC50) was calculated using non-linear 
regression analysis of the data (GraphPad Prism). 
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Figure 7. SL0101 is an isoform-selective inhibitor of RSK1/2. 
A) Immunoprecipitated RSK1-4 isoforms are enzymatically active. pSer signal in an 
in vitro kinase assay for each kinase was normalized to the signal of the negative 
control. combined N2 in triplicate, Bars mean SD. 
B) SL0101 inhibits in vitro kinase activity of immunoprecipitated RSK1 and RSK2, but 
does not inhibit the activities of immunoprecipitated RSK3 and RSK4. The bars 
represent kinase activity, normalized to DMSO-control treated kinase for each 
kinase separately, combined N2 in triplicate, SD, asterisk indicates p<0.01 
compared to respective control. 
C) BI-D1870 inhibits all three purified RSK isoforms tested, with similar potencies. 
Combined normalized activity of the kinase in a range of inhibitor concentrations, 
N=2 in triplicate, SD. 
D) SL0101 inhibits purified RSK2, but not purified RSK3 and RSK4 tested. Combined 
normalized activity of the kinase in a range of inhibitor concentrations, N=2 in 
triplicate, SD. 
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2.3. Results  
 The two most widely used small molecule inhibitors of RSK are BI-D1870 and 
SL0101 (Sapkota et al., 2007, Smith et al., 2005). BI-D1870 has been shown to inhibit 
all four isoforms of RSK with similar efficacies in vitro (Bain et al., 2007). However, 
SL0101 has only been confirmed to inhibit RSK1 and RSK2, and its ability to inhibit 
RSK3 and RSK4 is not known (Smith et al., 2005). To better understand the properties 
of SL0101 and its analogs as a potential novel therapeutic agents in cancer treatment 
we set out to characterize the isoform-selectivity of SL0101. Initially, we tested BI-
D1870 and SL0101 at concentrations ~100-fold higher than the reported in vitro IC50 of 
these compounds against RSK isoforms. Both inhibitors were used against the wild-type 
full-length isoforms of RSK that were immunoprecipitated from EGF-stimulated BHK 
cells. All immunoprecipitated kinases were active (fig. 7A). Consistently with the 
previous reports, BI-D1870 significantly inhibited all four isoforms of RSK at 1 M (fig. 
7B). SL0101 inhibited RSK1 and RSK2, which is in agreement with the reported activity 
of this inhibitor against these two isoforms (Smith et al., 2005, Bain et al., 2007). 
However, RSK3 and RSK4 isoforms were not inhibited by 30 M SL0101. These results 
suggested that SL0101 is an isoform-specific inhibitor of RSK1/2.  
 To further support the hypothesis that SL0101 is an isoform-specific inhibitor of 
RSK, we performed in vitro kinase assays using commercially available purified RSK 
proteins (Invitrogen, CA). Consistent with the previous findings, BI-D1870 inhibited all 3 
tested isoforms with similar potencies (fig. 1C). However, while SL0101 efficiently 
inhibited RSK2, the activities of RSK3 and RSK4 were not decreased (fig. 1D). 
Therefore, we conclude that SL0101 is an isoform-specific inhibitor of RSK1/2, and not 
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RSK3/4, and this ability differentiates it from another well-characterized inhibitor of RSK, 
BI-D1870. 
 Given very high similarity in the protein sequence of the four kinases, the 
specificity of SL0101 against RSK1/2 was very surprising. Therefore, we decided to 
further investigate the mechanism of RSK1/2 inhibition by RSK. The X-ray crystal 
structures of this inhibitor bound to the N-terminal kinase domain (NTKD) of RSK2, as 
well as the structure of RSK2 NTKD bound to the non-cleavable ATP analog, AMP-
PNP, have been previously reported (Utepbergenov et al., 2012, Malakhova et al., 
2009). These structures revealed a very unusual conformation of the kinase bound to 
the inhibitor, compared to AMP-PNP. The protein displayed extensive rearrangement of 
the N-lobe of the kinase with respect to the C-lobe, resulting in a formation of a new 
binding site for the inhibitor that was adjacent to the ATP-binding site in the groove 
between the two lobes. This structural rearrangement involved transitions of the 
secondary features of the kinase that appeared to be very energetically unfavorable and 
involved partial unfolding and re-folding of the kinase. Therefore, we hypothesized that 
the conformational change induced by SL0101 binding could occur only when the 
kinase is allowed to incubate with the inhibitor for extended period of time. In order to 
test this hypothesis, we performed in vitro kinase assays with SL0101 pre-incubated 
with full-length RSK2 protein for 15 min and 120 min, before adding the substrate 
(ATP). We first tested this hypothesis using the RSK2 Y707A mutant, which has an 
elevated basal activity (Poteet-Smith et al., 1999). The mutation is within the auto-
inhibitory loop of the C-terminal kinase domain of RSK, which causes an increase in 
basal activity of the CTKD. When tested in vitro against RSK2Y707A, SL0101 displayed 
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a significant difference in the ability to inhibit the kinase in 15 min vs. 120 min. pre-
incubation, with a ~14-fold higher IC50 at the shorter incubation time (fig. 8A,F). This 
inhibitor was much more potent against RSK2 when pre-incubated for extended period 
of time, suggesting that a conformational change of the kinase occurs between 15 min 
and 120 min of pre-incubation. When wild-type full length RSK2 was tested in vitro, it 
also displayed the change in IC50 of SL0101 between 15 min and 120 min (fig. 8B,F). 
The difference in the in vitro IC50 of SL0101 between 15 min and 120 min pre-
incubation was ~6-fold in the WT-RSK2, compared to ~14-fold in RSK2Y707A. Both 
variants of the protein displayed a very similar IC50 at 120 min pre-incubation, 
indicating equal sensitivity for the inhibitor. However, the IC50 of RSK2Y707A at 15 min 
pre-incubation was >4-fold higher. These results suggest that the mutationally activated 
CTKD of RSK interferes with the ability of its NTKD to undergo the conformational 
change upon SL0101 binding.  
 In order to test the hypothesis that the C-terminal part of RSK influences the 
ability of the NTKD to undergo the conformational change following SL0101 binding we 
tested in vitro a truncation mutant of RSK2 (RSK2(1-389)). This mutant contains the N-
terminus and the entire NTKD, as well as the majority of the linker region, including the 
PDK1-docking site that is required for the activation of the RSK2 NTKD (Frodin et al., 
2000, Frodin et al., 2002). The in vitro IC50 of SL0101 for the truncation mutant at 120 
min pre-incubation was consistent with that of both full-length RSK2 constructs, 
suggesting that all 3 variants of RSK2 were inhibited in a similar fashion by SL0101 in 
these conditions (fig. 8C,F). However, when pre-incubated for 15 min, RSK2(1-389) was 
equally sensitive to SL0101 as when pre-incubated for 120 min, suggesting that in both 
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pre-incubation conditions SL0101 is equally capable of forming the unusual complex 
with RSK2 NTKD (fig. 8C,F). These results further support the role of the CTKD of 
RSK2 in regulating the conformation of the NTKD. These results together indicate that 
SL0101 binding to RSK at extended periods of time allows for a formation of the 
unusual conformation of the kinase that is more efficiently inhibited by SL0101, and that 
the existence of this new conformation in solution is impeded by the CTKD of RSK2. 
 As mentioned above, we and others have shown that RSK1 is also inhibited by 
SL0101. Therefore, we investigated the ability of SL0101 to differentially inhibit RSK1 in 
15 min vs. 120 min pre-incubation. When tested in vitro, WT-RSK1 was more effectively 
inhibited by SL0101 at longer pre-incubation, compared to a 15 min pre-incubation (fig. 
8D,F). However, the difference in IC50 between two pre-incubation times was only 2.5-
fold, compared to 6-fold difference in the case of RSK2. The IC50 of SL0101 against 
RSK1 as measured at 120 min pre-incubation with the kinase was consistent with the 
IC50 of both WT-RSK2 and RSK2Y707A at longer pre-incubation condition. These 
results indicate that full-length wild-type RSK1 and RSK2 are equally sensitive to 
SL0101 at 120 min pre-incubation.   
 To further evaluate the role of the CTKD of RSK in regulating the affinity of 
SL0101 for the NTKD, we generated a chimeric protein, in which the C-terminal portion 
of RSK2 was replaced with the corresponding sequence of RSK1. The chimeric protein 
displayed the same ability to be differentially inhibited by SL0101 in long vs. short pre-
incubation conditions as the wild-type RSK2, as the IC50 of SL0101 for either condition 
was consistent with that found for the full-length wild-type RSK2 (fig. 8E,F).  
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These results suggest that the C-terminus of RSK1 can perform the same function as 
the C-terminus of RSK2 in regulating SL0101 affinity for the NTKD. Therefore, these 
results provide evidence for a common mechanism of the CTKD involvement on the 
binding of SL0101. 
 The IC50 of a compound is related to its affinity to the target protein, which is 
defined as the inhibition constant Ki (Cheng and Prusoff, 1973, Brandt et al., 1987).  
Therefore, we hypothesized that the inhibition constant of SL0101 for RSK was 
changing between the 15 min vs. 120 min pre-incubation. A change in inhibition 
constant can only occur as a result of an alteration in the conformation of the inhibitor-
molecule complex (Knight and Shokat, 2005). Therefore, variations in inhibition constant 
would provide direct evidence of the hypothesized switch in the conformation of the 
kinase. In order to measure the inhibition constant of SL0101 at 15 min and 120 min 
pre-incubation, the in vitro activity assays were performed at varying concentrations of 
inhibitor and ATP. Plotting the reciprocal of the reaction rate against the inhibitor 
concentration for each ATP concentration allows the identification the inhibition constant 
of the enzyme-substrate complex (Dixon, 1953). The abscissa of the intersection point 
of the lines for each ATP concentration defines the -Ki value. At 120 min pre-incubation, 
the Ki value of SL0101 was 7.81 M (fig. 9A,E). However, at 15 min pre-incubation the 
lines representing varying ATP concentrations were parallel, indicating no binding of the 
inhibitor to free enzyme in this condition (fig. 9B). Therefore, we observed a dramatic 
change in the ability of the inhibitor to bind to the enzyme between 15 min and 120 min 
pre-incubation times. 
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Figure 8. C-terminal kinase domain of RSK1/2 regulates potency of SL0101 against the 
N-terminal kinase domain of RSK. 
A) SL0101 is a 14-fold more potent inhibitor of purified recombinant RSK2Y707A when 
allowed to pre-incubate with the kinase for 120 min. Combined normalized kinase 
activity, N=3 in quadruplicate, SD. 
B) SL0101 is a 6-fold more potent inhibitor of immunoprecipitated RSK2 when allowed 
to pre-incubate with the kinase for 120 min. Combined normalized kinase activity, 
N=3 in triplicate, SD. 
C) SL0101 is equally potent against the RSK2(1-389) truncation mutant containing full 
NTKD and linker region of the kinase in both pre-incubation conditions. Combined 
normalized kinase activity, N=2 in triplicate, SD. 
D) SL0101 is a 2.5-fold more potent inhibitor of purified recombinant RSK2Y707A when 
allowed to pre-incubate with the kinase for 120 min. Combined normalized kinase 
activity, N=2 in quadruplicate, SD. 
E) SL0101 is a 4.5-fold more potent inhibitor of immunoprecipitated RSK2/1 chimeric 
protein when pre-incubated with the kinase for 120 min. Combined normalized 
kinase activity, N=3 in triplicate, SD. 
F) Summary table of the inhibitor concentration required for a 50% reduction in kinase 
activity (IC50) for given constructs at 120 min and 15 min pre-incubation times. IC50 
was calculated for each repeat of the experiment separately using the non-linear 
regression analysis of the data, values represent mean IC50 SD for N2 in 
triplicate or quadruplicate. p value, Student t-test of IC50 at 120 min vs. 15 min. 
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Figure 9. Conformation of RSK2 incubated with SL0101 changes between 120 min 
and 15 min incubation with the inhibitor. 
A) SL0101 binds to free RSK2 protein at 120 min with an inhibition constant of Ki of 
7.813.22 M. Representative Dixon plot of one experiment done in quadruplicate, 
mean SD, N=4. 
B)  SL0101 does not bind to free RSK2 protein at 15 min. Representative Dixon plot of 
one experiment done in quadruplicate, mean SD, N=3. 
C) SL0101 binds to RSK-ATP complex at 120 min with an inhibition constant Ki’ of 11.5 
6.69 M. Representative Cornish-Bowden plot of one experiment done in 
quadruplicate, mean SD, N=4. 
D) SL0101 binds to RSK-ATP complex at 15 min with an inhibition constant Ki’ of 12.52 
4.77 M. Representative Cornish-Bowden plot of one experiment done in 
quadruplicate, mean SD, N=3. 
E) SL0101 is a non-competitive inhibitor of RSK2 when incubated for 120 min, while at 
15 min pre-incubation it acts as an uncompetitive inhibitor. The abscissa of the 
intersection point of all lines in Dixon and Cornish-Bowden plots was calculated for 
each experiment separately, Ki and Ki’ values represent mean SD of 3 
experiments in quadruplicate. 
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Figure 10. SL0101 analogs display the same ability to induce conformational change of 
RSK2 as the parent compound. 
A) Compound 216, the C6’’-n-propyl cyclitol analog of SL0101, is a more potent 
inhibitor of RSK2Y707A in vitro when allowed to bind to the kinase for 120 min. The 
schematic represents the chemical structure of this SL0101 analog. Combined 
normalized activity of N=2 in quadruplicate, mean SD. Data was fit using the non-
linear regression analysis. 
B) Compound 249, the C6’’-n-propyl- 3,4’’-bicarbamate cyclitol analog of SL0101, is a 
more potent inhibitor of RSK2Y707A in vitro when allowed to bind to the kinase for 
120 min. The schematic represents the chemical structure of this SL0101 analog. 
Combined normalized activity of N=2 in quadruplicate, mean SD. Data was fit using 
the non-linear regression analysis. 
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 In addition to binding to the free enzyme, an inhibitor can act through binding to 
the enzyme-substrate complex. The inhibition constant of the enzyme-substrate 
complex is designated as Ki’ (Schlamowitz et al., 1969). Ki’ can be calculated by plotting 
the product of substrate concentration and the reciprocal of the reaction rate (S/V) 
against inhibitor concentration (Cornish-Bowden, 1974). The abscissa of the 
intersecting point of the lines representing different ATP concentration defines the –Ki’ 
value. We measured the ability of SL0101 to bind to the enzyme-substrate complex 
using this method at 15 min vs. 120 min pre-incubation. Interestingly, in both pre-
incubation conditions the lines intersected at a point with a similar X values suggesting 
a similar affinity of SL0101 for the enzyme-substrate complex in both conditions (fig. 9C-
E). Taken together, the values of Ki and Ki’ indicate that SL0101 displays different 
modes of inhibition between 15 min and 120 min pre-incubation times. At 15 min, 
SL0101 is unable to bind to the free enzyme and only binds to enzyme-substrate 
complex, therefore it acts as an uncompetitive inhibitor (Cornish-Bowden, 1974). At 120 
min, however, SL0101 binds to both free enzyme and the enzyme substrate complex, 
therefore it acts as a mixed inhibitor.  
 A special case of a mixed inhibitor is a compound that has equal affinities for the 
free enzyme and the enzyme-substrate complex. In such case the values of Ki and Ki’ 
for the inhibitor are equal (Cornish-Bowden, 1974). Another indication of a non-
competitive inhibitor is the intersection point of the both reciprocal plots lying on the Y 
axis of each plot (Cornish-Bowden, 1974). Interestingly, the values of Ki and Ki’ for 
SL0101 at 120 min pre-incubation were not significantly different (7.813.22 and 
11.576.69, respectively), suggesting that SL0101 is in fact a non-competitive inhibitor. 
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The lines intersected very close to the X-axis, further suggesting that SL0101 is a non-
competitive inhibitor in these conditions.  
  We have described several families of analogs of SL0101 (chapters 3-6). We 
sought to determine whether the conformational change induced by SL0101 was unique 
to this molecule, or whether it was preserved among diverse analogs. To address this 
hypothesis we tested two SL0101 analogs (fig. 10A-B). Interestingly, both analogs 
retained the ability to differentially inhibit RSK2Y707A in vitro. Therefore, the allosteric 
regulation of RSK2 kinase activity appears to be a common feature of diverse SL0101 
analogs. These results support the notion that SL0101 offers an attractive platform for 
the synthesis of novel analogs with improved biological properties. 
2.4. Discussion 
 Several selective RSK inhibitors have been described to date, and of those 
SL0101 remains to be exceptionally specific (Bain et al., 2007, Nguyen, 2008). 
However, all known inhibitors of the NTKD of RSK are equally potent against all 4 
isoforms of RSK. Here, we show for the first time that SL0101 is an isoform-selective 
inhibitor of RSK1/2 and not RSK3/4. Therefore, SL0101 is the only known isoform-
selective inhibitor of the NTKD of RSK. The structural basis for the selectivity of SL0101 
against RSK isoforms remains unknown. These results have major implications for the 
use of SL0101 as a tool compound in studying the functions of RSK. In addition to not 
inhibiting RSK3 and RSK4, SL0101 has very few off-target kinases, suggesting that the 
use of this inhibitor in cell-based studies should allow investigating the biological 
functions of RSK1 and RSK2 with little interference from the other kinases. Therefore, 
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the effects induced by SL0101 treatment in cells are most likely to be associated with 
the loss of RSK1 and RSK2 function. At the same time, BI-D1870 is equally potent 
against all RSK isoforms. As a result, it may elicit different responses in cells than 
SL0101.  
 The crystal structure of SL0101 bound to RSK2 NTKD has suggested a very 
unusual mode of inhibition of the kinase by this molecule. By analyzing the relative 
positions of catalytic and regulatory residues in the ATP-binding pocket it was 
suggested that SL0101 was binding to the conformation resembling the autoinhibited 
“DFG-out“ fold of the kinase (Utepbergenov et al., 2012, Taylor and Kornev, 2011). 
However, it was not a classical autoinhibited form of the kinase, as the inhibitor binding 
was associated with massive rearrangement of the parts of the kinase that do not 
undergo the conformational changes between the classical “on” and “off” states (Taylor 
and Kornev, 2011). Therefore, SL0101 is not likely to be a classical type 2 inhibitor, i.e. 
an inhibitor that binds to the inactive DFG-out conformation (Zhang et al., 2009). 
Instead, the conformational change would suggest that SL0101 is an allosteric inhibitor 
of RSK1/2 NTKD, as defined by its ability to bind to a site different than the typical ATP-
binding site. 
 The measurement of inhibition constants of the free enzyme and enzyme-
substrate complex revealed that initially SL0101 is not able to bind to RSK2 NTKD by 
itself, therefore at 15 min it acts as an uncompetitive inhibitor. When incubated for 
prolonged time, however, it gains the ability to bind to free enzyme, but without a loss of 
ability to bind to the enzyme-substrate complex. Therefore, it becomes a non-
competitive inhibitor. The crystal structure of RSK2 NTKD with SL0101 does not offer 
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the explanation to such mechanism. In the classical “DFG-out” conformation the Phe 
ring is occluding the adenine-binding site in the groove, preventing the binding of ATP 
(Zhang et al., 2009). Therefore, if SL0101 was a type 2 inhibitor, it would not be able to 
bind to RSK2-ATP complex. This observation raises the possibility that the crystal 
structure does not fully recapitulate the binding of SL0101 to RSK2 in solution. It has 
been noted that the difference in the folds of RSK2 bound to AMP-PNP and SL0101 
must most likely involve partial un-folding and re-folding of the kinase (Utepbergenov et 
al., 2012). Therefore, it is possible that SL0101 in solution binds to one of the 
transitional states that allow for accommodation of both SL0101 and ATP within the 
kinase fold.  
 The crystal structure of the active form of RSK2 NTKD with AMP-PNP showed a 
unique arrangement of residues involved in ATP binding (Malakhova et al., 2009). The 
typical C-helix was replaced in the structure by a novel B-sheet. This difference 
changed the pattern of bonds formed between the ATP molecule and amino acid side 
chains of the groove. In addition, the ATP-binding cleft appeared to have a larger 
volume, compared to a typical AGC kinase family member. SL0101 bound to RSK2 
deep inside the pocket, lodged between the -strands of the N-lobe (Utepbergenov et 
al., 2012). Therefore, it is possible that the plasticity of the NTKD of RSK would allow 
binding of both ATP and SL0101 at the same time. In a basal state RSK NTKD could 
potentially display relatively disordered, or flexible conformation, with only a small 
fraction of molecules in a fold that can bind SL0101. ATP binding could stabilize some 
discrete structure, allowing for simultaneous binding of SL0101. When pre-incubated for 
an extended period of time with the kinase, SL0101 could slowly bind to and stabilize 
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this infrequent conformation gradually increasing its population. As a result, in the short 
pre-incubation only the un-competitive mode of inhibition is present, whereas at longer 
timepoints the contribution of SL0101 binding to the kinase alone to the overall inhibitory 
effect would increase. The hypothesis that SL0101 could assist in stabilizing RSK NTKD 
conformation is supported by the fact that, despite no evidence in the crystal structure of 
phosphorylation of the conserved Ser227 residue in the activation loop, a large segment 
of this loop has a very well defined the crystal structure. In contrast, the activation loop 
of PKA in the absence of this phosphorylation has recently been described to be 
disordered (Steichen et al., 2012). Therefore, it appears that SL0101 can stabilize the 
section of the kinase that should normally be disorganized (Utepbergenov et al., 2012). 
 The results of the kinase activity assays of different RSK2 variants have 
suggested that the C-terminal portion of the kinase interacts with the NTKD and affects 
its ability to bind to SL0101. In the absence of the entire C-terminal portion of RSK2, the 
efficacy of SL0101 against RSK2 is equal at short and long pre-incubation, suggesting 
equal ability of the inhibitor to bind to the kinase. In the context of a proposed model, the 
CTKD would therefore enforce the lower frequency of the fold of the NTKD that SL0101 
can bind to on its own. As a result, when that inhibition by CTKD is removed, SL0101 
can more easily bind to and stabilize the preferred conformation. This interaction of 
CTKD and NTKD might depend on the active conformation of the CTKD itself, as the 
activating mutation in the C-terminus causes a decrease in the ability of SL0101 to 
inhibit the NTKD, compared to the wild-type kinase. The possibility of the two parts of 
the kinase interacting is supported by two observations. First, the two acetate residues 
within the sugar moiety of SL0101 are solvent-exposed in the crystal structure of RSK2-
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NTKD with SL0101 and do not participate in binding between the two entities 
(Utepbergenov et al., 2012). The structure of de-acetylated SL0101 bound to RSK2-
NTKD is identical to that of SL0101 (Utepbergenov et al., 2012). However, our previous 
studies have indicated that these two acetates are essential for the ability of SL0101 to 
bind to RSK, as their loss dramatically increases the IC50 of the inhibitor (Smith et al., 
2005; chapter 3). Therefore, additional parts of the kinase not included in the crystal 
structure have to participate in SL0101 binding to RSK2. The second observation 
suggesting that the interactions of the CTKD and the NTKD are possible comes from 
the fact that phosphorylation of Ser227 in the activation loop of the NTKD by itself can 
only increase the phosphotransfer ability of the kinase to 10% of its maximum. The 
remaining 90% of the maximum activity is obtained due to the interactions of the 
phosphorylated hydrophobic motif in the linker region of the kinase with the core of the 
NTKD (Frodin et al., 2002).  
 The complex and unusual mode of inhibition of RSK1/2 by SL0101 could explain 
its remarkable selectivity for other kinases. The active folds of kinases are very highly 
conserved, therefore inhibitors binding to an active conformation of one kinase are likely 
to also bind to other kinases (Knight and Shokat, 2005). In contrast, the inactive 
conformations of kinases display a remarkable diversity of structures (Taylor and 
Kornev, 2011, Huse and Kuriyan, 2002). As a consequence, the compounds that bind to 
the conformations other than the classical active fold of the kinase tend to be more 
selective for their targets and display far less off-target effects (Knight and Shokat, 
2005). 
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Chapter 3 
Improving the affinity of SL0101 for RSK using structure-based design 
Adapted from: 
Mrozowski, R.M., Vemula, R., Wu, V., Zhang, Q., Schroeder, B.R., Hilinski, M.K., Clark, 
D.E., Hecht S.M., O’Doherty, G.A., Lannigan, D.A. (2013) Improving the affinity of 
SL0101 for RSK using structure-based design. ACS Med Chem Lett, 4: 175-179 
 
Summary 
 Enhanced activity of the Ser/Thr protein kinase, RSK, is associated with 
transformation and metastasis, which suggests that RSK is an attractive drug target. 
The natural product, SL0101 (kaempferol 3-O-(3”,4”-di-O-acetyl--L-
rhamnopyranoside), has been shown to be a specific inhibitor of RSK.  However, the Ki 
for SL0101 is 1 M with a half-life of less than 30 min in vivo. To identify analogues with 
improved efficacy we designed a set of analogues based on the crystallographic model 
of SL0101 in complex with the RSK2 N-terminal kinase domain. We identified an 
analogue with a 5” n-propyl group on the rhamnose that has > 40-fold improved affinity 
for RSK than SL0101 in an in vitro kinase assay. This analogue preferentially inhibited 
the proliferation of the human breast cancer line, MCF-7, versus the normal 
untransformed breast line, MCF-10A, which is consistent with the results using SL0101. 
However, the efficacy of the 5” n-propyl analogue to inhibit MCF-7 proliferation was only 
two-fold better than for SL0101, which we hypothesize is due to limited membrane 
permeability. The improved affinity of the 5” n-propyl analogue for RSK will aid in the 
design of future compounds for in vivo use.  
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3.1. Methods 
In vivo studies 
 Absorption Systems LP (Exton, PA) performed the pharmacokinetic evaluation of 
SL0101 in male CD-1 mice according to their established protocol. 
Purified Recombinant RSK2 
 Baculovirus containing RSK2 cDNA was prepared using the Bac-to-Bac 
baculovirus expression system (Invitrogen, Carlsbad, California). His-tagged active 
RSK2 was expressed in Sf9 cells and purified using NiNTA resin (Qiagen, Valencia, 
California). 
In Vitro Kinase Assay 
 The assays were performed as previously described (Smith et al., 2005). Briefly, 
Glutathione-S-transferase (GST)-fusion protein (1 g) containing the ER-Ser167 
sequence- RLASTND was adsorbed in the wells of LumiNunc 96-well polystyrene 
plates (MaxiSorp surface treatment).  The wells were blocked with 3% tryptone in 
phosphate-buffered saline.  Kinase (5 nM) in 50 L of kinase buffer (5 mM -
glycerophosphate, pH 7.4, 25 mM HEPES, pH 7.4, 1.5 mM DTT, 30 mM MgCl2, 0.15 M 
NaCl) and 25 µL of the compound at the indicated concentrations or vehicle was added 
to each well.  Reactions were initiated by ATP (10 M) and were terminated after 120 
min by 500 mM EDTA, pH 7.5. All assays measured the initial velocity of reaction. After 
extensive washing of wells, a polyclonal anti-ER-pSer167 antibody (Smith et al., 2005) 
and HRP-conjugated anti-rabbit antibody (211-035-109, Jackson ImmunoResearch 
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Laboratories, West Grove, Pennsylvania) were used to detect serine phosphorylation of 
the substrate. HRP activity was measured using Western Lightning Chemiluminescence 
Reagent (NEL102, Perkin Elmer Life Sciences) according to the manufacturer’s 
protocol.  Maximum responses and the concentrations at half the inhibitory response 
(IC50) were determined by performing a best-fit analysis of the data (GraphPad Prism). 
Proliferation Assays 
 The assays were performed as previously described (Smith et al., 2005). Briefly, 
cells were seeded at 2000 cells per well in 96-well tissue culture plates in the 
appropriate medium as described by American Type Culture Collection. After 24 h, 
compound or vehicle was added. Cell number was measured 48 h later using CellTiter-
GloTM assay reagent (Promega, Madison, Wisconsin) according to the manufacturer’s 
protocol. Maximum responses and the concentrations of half the effective response 
(EC50) were determined by performing a best-fit analysis of the data (GraphPad Prism).  
Cell-based inhibition assays 
 The assays were performed as described previously (Smith et al., 2005). Briefly, 
250,000 cells were seeded onto 60 mm dishes and after 24 hours the inhibitor 
treatments were commenced. Compound 7 was used at 25 M for 24 h, and SL0101 (1) 
was used at 100 M for 2 hours. 20 minutes before lysing the cells phorbol myristate 
acetate (PMA) at 500 nM was added to the media. Lysis was performed as described 
previously (Joel et al., 1998). The lysates were normalized to total protein, 
electrophoresed and immunoblotted. Antibodies used on cell lysates include anti-
(Lys/Arg)X(Lys/Arg)XX(pSer/pThr) motif (9611), anti-eEF2 (2332), anti-peEF2 (2331), 
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monoclonal anti-cyclin D1 (2926) from Cell Signaling Technology (Danvers, MA), and 
monoclonal anti-Ran (610341) from BD Tranduction Laboratories (Franklin Lakes, NJ). 
Secondary antibodies used were donkey anti-rabbit and goat anti-mouse conjugated 
with horseradish peroxidase (HRP) from Jackson ImmunoResearch Laboratories (West 
Grove, PA). 
General chemistry methods and materials  
 1H and 13C spectra were recorded on 270 MHz, 400 MHz and 600 MHz 
spectrometers. Chemical shifts were reported relative to benzene-d6 ( 7.16 ppm), 
CDCl3 ( 7.26 ppm), CD3OD ( 3.31 ppm), acetone-d6 ( 2.05 ppm), D2O ( 4.80 ppm) 
for 1H, and benzene-d6 ( 127.68 ppm), CDCl3 ( 77.0 ppm), CD3OD ( 49.15 ppm), 
acetone-d6 ( 29.92 ppm) for 13C. Optical rotations were measured with a digital 
polarimeter at sodium D line (589 nm) and were reported in concentration of g / 100 mL 
at 25 °C in the solvent specified. Infrared (IR) spectra were obtained on a FT-IR 
spectrometer. Flash chromatography was performed using the indicated solvent system 
on silica gel standard grade 60 (230-400 mesh). Rf values are reported for analytical 
TLC using the specified solvents and 0.25 mm silica gel 60 F254 plates that were 
visualized by UV irradiation (254 nm) or by staining with KMnO4 stain or p-anisaldehyde 
stain. Ether, tetrahydrofuran, methylene chloride, toluene, and triethylamine were dried 
by passing through activated alumina (8 x 14 mesh) column with argon gas pressure. 
Commercial reagents were used without purification unless otherwise noted. Air and/or 
moisture-sensitive reactions were carried out under an atmosphere of argon/nitrogen 
using oven/flamed-dried glassware and standard syringe/septum techniques.  
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General Synthetic Procedures 
 To a solution of tri-benzyl protected compounds (0.08 mmol) in 2 mL THF-EtOH 
(1:1) was added 20 mg Pearlman’s catalyst (Pd-C, 10%). The reaction mixture was 
degassed using vacuum at 90 °C and refilling with H2. This procedure was repeated 
three times, then the bath was removed and the reaction was warmed up to room 
temperature. The reaction mixture was stirred under a H2 atmosphere for 3-4 hours. The 
reaction mixture was loaded onto silica gel and elution with hexane-EtOAc (7:3 to 1:3) 
to give deprotected products 1-8 (54 to 91 % yield). 
3.2. Results 
 The family of Ser/Thr protein kinases, RSK, has been implicated in numerous 
different cancers including breast, lung and prostate cancer (Eisinger-Mathason et al., 
2010, Clark et al., 2005, Lara et al., 2011). There are four RSK family members and of 
these RSK1 and RSK2 promote metastasis. RSK is an unusual kinase in that it contains 
two non-identical functional kinase domains, an N-terminal (NTKD) and a C-terminal 
(CTKD) kinase domain (Anjum and Blenis, 2008). The NTKD, which has a high 
sequence homology between family members, belongs to the AGC kinase family and is 
responsible for phosphorylation of target substrates. We previously identified that 
SL0101 (1) (Fig. 11A), a kaempferol--L-(3”,4”)-diacylrhamnoside, was a specific 
inhibitor of the NTKD of RSK, and did not inhibit the two most closely related kinases, 
p70 S6-inase and mitogen- and stress-activated kinase (Smith et al., 2005). In in vitro 
kinase assays with ~70 kinases, SL0101 (1) was found to partially inhibit Aurora B and 
PIM3 (Doehn et al., 2009, Bain et al., 2007).  
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Figure 11*. Structure-based design of novel analogues of SL0101 (1) 
A) The RSK inhibitor, SL0101 (1), and analogues examined in this study. 
B) Pharmacokinetic analysis of SL0101 (1) in male CD-1 mice. AUC/D: area under the 
curve, extrapolated to infinity and normalized to the dose in mg/kg. C0 (ng/mL): 
maximum plasma concentration extrapolated to t=0. Cmax (ng/mL): maximum plasma 
concentration. t1/2 (h): half-life 
C) A hydrophobic pocket within the RSK2 NTKD allows for an extended 5” aliphatic 
chain on the rhamnose. Molecular docking of analogues 3”, 4” di-acetyl versions of 3 
and 4 (inset) were performed using the X-ray crystallographic structure of SL0101 in 
complex with RSK2 NTKD. 
 
* B) performed at Absorption Biosystems 
* C) contributed by Michael K. Hilinski 
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 However, these results are not straightforward to interpret because the relative 
kinase inhibition is dependent on the [ATP] in the assay. In both screens the [ATP] was 
higher in the RSK kinase assay than in Aurora B and PIM3, which would result in 
SL0101 (1) being less effective against RSK than in the assay conditions used for 
Aurora B and PIM3. 
 An effective inhibitor of RSK in vivo would be invaluable in the study of RSK 
function in homeostasis and in disease states. To evaluate the suitability of SL0101 (1) 
for in vivo use we analyzed its pharmacokinetic behavior by intravenous (i.v.) and 
intraperitoneal (i.p.) administration of a single dose into male CD-1 mice. Because of the 
limited solubility of SL0101 (1) a carrier of 1:1:15 Cremophor:EtOH:PBS was required.  
Regardless of the dosing method, the half-life (t1/2) of SL0101 (1) was < 30 min (fig. 
11B). More importantly, the maximum concentration achieved was ~ 10-fold below that 
required to completely inhibit proliferation of the breast cancer cell line, MCF-7, in 
culture (Smith et al., 2005). Thus, SL0101 (1) is not suitable for in vivo testing and a 
medicinal chemistry effort is required to identify analogues with improved 
pharmacokinetic properties, as well as potency and stability. 
 The crystal structure of SL0101 (1) in complex with the RSK2 NTKD has been 
reported (Utepbergenov et al., 2012). The SL0101 (1) binding pocket overlaps with the 
ATP binding site of the NTKD but is distinct from it, as it is formed by a substantial 
structural rearrangement of the N-lobe of the kinase domain. The interaction of SL0101 
(1) with RSK is partially stabilized by hydrogen bonds between the protein and phenolic 
hydroxyls on the kaempferol backbone in which the hydroxyl groups serve as hydrogen 
bond donors. Previously, we determined that loss of any of these hydroxyl groups 
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substantially decreased the affinity of RSK for SL0101 (1) (Smith et al., 2007). 
Furthermore, an analogue in which the hydroxyl groups were O-methylated and 
therefore could not donate hydrogen bonds did not inhibit RSK (Smith et al., 2007). 
Thus our previous experience with the SAR of SL0101 (1) analogues is in good 
agreement with the crystallographic model, which supports its use in designing future 
analogues. 
 The crystallographic model of the RSK2 NTKD in complex with SL0101 (1) 
indicates that the 5” methyl of the rhamnose only partially fills a hydrophobic pocket 
(Utepbergenov et al., 2012). We modeled a set of analogues bearing longer aliphatic 
chains at the 5” position using the docking function of the Molecular Operating 
Environment (MOE) program. The RSK2 NTKD in complex with SL0101 (1) was used 
as a starting point for the calculations. The kinase was processed and the analogues 
constructed in the binding pocket from the crystallized inhibitor SL0101 (1) using the 
build function. We performed a docking calculation using the “rigid receptor” presets on 
both SL0101 (1) and the analogues, and the highest-scoring binding pose as 
determined by the calculated binding free energy in each case was consistent with the 
crystal structure of the complex. The results clearly show that the longer aliphatic chains 
occupy a hydrophobic area in the binding pocket unoccupied by any fragment of 
SL0101 (1) (Fig. 11C). Thus, we envisioned a series of C-5” substituted analogues of 
SL0101 (2–4, Fig. 11A). The acetyl groups on the rhamnose contribute substantially to 
the IC50 for RSK inhibition as deacetylated SL0101 is ~ 10-fold less potent than SL0101 
(Smith et al., 2007). Therefore, we also envisioned a series of analogues in which the 
number and positioning of the acetyl groups were varied in combination with the 5” n-
119 
 
propyl group. Efficacy of SL0101 analogues in cell-based assays can be limited by their 
solubility (Hilinski et al., 2012) so we selected the 5” n-propyl analogue (3) as the parent 
compound based on its lower LogP compared to 4 (fig. 12). 
 Previously, we reported both a traditional carbohydrate (Maloney and Hecht, 
2005) and a de novo asymmetric approach (Shan et al., 2010, Borisova et al., 2010, 
Guo and O'Doherty G, 2005, Baiga et al., 2008) to SL0101 (1) (Shan and O'Doherty, 
2006) and several carbohydrate analogues (1,1a-d, fig. 13A) (Shan and O'Doherty, 
2010). While the carbohydrate approach has some real advantages in terms of 
convergency, the de novo approach has the advantage of being amenable to the 
divergent late stage substitution of the pyranone ring (Elbaz et al., Wang et al., 2011a, 
Wang et al., 2011b, Wang et al., 2011c, Iyer et al., 2010, Zhou and O'Doherty, 2006, 
Zhou and O'Doherty, 2007, Zhou and O'Doherty, 2008a). Because of its inherent ability 
to incorporate C-5” substitution, we decided to further develop the de novo approach to 
pursue the synthesis and evaluation of the rhamno-sugar of SL0101 analogues 2 - 8. 
 Based on or previous experience with SL0101 (1), we envisioned the desired 
target molecules 2-8 as being derived from the appropriately substituted pyranones 
12a-d (fig. 13B). Key to the overall efficiency of this approach is that the enone served 
as precursor for the installation of the desired triol functionality in 2-8 for further 
acylation.  
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Figure 12. In vitro potency of SL0101 (1) and analogues 
IC50: Concentration needed for 50% inhibition of RSK2; the 95% CI is shown in 
parentheses; n>2 in quadruplicate; p(1): student’s t-test compared to SL0101 (1); p(3): 
student’s t-test compared to analogue 3. 
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Figure 13*. Synthesis of SL0101 analogues 
A) De novo approach to SL0101 (1) 
B) Retrosynthetic analysis of SL0101 (1) analogues 
C) Synthesis of SL0101 analogues 2-8 
*Figure contributed by George O’Doherty.
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 Similarly, pyranones 12a-d could be prepared from a palladium-catalyzed 
glycosylation of aglycon 10 with Boc-pyranones 11a-d serving as the glycosyl-donor 
(Babu et al., 2004a, Babu et al., 2006, Babu and O'Doherty G, 2005, Zhou and 
O'Doherty, 2008b, Guo and O'Doherty, 2008, Yu and O'Doherty, 2008, Wu et al., 2010). 
Finally, pyranones 11a-d could be derived from furans 13a-d (Harris et al., 1999, Harris 
et al., 2000a, Li et al., 2004, Yu et al., 2011). To accomplish this divergent synthetic 
effort we planned on preparing all the desired target molecules 2-8 by executing 
multistep parallel reactions on three key intermediates (14b-d). 
 With the desired coupling partners in hand (10 and 11b-d), we first pursued their 
coupling and diastereoselective transformation into the two divergent points allylic 
alcohols 14b-d. Exposure of 11b-d and 10 to our typical Pd-catalyzed glycosylation 
procedure (2.5 mol % Pd2(DBA)3•CHCl3 and 10 mol% of PPh3) gave the coupling 
products 12b-d with complete transfer of anomeric stereochemistry (fig. 13C). A 
subsequent Luche reduction (NaBH4 at -78 °C) diastereoselectively converted the 
pyranones 12b-d into the desired allylic alcohols 14b-d (dr > 20:1).  
 We next pursued the direct conversion of allylic alcohols 14b-d into the desired 
triols 2-4 with rhamno-stereochemistry. This was accomplished in parallel by exposing 
14b-d to typical Upjohn dihydroxylation conditions (NMO/OsO4 in t-BuOH/acetone). The 
crude products from the dihydroxylation reactions were filtered through a pad of silica 
gel (to remove osmium, N-methylmorpholine and its N-oxide (NMO)) and subjected to 
typical hydrogenolysis conditions (10% Pd/C, 1 atm H2). To our delight, the three 
desired SL0101 (1) analogues 2-4 could be isolated in pure form after careful silica gel 
chromatography (43-63% yield). 
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 Buoyed by our success, we next pursued the direct conversion of 14c into 5-8, 
by incorporating selective acylation steps to the previous 2-step sequence. For 
instance, the allylic alcohol 14c, with an n-Pr-group, was cleanly converted to the C-4 
acetylated rhamno-diol 5 (i.e. acylation/dihydroxylation/hydrogenolysis) in 15% yield 
after silica gel chromatography. By simply switching the order of acylation and 
dihydroxylation, the triacetate 8 was similarly prepared in a 60% overall yield. In 
contrast, the synthesis of diacetates 6 and 7 required selective diacylation using the 
orthoester/acylation/hydrolysis/hydrogenolysis protocol to give 6 (57% overall yield). 
Finally, by incorporating an isomerization step in the sequence (i.e. 
orthoester/acylation/isomerization/hydrogenolysis) C-3/C-4 diacetate 7 could be 
prepared in a 25% overall yield. 
 The affinities of the C5”- substituted analogues for RSK were determined by their 
ability to inhibit the activity of purified, recombinant RSK2 in an in vitro kinase assay 
(Smith et al., 2005). The data were fit using nonlinear regression analysis. There was a 
trend toward improving the in vitro potency by increasing the chain length, which is 
consistent with the modeling results indicating that longer chains would be preferred, 
although the differences did not obtain statistical significance (fig. 12). We have 
reported a lower IC50 for the synthesized SL0101 (1) (Smith et al., 2006). However, the 
IC50 is relative and dependent on numerous variables including the batch of purified, 
recombinant RSK2. Therefore, to accurately evaluate the relative potencies of the 
various analogues each assay was performed in parallel with SL0101 (1). 
 In the in vitro kinase assay, introduction of a single acetyl group as in analogue 5 
increased the IC50, but this difference was not statistically significant (fig. 12). Acetyl 
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groups on the 2”, 3” and 4” position (analogue 8) doubled the IC50 in comparison to the 
5” n-propyl (analogue 3) (fig. 12). Acetyl groups on the 2” and 4” positions (analogue 6) 
did not alter the IC50.  Surprisingly, analogue 7 with acetyl groups on the 3” and 4” 
position has an IC50 >40-fold lower than SL0101 (1) (fig. 12). These results were 
unexpected because, although previously we had found acetylation to be important, the 
number or positioning of the acetyl groups was not (Smith et al., 2007). In the crystal 
structure of SL0101 (1) in complex with the RSK2 NTKD the acetyl groups are 
unresolved (Utepbergenov et al., 2012). However, we speculate that the favorable van 
der Waals interactions between the 5” n-propyl group and hydrophobic residues in the 
binding pocket restrict the binding orientation of this set of analogues in such a way that 
only acetyl groups in the 3” and 4” positions can be accommodated without causing 
unfavorable interactions in the binding pocket. 
 Analogue 7 was further evaluated for its ability to inhibit the proliferation of the 
breast cancer cell line, MCF-7, in comparison to SL0101 (1). The aqueous solubility of 7 
limited the concentrations that could be tested to ≤25 M. At 25 M compound 7 was 
~50% more potent at inhibiting proliferation than SL0101(1)(fig. 14A). To determine 
whether analogue 7 was specific for RSK we compared the ability of the compound to 
inhibit proliferation of MCF-7 versus the immortalized, normal breast line, MCF-10A. We 
have previously found that a preferential ability to inhibit MCF-7 compared to MCF-10A 
proliferation indicates specific inhibition of RSK (Smith et al., 2005, Smith et al., 2006, 
Smith et al., 2007, Hilinski et al., 2012). We observed that compound 7 inhibits MCF-7 
but not MCF-10A proliferation (Fig. 14B). These results suggest that compound 7 and 
SL0101 (1) have similar specificities. 
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Figure 14*. Specificity and efficacy of SL0101 (1) and 7 in cell-based assays 
A) Efficacy of SL0101 (1) and 7 in MCF-7 cells. Various concentrations of inhibitors 
were added at time 0 and ATP content was measured after 48 h of treatment. 
Values are the fold proliferation as a percentage of that obtained with vehicle-treated 
cells. (n=3 in quadruplicate; bars =SD; * p<0.05 in a student’s t-test compared to the 
vehicle. ^ p<0.05 in a student’s t-test compared to SL0101 (1)). 
B) Specificity of analogue 7 for inhibition of RSK activity. Various concentrations of 7 
were added to MCF-7 or MCF-10A cells and the assay performed as described in 
panel A. (n=3 in quadruplicate; bars =SD; * p<0.05 in a student’s t-test compared to 
the vehicle). 
C) Comparison of compound 7 and SL0101 (1) on altering RSK biomarkers in intact 
cells. Lysates of MCF-7 cells that were pretreated with inhibitor (SL0101 (100 mM); 
7 (25 mM)) and then treated with vehicle (DMSO) or PMA were analyzed by 
immunoblotting. The arrow indicates a band whose intensity decreases upon 
treatment of cells with SL0101 (1) and analogue 7. 
* Panels A and B contributed by David Clark. 
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 To further examine the specificity of analogue 7 we compared the ability of 
SL0101 (1) and compound 7 to alter the phosphorylation of eukaryotic elongation factor 
2 (eEF2). Inhibition of RSK is known to activate EF2 kinase, which phosphorylates 
eEF2 (Wang et al., 2001a). MCF-7 cells were treated with inhibitor or vehicle and then 
stimulated with the mitogen, phorbolmyristate acetate (PMA). In the presence of PMA, 
peEF2 levels decreased as expected as RSK is active and inhibits EF2 kinase. 
Treatment with SL0101 (1) and compound 7 both increased pEF2 levels compared to 
the PMA control (fig. 14C), which is consistent with inhibition of RSK. We have also 
found that the levels of the oncogene, cyclin D1, are dependent on RSK activity in MCF-
7 cells (Eisinger-Mathason et al., 2008). Consistent with these data SL0101 (1) and 
compound 7 decreased cyclin D1 levels. As a further comparison of the inhibitory 
profiles of SL0101 (1) and analogue 7, we immunoblotted the lysates with an antibody 
that recognizes the (Lys/Arg)X(Lys/Arg)XX(pSer/pThr) motif, where X is any amino acid 
(Anjum and Blenis, 2008). This motif is recognized by a number of kinases including 
RSK. Treatment with the inhibitors resulted in a decrease in the intensity of a band at 
~27 kDa. It is not surprising that we only observed a decrease in a single band as PMA 
is a potent mitogen that will activate many kinases. The intensities of the bands in the 
immunoblot were similar between SL0101 (1) and analogue 7. Taken together, these 
results indicate that SL0101 (1) and compound 7 have similar specificities. 
 In summary, we used structure-based design to identify new SL0101 (1) 
analogues that improve on the in vitro potency of SL0101 (1). A 5” n-propyl substituent 
in combination with 3” and 4” acetyl groups (7) on the rhamnose improved the in vitro 
affinity for RSK by > 40-fold compared to SL0101 (1). Analogue 7 specifically inhibits 
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RSK but its ability to inhibit the proliferation of the breast cancer cell line, MCF-7, is only 
2-fold better compared to SL0101 (1), which we hypothesize is due to limited membrane 
permeability. These studies will provide further guidance in designing a potent SL0101 
(1) analogue that can be used in vivo. 
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Chapter 4 
De novo synthesis and biological evaluation of C6”-substituted C4’’-amide 
analogues of SL0101 
Adapted from: 
Mrozowski, R.M., Sandusky, Z.M., Vemula, R., Wu, B., Zhang, Q., Lannigan, D.A., 
O'Doherty, G.A. De novo synthesis and biological evaluation of C6”-substituted C4’’-
amide analogues of SL0101 (2014) Org. Lett., 16: 5996-5999. 
 
Summary 
 In an effort to improve upon the in vivo half-life of SL0101, C4”-amides/C6”-alkyl 
substituted analogues of SL0101 were synthesized and evaluated in cell-based assays. 
The analogues were prepared using a de novo asymmetric synthetic approach, which 
featured Pd--allylic catalyzed glycosylation for the introduction of a C4”-azido group.  
Surprisingly replacement of the C4”-acetate with a C4”-amide resulted in analogues that 
were no longer specific for RSK in cell-based assays. 
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4.1. Methods 
Purified recombinant RSK2 
 Baculovirus expressing RSK2 cDNA was produced using Bac-to-Bac baculovirus 
expression system (Invitrogen, Carlsbad, CA). His-tagged RSK2 was expressed and 
activated in Sf9 cells by stimulating with mitogen, phorbol myristate acetate (PMA). 
Recombinant protein was purified using NiNTA resin (Qiagen, Valencia, CA). 
In vitro kinase assays 
 The assays were performed as previously described (Smith et al., 2005). Briefly, 
glutathione-S-transferase (GST)- tagged fusion protein (1 g) containing the ER-
Ser167 sequence RLASTND was adsorbed onto a 96-well MaxiSorp-treated white 
polystyrene plate (Thermo Scientific Nunc, Roskilde, Denmark). The wells were blocked 
with 3% tryptone in phosphate-buffered saline. 50 L of kinase (5 nM) in kinase buffer 
(25 mM HEPES, 150 mM NaCl, 5 mM -glycerophosphate, 1.5 mM DTT, 30mM MgCl2, 
pH 7.4) and 25 L of the compound at the indicated concentrations were added to each 
well and incubated for 120 min. The reactions were initiated by adding 25 L of ATP 
(final concentration 10 M) and terminated 20 minutes later by addition of 0.5 M EDTA, 
pH 8.0. All assays measured initial reaction velocity.  The plates were extensively 
washed and phosphorylation of substrate was detected using rabbit polyclonal anti-
ER-pSer167 antibody (Smith et al., 2005) and horseradish peroxidase (HRP)-
conjugated donkey anti-rabbit antibody (Jackson ImmunoResearch Laboratories, West 
Grove, PA). HRP activity was measured using Western Lightning Plus-ECL 
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(PerkinElmer Life Sciences, Waltham, MA). Half-inhibitory concentration (IC50) values 
were calculated using non-linear regression analysis of the data (GraphPad Prism 6). 
Proliferation assays 
 The assays were performed as previously described (Smith et al., 2005). Briefly, 
MCF-7 cells were seeded at 20,000 cells/well into 24-well tissue culture plates in DMEM 
low-glucose medium with 5% fetal bovine serum (FBS). Compound or vehicle was 
added and proliferation was measured 48 hours later using CellTiterGlo assay reagent 
(Promega, Madison, WI) according to the manufacturer’s protocol. Concentration of 
50% inhibition in proliferation (IC50) was determined using non-linear regression 
analysis of the data (GraphPad Prism 6). 
Cell-based inhibition assays 
 The assays were performed as previously described (Smith et al., 2005). Briefly, 
200,000 MCF-7 cells were seeded onto a 35 mm dish in DMEM low-glucose medium 
with 5% FBS. 24 hours later medium was changed for a serum-free medium. 16 hours 
later vehicle DMSO was added with or without serum, and inhibitors were added in 
serum-containing medium, for 2 hours. 20 minutes prior to collecting lysates, cells in 
serum-containing medium were further stimulated with PMA (500 nM). Lysis was 
performed as described previously (Joel et al., 1998). Equal amounts of total protein 
were electrophoresed and immunoblotted. Antibodies used for immunoblotting include 
anti-RxRxx(pS/T) (9611), anti-eEF2 (2332), anti-peEF2 (2331), anti-S6 protein (2217), 
anti-p-S6 protein (2211) and monoclonal anti-cyclin D1 (2926) from Cell Signaling 
Technology (Danvers, MA). 
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General chemistry methods and materials 
1H and 13C spectra were recorded on 270 MHz, 400 MHz and 600 MHz spectrometers. 
Chemical shifts were reported relative to benzene-d6 (δ 7.16 ppm), CDCl3 (δ 7.26 ppm), 
CD3OD (δ 3.31 ppm), acetone-d6 (δ 2.05 ppm) for 1H, and benzene-d6 (δ 127.68 ppm), 
CDCl3 (δ 77.0 ppm), CD3OD (δ 49.15 ppm), acetone-d6 (δ 29.92 ppm) for 13C. Optical 
rotations were measured with a digital polarimeter at sodium D line (589 nm) and were 
reported in concentration of g/100 mL at 25 ºC in the solvent specified. Infrared (IR) 
spectra were obtained on a FT-IR spectrometer. Flash chromatography was performed 
using the indicated solvent system on silica gel standard grade 60 (230-400 mesh). Rf 
values are reported for analytical TLC using the specified solvents and 0.25 mm silica 
gel 60 F254 plates that were visualized by UV irradiation (254 nm) or by staining with 
KMnO4 stain or p-anisaldehyde stain. Ethyl ether, tetrahydrofuran, methylene chloride, 
toluene, and triethylamine were dried by passing through activated alumina (8 x 14 
mesh) column with argon gas pressure. Commercial reagents were used without 
purification unless otherwise noted. Air and/or moisture-sensitive reactions were carried 
out under an atmosphere of argon/nitrogen using oven/flamed-dried glassware and 
standard syringe/septum techniques.  
4.2. Results 
 RSK is a family of Ser/Thr kinases, which are downstream effectors of the 
extracellular signal-regulated kinase 1/2 pathways (Eisinger-Mathason et al., 2010). 
RSK appears to be involved in the etiology of a number of different cancers and 
importantly, regulates a motility/invasive gene program (Lara et al., 2011, Doehn et al., 
2009).  
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 RSK is a dual kinase domain protein with the N-terminal kinase domain (NTKD) 
responsible for phosphorylation of target substrates (Anjum and Blenis, 2008). In a 
screen of botanical extracts SL0101 (1), a flavonoid glycoside, was identified as an 
inhibitor of the NTKD of RSK (Smith et al., 2005). SL0101 (1) is a relatively selective 
inhibitor for RSK with a Ki of ~ 1 M. From the crystal structure of SL0101 (1) 
complexed with the NTKD isoform of RSK2 (Utepbergenov et al., 2012) and de novo 
synthetic studies (Maloney and Hecht, 2005, Shan and O'Doherty, 2010, Shan and 
O'Doherty, 2006, Aljahdali et al., 2013, Bajaj et al., 2014) we identified analogues (2 and 
3) with C6”-substitutions of the rhamnose that showed improved efficacy in the in vitro 
kinase assays (chapter 3).  
 SL0101 (1) has a short biological half-life in vivo (chapter 3), which is presumably 
due to hydrolysis of the C3”/C4”-acetates which are necessary for high affinity 
interaction with RSK (Smith et al., 2005). To identify less labile groups that could 
replace the ester without loss of affinity, we investigated replacing the C4”-acetate with 
a C4”-acetamide in combination with the C6” substitution that we previously identified 
(chapter 3). Specifically, we targeted six C4”-acetamide analogues 4a-d and 5a-b (fig. 
15).   
 Retrosynthetically, we envisioned that C4”-acetamide substituted analogues 6 
could arise from C4”-azido sugar 7a, which could be prepared from enone sugar 7c via 
allylic carbonate 7b (fig. 16A). Previously we have shown that C4 allylic azides like 7a 
could be prepared from C4 allylic carbamates like 7b via Pd-catalyzed allylic alkylation 
(Guo and O'Doherty, 2006, Abrams et al., 2008, Borisova et al., 2010). However, this 
approach was not compatible for pyran rings with a C1 kaempferol group.  
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Figure 15. C4”-amide analogues of SL0101.
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To address this issue, a Pd-glycosylation method was developed for the direct 
incorporation of a C4 azido sugar. 
 Our synthesis started with exposure of flavonol 9 and Boc-pyranone 13 to our 
typical glycosylation conditions (2.5 mol % Pd2(DBA)3•CHCl3 and 10 mol % of PPh3 in 
CH2Cl2 at 0 ºC; 95%), which produced glycosylated pyranone 14 with complete a-
selectivity (fig. 16B). Reduction of the enone 14 (NaBH4, -78 ºC in CH2Cl2/MeOH; 72%) 
resulted stereoselectively in allylic alcohol 15 (Maloney and Hecht, 2005, Shan and 
O'Doherty, 2010, Shan and O'Doherty, 2006, Aljahdali et al., 2013, Bajaj et al., 2014). A 
methyl carbonate leaving group was installed on the allylic alcohol by reaction of 15 with 
methyl chloroformate to form the C4”-carbonate 16 in 75% yield. Unfortunately, 
exposure of carbonate 16 to the Sinou conditions (TMSN3, (Pd(allyl)Cl)2/1,4-
bis(diphenylphosphino)-butane) failed to afford the desired regio- and stereoisomeric 
allylic azide 17. The C-1 kaempferol proved to be the better leaving group, as only 
products consistent with the hydrolysis at the anomeric position were observed.(Babu et 
al., 2006, Guppi and O'Doherty, 2007). 
 To solve this problem, we decided to try reversing the sequence of the two Pd--
allyl substitution reactions, which required the synthesis of allylic azides 29 and 30 (fig. 
16C). This began with a palladium-catalyzed glycosylation (Pd(0)/PPh3, 1:2) of p-
methoxybenzyl alcohol with Boc-pyranones 13 and 18 which stereoselectively afforded 
PMB-pyranones 19 and 20 (95% and 92% respectively). Diastereoselective reduction of 
the two enones (NaBH4, -78 ºC in CH2Cl2/MeOH; 92% and 84%) gave allylic alcohol 21 
and 22. Treatment of the two allylic alcohols with methyl chloroformate in the presence 
of a catalytic amount of DMAP gave the allylic carbonates 23 and 24 (94% and 90%).  
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Figure 16*. Synthesis of C4”-amide analogues of SL0101, part 1. 
A) Retrosynthesis of C4”-amide SL0101 analogues 
B) Unsuccessful approach to C4”-azide sugar 17 
C) Synthesis of C4”-azide sugar glycosyl donors 29/30. 
*Figure contributed by George O’Doherty. 
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Figure 17*. Synthesis of C4”-amide analogues of SL0101, part 2. 
A) Synthesis of C4”-azido rhamno-sugars 32/33 SL0101 analogues. 
B) Synthesis of C4”-amide analogues of SL0101 (4/5). 
* Figure contributed by George O’Doherty.
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Figure 18*. Evaluation of in vitro and cell-based potency of SL0101 (1) and analogues. 
A) In vitro potency of SL0101 (1) and analogues. RSK2 IC50: concentration needed for 
50% RSK2 inhibition (n > 2; quadruplicate: mean, S.D.; p: Student’s t test compared 
to SL0101).  
B) Inhibition of MCF7 proliferation at 100 mM SL0101 (1) and analogues. MCF7 
proliferation: (n > 2; triplicate: mean, S.D.; * Student’s t-test compared to control; # 
Student’s t test compared to SL0101). p < 0.01 significant 
C) Compound 4d significantly inhibits proliferation of MCF7 and MCF10A cells. n > 2; 
triplicate: mean, S.D.; * Student’s t-test compared to control. 
D) RSK biomarkers comparison of 4d and 1. Comparison of analogue 4d and SL0101 
(1) was made against known RSK biomarkers in intact cells. MCF-7 cells were pre-
treated with 4d at the indicated concentrations and then treated with vehicle or PMA. 
Lysates were analyzed by immunoblotting. The motif, (K/R)x(K/R)xx(pS/pT), is 
recognized by a number of kinases, including RSK. The arrows indicate bands 
whose intensity is altered upon treatment of cells with SL0101 (1). 
* Panels B and C contributed by Deborah Lannigan. 
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 Exposure of the carbonates to the Sinou conditions (TMSN3, (Pd(allyl)Cl)2/1,4-
bis(diphenylphosphino)-butane) regio- and stereospecifically afforded the desired allylic 
azides 25 and 26 (73% and 75%). An oxidative PMB deprotection (DDQ/H2O) of 25 and 
26 provided anomeric alcohols 27 and 28 as a 13:1 mixture of anomers in 73% and 
78% yields. The following Boc-protection of the two alcohols produced the key azido 
containing intermediates 29 and 30 in 84% and 82% yields and with excellent 
diastereoselectivity. 
 To our delight, exposure of sugar donor Boc-allylic azides 29 and 30 and 
acceptor 9 to our typical Pd-catalyzed glycosylation condition provided our desired 
glycosylated allylic azides 17 and 31 in excellent yield (98% and 90%) with complete -
selectivity and no sign of hydrolysis at the anomeric position. Exposure of the two allylic 
azides to Upjohn conditions (OsO4/NMO; 91% and 87%) stereoselectively converted 
them into the two rhamno-diols 32 and 33, which are poised for further manipulation into 
the desired SL0101 analogues (fig. 17A). 
 We next investigated the reduction and acylation of azido/diols 32 and 33 (fig. 
17B) (Maloney and Hecht, 2005, Shan and O'Doherty, 2010, Shan and O'Doherty, 
2006, Aljahdali et al., 2013, Bajaj et al., 2014). Fortuitously, both the C4 acylated 
amides 36 and 37 and C3/C4 bis-acylated products 34 and 35 were generated at a ~1:1 
mixture in one pot from the reduction of 32 and 33 with zinc dust in the presence of 
acetic anhydride and acetic acid. Thus, the reduction acylation of 32 gave the desired 
C4”-acetamides 36 (29%) and 34 (27%), whereas the reduction acylation of 33 gave the 
desired C4”-acetamides 37 (36%) and 35 (32%). 
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 The intermediates 34-37 were globally deprotected by an exhaustive 
hydrogenolysis, which produced four of the desired analogues. Thus, exposure of 34 
and 35 to typical hydrogenolysis conditions (1 atm. of hydrogen with Pearlman’s catalyst 
(Pd/C)) furnished 4b and 5b in good yields (86% and 88%, respectively).  Exposure of 
36 and 37 to similar hydrogenolysis conditions furnished 4a and 5a in good yields (90% 
and 86%, respectively). Finally the last two analogues 4c and 4d were prepared by an 
acylation deprotection sequence. The peracylated product 4d was prepared from 34 in 
91% overall yield by bis-acylation (Ac2O, DMAP/Py; 97%) and exhaustive 
hydrogenolysis. Similarly, the C2 acylated product 4c was prepared from 36 via an 
ortho-ester mediated C2-acylation (CH3C(OMe)3, 10% p-TsOH in CH2Cl2; then excess 
90% AcOH/H2O; 85%) and per-hydrogenolysis (94% overall yield). 
 The efficacy of the analogues 4a-d and 5a-b to inhibit RSK2 activity was 
determined in an in vitro kinase assays using purified recombinant RSK2 (fig. 18A) 
(Smith et al., 2005). The data were fit using nonlinear regression analysis.  In the n-Pr 
series 4b and 4c with a single acetate at C3” or C2”-position, had significantly lower 
IC50’s compared to SL0101 (1). However, when compared with our best analogue 2a, 
(C3”/C4”-diacetate, fig. 15) the related C4”-acetamide 4b had a 10-fold increase in IC50 
(chapter 3). The IC50’s for 4a with no C2”- or C3”- acetate and 4d with two acetates 
were not statistically different from that of SL0101 (1). These results are similar to those 
obtained in the series in which the acetyl group was at the C4” position (chapter 3). In 
the isobutyl series the C3”-acetate 5b had a three-fold improved IC50 compared to that 
of SL0101 (1), whereas, 5a with no C2”- or C3”- acetate had a much poorer IC50 than 
SL0101 (1). These data suggest that in the n-Pr-series, the C”4-acetamide can replace 
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the C”4-acetate without dramatically compromising the affinity of the analogues for 
RSK2.   
 The six analogues were evaluated for their ability to decrease proliferation of the 
breast cancer cell line, MCF-7 (fig. 18B). Initially, each analogue was tested at a dose of 
100 M and compared to SL0101 (1). Analogue 4d was the only analogue that inhibited 
proliferation to a greater extent than SL0101 (1) (fig. 18B). A dose response curve with 
4d showed that cytostasis occurred at ~ 35 M and substantial cell death occurred at ~ 
50 M (fig. 18C). For comparison SL0101 (1) at 100 M (maximum soluble 
concentration in biological media) induces an ~ 60% reduction in proliferation. To 
evaluate whether 4d was specific for RSK, we compared its anti-proliferative effects in 
MCF-7 cells versus MCF-10A, an immortalized nontransformed human breast cell line. 
We previously found that a preferential ability to inhibit MCF-7 compared to MCF-10A 
proliferation correlates with specificity for RSK inhibition (Smith et al., 2005, Smith et al., 
2007, Hilinski et al., 2012, Smith et al., 2006, chapter 3). At 25 M 4d inhibited 
proliferation of MCF-7 cells by 50% and marginally inhibited MCF-10A proliferation (fig. 
18C).  However, at 50 M of 4d, a cytotoxic dose in MCF-7 cells, proliferation of MCF-
10A cells was inhibited by 70%. Thus 4d shows a very limited ability to preferentially 
inhibit MCF-7 proliferation and survival compared to MCF-10A cells.  These results 
suggest that 4d is not a specific RSK inhibitor in intact cells. 
 To further evaluate the specificity of 4d at inhibiting RSK we compared the 
efficacy of SL0101 (1) and 4d to alter the phosphorylation of known RSK substrates. 
We chose to test 4d at both cytostatic (25 M) and cytotoxic (50 M) concentrations. To 
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increase the phosphorylation of substrates MCF-7 cells were stimulated with the 
mitogen, phorbol myristate acetate (PMA) after a pre-treatment with inhibitor or vehicle. 
RSK phosphorylates and inhibits the activity of eukaryotic elongation factor 2 (eEF2) 
kinase (Wang et al., 2001a). Thus inhibition of RSK relieves the inhibition of eEF2 
kinase, which results in an increase in phosphorylation of the eEF2 kinase substrate, 
eEF2. As expected, activation of RSK by PMA led to a decrease in eEF2 
phosphorylation and inhibition of RSK with SL0101 (1) increased eEF2 phosphorylation 
compared to the PMA control (fig. 18D).  
 Ribosomal protein S6, a component of the 40S ribosomal subunit, is 
phosphorylated by RSK (Erikson and Maller, 1985), and in agreement with these data 
SL0101 (1) inhibits PMA-induced phosphorylation of S6. We have also found that RSK 
regulates the levels of the oncogene, cyclin D1, in MCF-7 cells (Eisinger-Mathason et 
al., 2008). Consistent with these observations SL0101 (1) inhibited cyclin D1 levels. In 
contrast with our observations with SL0101 (1), the analogue 4d did not alter the 
phosphorylation status of eEF2, S6 or the levels of cyclin D1 (fig. 18D). To further 
investigate the ability of 4d to inhibit RSK in intact cells, we immunoblotted the lysates 
with an antibody against the phosphorylation motif that is recognized by numerous 
kinases, including RSK. Treatment with SL0101 increased the phosphorylation of a 
band ~ 60 kDa and decreased the intensity of a band at ~ 27 kDa. Analogue 4d did not 
alter the phosphorylation pattern compared to the PMA control. Consistent with these 
results we observed that analogue 4b (100 M) did not alter the phosphorylation of RSK 
biomarkers or cyclin D1 levels in intact cells (data not shown). These results suggest 
that the amide analogues of SL0101 (1) are not specific for RSK. 
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 In conclusion, using de novo synthesis C4”-acetamide analogues of SL0101 with 
a C”6 substitution were prepared and evaluated as RSK inhibitors. Analogues with 
improved in vitro kinase inhibitory activity were identified. However, this increase in 
activity came at a loss of selectivity for RSK. Thus an acetate at the C4” position 
appears to be a requirement to maintain specificity for RSK inhibition.   
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Chapter 5 
Synthesis and Structure-Activity-Relationship Study of 5a-Carbasugar Analogues 
of SL0101 
Adapted from: 
Li, M., Li, Y., Mrozowski, R.M., Sandusky, Z.M., Shan, M., Song, X., Wu, B., Zhang, Q., 
Lannigan, D.A., O’Doherty, G.A. (2014) Synthesis and Structure-Activity-Relationship 
Study of 5a-Carbasugar Analogues of SL0101. ACS Med. Chem. Lett. 6: 95-99 
 
Summary 
 The Ser/Thr protein kinase, RSK, is associated with oncogenesis and therefore, 
there are ongoing efforts to develop RSK inhibitors that are suitable for use in vivo. 
SL0101 is a natural product that demonstrates selectivity for RSK inhibition. However, 
SL0101 has a short biological half-life in vivo. To address this issue we designed a set 
of eight cyclitol analogues, which should be resistant to acid catalyzed anomeric bond 
hydrolysis. The analogues were synthesized and evaluated for their ability to selectively 
inhibit RSK in vitro and in cell-based assays. All the analogues were prepared using a 
stereo-divergent palladium-catalyzed glycosylation/cyclitolization for installing the 
aglycon. The L-cyclitol analogues were found to inhibit RSK2 in in vitro kinase activity 
with a similar efficacy to that of SL0101, however, not specific for RSK in cell-based 
assays. In contrast, the D-isomers showed no RSK inhibitory activity in in vitro kinase 
assay. 
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5.1. Materials and Methods 
Purified recombinant RSK2 
 Baculovirus encoding His-tagged RSK2 cDNA was generated using the Bac-to-
Bac Baculovirus Expression System (Invitrogen, Carlsbad, CA). Recombinant RSK2 
was expressed in Sf9 cells and activated by stimulation with phorbol 12-myristate 13-
acetate (PMA). Protein was purified using the Ni-NTA Spin Kit (Qiagen, Valencia, CA). 
In vitro kinase assays 
 The assays were performed as previously described (Smith et al., 2005). Briefly, 
glutathione S-transferase (GST) ER Serine167 fusion protein containing the amino 
acid sequence RRRLASTNDKG was adsorbed in the wells (1 g/well) of MaxiSorp-
treated LumiNunc 96-well white polystyrene plates (Thermo Scientific, Roskilde, 
Denmark). The wells were blocked with 3% tryptone in PBS and stored at 4°C. Kinase 
(5 nM) in kinase buffer (25 mM HEPES, 150 mM NaCl, 5 mM -glycerophosphate, 1.5 
mM DTT, 30mM MgCl2, pH 7.4) and 1% bovine serum albumin was added to each well. 
Reactions were incubated for 120 minutes in the presence of vehicle or inhibitor at 
indicated concentrations. Reactions were then initiated by the addition of ATP (10 M) 
for 20 minutes. The reactions were terminated by addition of EDTA (500 mM, pH 8.0). 
The plates were washed and phosphorylation was measured using rabbit polyclonal 
anti-ER phospho-Serine167 antibody (Smith et al., 2005) followed by horseradish 
peroxidase (HRP)-conjugated donkey anti-rabbit antibody (Jackson ImmunoResearch 
Laboratories, West Grove, PA). Western Lightning Enhanced Chemiluminescent 
Reagent Plus (PerkinElmer Life Sciences, Waltham, MA) was used to measure HRP 
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activity. To determine IC50 values, non-linear regression analysis was performed using 
GraphPad Prism version 6.0a (La Jolla, CA). 
Proliferation assays 
 The assays were performed as previously described (Smith et al., 2005). Briefly, 
MCF-7 or MCF-10A cells were seeded at a density of 200,000 cells per well in 24-well 
tissue culture treated plates. Inhibitor or vehicle was added and proliferation was 
measured after 48 hours using CellTiterGlo reagent (Promega, Madison, WI) according 
to the manufacturer’s protocol. To determine IC50 values, non-linear regression analysis 
was performed using GraphPad Prism version 6.0a (La Jolla, CA). 
Cell-based inhibition assays 
 The assays were performed as previously described (Smith et al., 2005). Briefly, 
250,000 MCF-7 cells were seeded onto a 35-mm tissue culture dish. The next day the 
medium was replaced with serum-free medium. After 16 hours, the medium was 
changed for serum-free medium with DMSO, serum-containing medium with DMSO, or 
serum-containing medium with inhibitor. Cells were treated for 2 hours before 
stimulation with PMA (500 nM) for 20 minutes. Cell lysis was performed as previously 
described (Joel et al., 1998). Lysates were normalized for total protein, electrophoresed, 
and immunoblotted. Antibodies used for immunoblotting include; anti-
(K/R)X(K/R)XX(pS/pT) motif (9611), anti-eEF2 (2332), anti-phospho-eEF2 (2331), anti-
cyclin D1(2926), anti-S6 (2217), and anti-phospho-S6 (2211) from Cell Signaling 
Technology (Danvers, MA). Secondary antibodies used were HRP-conjugated donkey 
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anti-rabbit and goat anti-mouse (Jackson ImmunoResearch Laboratories, West 
Grove, PA). 
General chemistry methods and materials 
1H and 13C spectra were recorded on 400 MHz and 500 MHz spectrometers. Chemical 
shifts were reported relative to CDCl3 (δ 7.26 ppm), CD3OD (δ 3.31 ppm), acetone-d6 (δ 
2.05 ppm) for 1H, and CDCl3 (δ 77.0 ppm), CD3OD (δ 49.15 ppm), acetone-d6 (δ 29.92 
ppm) for 13C. Optical rotations were measured with a digital polarimeter at sodium D 
line (589 nm) and were reported in concentration of g/100 mL at 25 ºC in the solvent 
specified. Infrared (IR) spectra were obtained on a FT-IR spectrometer. Flash 
chromatography was performed using the indicated solvent system on silica gel 
standard grade 60 (230-400 mesh). Rf values are reported for analytical TLC using the 
specified solvents and 0.25 mm silica gel 60 F254 plates that were visualized by UV 
irradiation (254 nm and 365 nm) or by staining with KMnO4 stain or p-anisaldehyde 
stain. Ethyl ether, tetrahydrofuran, methylene chloride, toluene, and triethylamine were 
dried by passing through activated alumina (8 x 14 mesh) column with argon gas 
pressure. Commercial reagents were used without purification unless otherwise noted. 
Air and/or moisture-sensitive reactions were carried out under an atmosphere of 
argon/nitrogen using oven/flamed-dried glassware and standard syringe/septum 
techniques. Melting points are uncorrected. Matrix-assisted laser desorption ionization 
time-of-flight (MALDI-TOF) mass spectra were obtained using α-cyano-4-
hydroxycinnamic acid (CCA) as the matrix on a MALDI-TOF mass spectrometer. 
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5.2. Results 
 The Ser/Thr kinases, RSK, have emerged as a potential drug target for 
numerous cancers (Eisinger-Mathason et al., 2010). A number of RSK inhibitors have 
been identified (Aronchik et al., 2014, Cohen et al., 2007, Cohen et al., 2005, Nguyen et 
al., 2006, Bain et al., 2007, Costales et al., 2014, Zhong et al., 2013, Doehn et al., 2009, 
Utepbergenov et al., 2012), and of these the kaempferol L-rhamnoside SL0101 (1a) is 
the only allosteric inhibitor of RSK (fig. 19A) (chapter 2)(Utepbergenov et al., 2012), 
which most likely accounts for its specificity (Bain et al., 2007). RSK is unusual in that it 
contains two nonidentical kinase domains (Anjum and Blenis, 2008).  
On the basis of the crystal structure of SL0101 (1a) in complex with the RSK2 N-
terminal kinase domain (NTKD) we generated the derivative, C3”/C4”-diacetate with a 
C6”-n-propyl substituent 2, which has a 50-fold higher affinity for RSK than SL0101 (1a) 
(chapters 3-4). In an effort to further explore the structure activity relationship of SL0101 
(1a) as it relates to RSK1-2 inhibition and anticancer activity, we targeted for synthesis 
cyclitol (aka, 5a-carbasugar) analogues of SL0101 (e.g., 3 and 4, 19B). We 
hypothesized that the cyclitol analogues (3a-c) (i.e., sans-anomeric stabilization) would 
serve as exact conformational mimics of the natural sugar; whereas the enantiomeric 
analogues (ent)-3a-c serve as control molecules. Finally, to further test the importance 
of the C6” alkyl group, we envisioned preparing and evaluating the desmethyl cyclitol 
analogue 4. 
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Figure 19. Structures of SL0101, top analogue 2 and D-/L- analogues 1-4. 
A) Structures of SL0101 (1) and top analogue 2. 
B) Structure of D-/L- SL0101 analogues 1-4. 
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Figure 20*. Synthesis of carbasugar analogues of SL0101 (1a) 
A) Enantiodivergent synthesis of SL0101 analogues 1 and 3. 
B) Enantiodivergent cyclitolization of aglycon 7 
C) Synthesis of SL0101 cyclitol analogue 4 
D) Synthesis of SL0101 cyclitol analogue (ent)-4 
* Figure contributed by George O’Doherty. 
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 We have been developing practical and generalizable approaches to both 
pyranose and 5a-carbasugar and have reported synthetic approaches to SL0101 and its 
derivatives (Bajaj et al., 2014, Harris et al., 1999, Harris et al., 2000b, Babu et al., 
2004b, Guo and O'Doherty, 2007, Zhou and O'Doherty, 2008b). The general approach 
to these analogues is outlined in fig. 20A. The technology that enables this approach 
was the use of Pd-catalyzed glycosylation (Shan et al., 2010, Shan and O'Doherty, 
2008, Babu and O'Doherty, 2003, Guo and O'Doherty, 2008) or cyclitolisation (Shan 
and O'Doherty, 2006, Shan and O'Doherty, 2010) and subsequent post-glycosylation 
transformations. Using the Pd-catalyzed glycosylation, the desired pyranose analogues 
1a-c and (ent)-1a-c were produced in five to seven steps from pyranones -L-5 and -
D-5, respectively. Using the related Pd-catalyzed cyclitolization and in the same number 
of steps, the desired cyclitol analogues 3a-c and (ent)-3a-c were produced from the 
corresponding enones -L-6 and -D-6. 
 Key to the success of this approach is the reliance of an enantio-divergent (i.e., 
D/L) and highly stereo-controlled synthesis of both glycosyl- and cyclitol-donors from 
readily available intermediates (8 and 9, fig. 20A). For instance, the pyranose glycosyl-
donors were readily prepared in three steps from achiral acylfuran intermediate 8. In 
contrast, the carbasugar cyclitol-donors 6 were significantly more difficult to prepare. 
Like the pyranones 5, the cyclitols 6 can also be prepared from a single intermediate, D-
quinic acid 9. Thus in 11 steps, D-quinic acid can be converted into -D-enone -D-6, 
whereas, in a related 12 step sequence quinic acid can be also converted into its 
enantiomeric enone, -L-6.  
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 With access to the cyclitol analogues 3, we next pursued the de novo asymmetric 
synthesis of the des-methylcycltiol analogues 4 and (ent)-4 (fig. 20C,D). Interestingly, 
the removal of the C6”-methyl group greatly simplifies the analogue synthesis. The 
simplicity of this approach is enabled by the use of the Trost asymmetric allylation of 7 
with meso-1,4-bis-benzoate 10 to form either enantiomer of cyclitol 11 (Trost and Van 
Vranken, 1996, Trost and Crawley, 2003, Trost et al., 2006). Thus by appropriate choice 
of the chiral ligand, cyclitol 11 (via (S,S)-DACH) or its enantiomer (ent)-11 (via (R,R)-
DACH) can be prepared in only one stereo-divergent step. The enantiomeric excess of 
12 and (ent)-12 were determined to be >96% ee by Mosher ester analysis. This was 
accomplished by converting 12 and (ent)-12 into their corresponding Mosher ester and 
integrating resolved diastereomeric vinyl protons in the 1H NMR. 
 With the C1”/C4” stereochemistry installed in 11, the C4” benzoate was 
transformed into an acetate (fig. 20C), via a hydrolysis and acylation sequence (11 to 
13). Using an Upjohn dihydroxylation (1% OsO4/NMO), the C2”/C3”-hydroxyl groups 
were stereoselectively installed in 14. The required C-3” acetate was regioselectively 
installed by means of the Taylor catalysis (14 to 15). Finally hydrogenolysis was used 
for a global per-debenzylation of 15 to give the desired cyclitol analogue 4. Using an 
identical sequence, the enantiomer 11 was converted into the enantiomeric analogue 
(ent)-4 (fig. 20D). 
 Using purified recombinant enzyme in an in vitro kinase assay, the analogues 
(ent)-1a, 3a-c, (ent)-3a-3c, 4 and (ent)- 4 were evaluated for their ability to inhibit RSK2 
kinase activity (Smith et al., 2005). Nonlinear regression analysis was used to fit the 
data (fig. 21A). Regardless of substitution, we found an absolute requirement for the L-
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isoform, as none of the D-isoforms displayed any RSK2 kinase inhibitory activity at 
concentrations < 30 μM. 
 Interestingly, we found that replacing the ring oxygen in the rhamnose ring with a 
methylene did not interfere with in vitro RSK2 inhibitory activity (fig. 21A). In fact, the 
cyclitol analogue 3a was a slightly better inhibitor of RSK than SL0101, albeit the 
difference is unlikely to be biologically meaningful. In contrast, the cyclitols with varied 
acetate substitution (3b and 3c) had higher IC50’s. This trend was consistent to what 
was observed for the related rhamnose sugar analogues (1b and 1c) (Smith et al., 
2006). The C6” methyl group proved to be important for activity, as the desmethyl 
analogue 4 was a poor inhibitor. Even in the less active desmethyl series, the important 
of the sugar absolute stereochemistry could be seen, as the 4 was significantly more 
active than its enantiomer (ent)-4. This result is consistent with our crystal structure of 
the RSK2 NTKD/SL0101 complex. Specifically, we observed SL0101 in a specific 3D 
orientation with the C6” methyl group residing in a key hydrophobic pocket 
(Utepbergenov et al., 2012) and that alkyl substitution of the C6” alkyl group (Me to n-
Pr) increased the affinity for RSK2 (chapter 3). 
The ability of the analogues to inhibit the proliferation of the breast cancer cell line, 
MCF-7, was compared to that obtained with the immortalized non-transformed human 
breast cell line, MCF-10A. We have found that a preferential ability to inhibit MCF-7 
compared to MCF-10A proliferation correlates with RSK inhibition (Smith et al., 2005, 
Smith et al., 2007, Smith et al., 2006). The cyclitol analogue 3b inhibited both cell lines 
to the same extent, which suggests that it does not specifically inhibit RSK (fig. 21B). 
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Figure 21*. Evaluation of in vitro and cell-based potency of SL0101 analogues. 
A) In vitro potency of SL0101 (1a) and analogues. RSK2 IC50: concentration needed 
for 50% RSK2 inhibition (n > 2; quadruplicate: mean; S.D., p(1a) Student’s t test 
compared to SL0101(1a)). N.D.: no inhibition detected. 
B) C3″,C4″ acetates are essential for preferential inhibition of MCF-7 proliferation. The 
inhibitors were added at time 0, and ATP content was measured after 48 h of 
treatment. Values are the fold proliferation as a % of the control (n ≥ 2 in triplicate; 
mean, S.D.; *p < 0.01 in a Student’s t test compared to the appropriate cell line in 
the presence of vehicle). 
C) Efficacy and specificity of analogue 3a for inhibition of RSK. As described in Figure 
B (n ≥ 2 in triplicate; mean, S.D.; *p < 0.01 in a Student’s t test compared to control). 
D) Efficacy and specificity of analogue 3c for inhibition of RSK. As described in Figure B 
(n ≥ 2 in triplicate; mean, S.D.; *p < 0.01 in a Student’s t test compared to control). 
*Figure contributed by Zachary Sandusky. 
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Figure 22. Evaluation of 3a and 3c as RSK-specific inhibitors in MCF-7 cells.  
 
A) Comparison of analogues 3a and 3c and SL0101 (1a) against known RSK 
biomarkers in intact cells. MCF-7 cells were treated with PMA after pretreatment with 
the indicated inhibitors. Lysates of the cells were immunoblotted.  
B) The motif, (K/R)x(K/R)xx(pS/pT), is recognized by a number of kinases, including 
RSK and AKT. The arrows indicate bands whose intensity is altered upon treatment 
of cells with SL0101 (1).  
C) The motif, (K/R)(K/R)x(pS/pT), is recognized by a number of kinases, including RSK 
and PKA. The arrows indicate bands whose intensity is altered upon treatment of 
cells with SL0101 (1).  
D) The motif, (K/R)x(pS/pT)(K/R), is recognized by a number of kinases, including 
RSK and PKC.  
E) Global changes in phosphorylated Tyr residues do not differ between SL0101 and 
3a and 3c. 
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 In contrast, the enantiomer (ent)-3b showed no inhibition of either cell line. At 25 
M the analogue 3a inhibited MCF-7 proliferation by ~ 60% but also significantly 
inhibited MCF- 10A proliferation (fig. 21C). For comparison, at 100 M SL0101 (1a) 
inhibited MCF-7 proliferation by ~ 60% but had no effect on MCF-10A proliferation (fig. 
21B). 
 Both analogues 3a and 3c were able to completely inhibit proliferation of MCF-7 
cells at ~ 50 M but they also significantly inhibited MCF-10A proliferation at that 
concentration (fig. 21C,D). For both 3a and 3c the dose response differed by ~ 3- fold 
between MCF-7 and MCF-10A cells. This modest differential effect suggests that the 
inhibitors are not specific for RSK, as we have found that MCF-10A proliferation is not 
dependent on RSK. 
 To further investigate the specificity of 3a and 3c for inhibition of RSK we 
determined their ability to inhibit known RSK substrates in comparison to SL0101. We 
tested the compounds 3a and 3c at 50 M, which is the cytostatic concentration. 
Lysates were generated from MCF-7 cells that had been treated with the mitogen, 
phorbol myristate acetate (PMA) after a pre-treatment with inhibitor or vehicle. Inhibition 
of RSK is known to result in an increase in the phosphorylation of eukaryotic elongation 
factor 2 (p-eEF2) via release of the RSK-induced repression of eEF2 kinase (Wang et 
al., 2001b). As expected SL0101 dramatically enhanced p-eEF2 levels but 3a and 3c 
induced only a minor increase (fig. 22A). To further evaluate whether the analogues 
could alter RSK biomarkers we used an antibody against a phosphorylation motif, which 
is recognized by numerous kinases, including RSK. SL0101 decreased the intensity of a 
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band at ~ 65 and ~ 27 kDa but 3a and 3c did not alter the phosphorylation pattern 
compared to the PMA control (fig. 21B). We have also determined that RSK regulates 
the levels of the oncogene, cyclin D1 (Eisinger-Mathason et al., 2008). In agreement 
with our previous observations SL0101 decreased cyclin D1 levels but 3a and 3c had 
no effect (fig. 22A). We conclude that 3a and 3c are not specific for RSK inhibition in 
cell-based assays. 
 To obtain insight into kinases that 3a and 3c could target we used antibodies that 
detect the phosphorylation motif of protein kinase A (PKA), protein kinase C (PKC), and 
tyrosine kinases. Cyclitols 3a and 3c did not alter the phosphorylation pattern obtained 
with antibodies to the PKC and tyrosine kinase phosphorylation motifs (fig. 22D-E). 
However, 3a and 3c resulted in the partial increase in the intensity of a band at ∼90 
kDa. In contrast, SL0101 dramatically increased the intensity of this band compared to 
PMA (fig. 22C). The PKA motif antibody is able to detect phosphorylations generated by 
RSK, and therefore, observing changes with SL0101 is expected. On the basis of our 
immunoblot analysis, 3a and 3c do not inhibit kinases that prefer an Arg at the -5 
position but do inhibit kinases that prefer an Arg at the -3 and -2 positions from the Ser 
or Thr phosphorylation site. This information narrows down the possible candidate 
kinases from within the AGC kinase family that 3a and 3c target. 
 In conclusion, using a Pd-catalyzed glycosylation or cyclitolization in combination 
with post-glycosylation transformation, an enantiomerically diverse set of SL0101 
analogues were prepared and evaluated as RSK inhibitors. Replacement of the L-
rhamno-sugar with a L-rhamno-5a-carbasugar did not substantially alter the ability of 
the analogues to inhibit RSK kinase activity in vitro; however, the compounds 
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demonstrated off-target effects in cell-based assays. Further efforts aimed at identifying 
cyclitol analogues that specifically target RSK inhibition are ongoing and will be reported 
in due course. 
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Chapter 6 
Identification of potential novel RSK1-interacting proteins and phosphorylation 
targets in breast cancer 
 
Summary 
 The RSK family of Ser/Thr protein kinases consists of four isoforms that are 
products of separate genes and share very high degree of sequence similarity. RSK is 
activated by the extracellular signal regulated kinase ERK1/2 in response to various 
stimuli, including growth factors, cytokines and neurotransmitters. RSK1 and RSK2 
were found to be frequently overexpressed in cancers and were shown to promote 
proliferation and migration of multiple cancer cell types. Therefore, RSK1 and RSK2 are 
thought to be tumor promoters. RSK3 and RSK4 appear to have opposite effects on 
tumor growth and are thought to be tumor suppressors. However, the specific 
mechanisms controlled by individual RSK isoforms are not very well understood. We set 
out to characterize the specific functions of RSK1 though identification of novel 
interacting partners by means of high-throughput proteomics. In order to achieve this 
goal, we utilized a labeling approach in intact cells. We discovered that a portion of 
RSK1, and not RSK2, associates with intracellular membranes in multiple cell lines. We 
identified potential interacting partners of RSK1 that localized to ribosomes, 
mitochondria and endoplasmic reticulum membranes. Therefore, RSK1 could regulate 
protein synthesis, as well as energy homeostasis. 
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6.1. Introduction 
 The Mitogen Activated Protein Kinase (MAPK) pathway represents the critical 
element of the signaling network regulating cellular growth and proliferation (Meloche 
and Pouyssegur, 2007). This cellular pathway is very frequently deregulated in a variety 
of cancers and therefore has been extensively studied as a potential target for 
therapeutic intervention (Sebolt-Leopold and Herrera, 2004). However, MAPK pathway 
modulates a wide variety of downstream targets, and some of these targets are 
important for the survival and growth of normal proliferating cells, such as those in the 
skin and gut epithelium. (Sebolt-Leopold and Herrera, 2004). Therefore, an alternative 
strategy is to inhibit downstream effectors of the MAPK pathway that mediate pro-
survival signals in cancer cells. One of such classical effectors of the pathway is the p90 
RSK family of kinases (Anjum and Blenis, 2008). 
 RSK is a family of Ser/Thr protein kinases activated by ERK1/2 signaling in 
response to various stimuli, including growth factors, peptide hormones and 
neurotransmitters (Romeo et al., 2012). The four members of the family share a very 
high degree of peptide similarity, but are products of separate genes. With the exception 
of RSK4, which was found to be constitutively active in cells, all RSK isoforms are 
activated in a similar mechanism downstream of the MAPK pathway (Romeo et al., 
2012). However, RSK isoforms appear to perform non-overlapping, and sometimes 
opposing functions in cells (Lara et al., 2013). It is increasingly appreciated that, 
whereas RSK1 and RSK2 serve pro-tumorigenic and pro-metastatic functions, RSK3 
and RSK4 appear to be putative tumor suppressors (Lara et al., 2013). In addition, even 
though all four isoforms of RSK are often expressed in one cell, it has been observed 
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that these isoforms can have distinct intracellular localizations (Heffron and Mandell, 
2005, Eisinger-Mathason et al., 2008, Lara et al., 2013). Therefore, different RSK 
isoforms can interact with and phosphorylate distinct cellular targets. However, the 
paucity of isoform-specific antibodies recognizing the active phosphorylated forms of 
RSK, as well as lack of isoform-specific small molecule inhibitors have hindered the 
efforts to characterize the divergent signaling landscapes of RSK isoforms. 
 A novel method of labeling of interacting proteins in intact cells has recently been 
characterized (Hung et al., 2014, Rhee et al., 2013). In this method, a promiscuous 
ascorbate peroxidase APEX was fused with a short peptide targeting it to the 
mitochondria, or the mitochondrial intramembrane space, and expressed in HEK cells. 
In response to biotin-phenol and hydrogen peroxide APEX peroxidase oxidized biotin-
phenol to form a phenoxyl radical (Martell et al., 2012). This radical could rapidly attach 
to electron-negative amino acid side chains of proteins, such as Tyr, Trp, His and Cys 
(Amini et al., 2002). Due to its very short half-life (< 1ms) and very small labeling radius 
(< 20 nm) the phenoxyl radical labeled only proteins that were in a very close proximity 
to APEX (Rhee et al., 2013). Therefore, APEX could aid in identifying proteins that only 
transiently interacted with a fusion protein, as well as stably bound partners. The 
biotinylated proteins can then be affinity-purified using streptavidin, and analyzed by 
liquid chromatography mass spectrometry (LC/MS). These studies provided very 
detailed analysis of the proteins localized to the mitochondria, as well as the topology of 
the mitochondrial transmembrane protein complexes. 
 Given the limited knowledge of the isoform-specific downstream targets of RSK1, 
as well as the increasing evidence for the role of RSK1 in promoting tumorigenesis and 
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invasiveness (Larreaa et al., 2009, Lara et al., 2011), we set out to characterize the 
RSK1 interactome in breast cancer cells. We decided to employ the APEX-mediated 
labeling of RSK1-interacting partners in intact cells. This method allowed us to 
investigate proteins that bind in a stable, as well as transient fashion, as in the case of 
the kinase substrates. We discovered that a significant fraction of RSK1 was stably 
associated with intracellular membranes in multiple cell lines. Contrary to RSK1, RSK2 
was found exclusively in the cytosol. Through mass spectrometry analysis of labeled 
proteins we identified potential RSK1-binding partners in the ribosomes, as well as 
mitochondrial and endoplasmic reticulum membranes. Therefore, RSK1 could regulate 
such cellular processes as protein synthesis and energy production.  
6.2. Materials and methods 
Plasmids and lentiviral production 
 Plasmids used for lentivirus production, pSPAX2 and pMD2G, were generously 
provided by D. Trono (Swiss Federal Institute of Technology, Lausanne, Switzerland). 
pLentiPuro plasmid was generously provided by I. Macara (Vanderbilt University, 
Nashville, TN). pcDNA3-mito-APEX was purchased from AddGene (Cambridge, MA). 
APEX was cloned into pLentiPuro and the virus was produced according to a previously 
described protocol (McCaffrey and Macara, 2009). 
Reagents and antibodies 
 Mitochondria isolation kit from cell lines and streptavidin-conjugated magnetic 
beads were purchased from ThermoScientific (Rockfolrd, IL). AlexaFluor488-conjugated 
streptavidin was purchased from Life Technologies (Carlsbad, CA). Ponceau S stain 
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concentrate, PMSF, protease inhibitor cocktail, sodium azide, sodium ascorbate, Trolox 
and 30% hydrogen peroxide were from Sigma (St. Louis, MO). Biotin-phenol conjugate 
was synthesized in-house according to previously published protocol (Rhee et al., 
2013), and purchased from Berry and Associates (Ann Arbor, MI). RapiGest was 
purchased from Waters Corporation (Milton, MA). Bovine serum albumin (BSA) was 
from Roche (Germany). The antibodies used in the study were: rabbit anti-RSK1, 
mouse monoclonal anti-RSK2 and goat anti-EEA1 from Santa Cruz Biotechnology 
(Santa Cruz, CA); mouse anti-catalase, mouse anti-MTCO2 and mouse anti-VDAC1 
from AbCam (Cambridge, MA); mouse monoclonal anti-Ran and mouse anti-PanERK 
from BD Biosciences (San Jose, CA); rabbit anti-pThr359/pSer363-RSK from Cell 
Signaling Technology (Danvers, MA); mouse anti-V5 and Alexa546-conjugated goat 
anti-mouse were from Life Technologies (Carlsbad, CA).  
Cell culture and treatments 
 MCF7, MCF10A and HEK293T cell lines were cultured according to the 
instructions from the American Type Culture Collection. For viral transductions, cells 
were passaged and resuspended in full growth medium, and appropriate amount of 
virus was added at MOI 1.5. Cells were seeded onto a 12-well plate at 100,000 
cells/well and grown for 2 days, followed by a passage for experiments. For serum 
starvation, cells were washed 3 times with phosphate buffered saline and fresh serum-
free medium was added for 16 hours. Cells were then stimulated with 500 mM phorbol 
myristate acetate (PMA) in fresh serum-containing growth medium for 20 minutes, and 
lysates were collected. Lysis was done in boiling 4% SDS loading buffer (120 mM Tris 
pH 6.8, 200 mM DTT, 10% glycerol).  
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Cellular fractionation 
 Mitochondria isolation kit was used for cellular fractionation, according to 
manufacturer’s instructions. All steps were preformed at 4 C. 10*106 cells were washed 
3 times with ice-cold PBS, lysed in mitochondria isolation buffer A and homogenized by 
80 strokes in Dounce homogenizer. Lysate was combined with buffer B and centrifuged 
at 700 g for 10 min to separate nuclei and plasma membrane, as well as unlysed cells. 
5 mM EDTA was added to the supernatant at this step to prevent aggregation of 
proteins in subsequent centrifugations. The supernatant was centrifuged for 10 min at 
700 g and the heavy mitochondrial pellet was separated. The supernatant was 
centrifuged at 16000 g for 15 min to separate light mitochondrial pellet. The supernatant 
was subjected to an ultracentrifugation at 100000 g for 1 h and the microsomal pellet 
was separated. Each pellet was washed once in the buffer A/B mixture and repelleted. 
All fractions were lysed by boiling for 5 min in lysis buffer and electrophoresed. 
Immunofluorescence 
 For immunofluorescene imaging, MCF7 cells were seeded onto poly-L-lysine 
coated glass coverslips and 2 days later biotin-phenol was added in fresh growth 
medium for 16 hours. 1 mM hydrogen peroxide was added to cells for 15 min, and the 
labeling was terminated by 3 washes with quencher buffer (PBS pH 7.4 with 10 mM 
sodium ascorbate, 10 mM sodium azide and 5 mM Trolox). Cells were fixed with 4% 
para-formaldehyde in PBS pH 7.4 for 15 min and permeabilized with 0.0025% digitonin 
in PBS for 10 min. Coverslips were blocked with 10% BSA. Primary antibody against V5 
tag was incubated for 16 h at 4 C in 3% BSA in PBS, and secondary antibody together 
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with Alexa546-conjugated streptavidin were incubated for 1 hour at room temperature. 
Cells were imaged on 510-META confocal microscope using 63X apochromat lens 
(N.A. 1.4) (Zeiss, Germany). 
In vivo biotin labeling 
 The protocol was adapted from (Rhee et al., 2013). Briefly, a 80% confluent late 
of MCF7 cells was treated with 50 mM biotin-phenol in growth medium for 16 h, 
followed by 15 min stimulation with 1 mM hydrogen peroxide in fresh growth medium. 
Labeling was terminated with 3 washes with ice-cold quencher buffer. Cells were lysed 
in 200 L of ice-cold RIPA lysis buffer (50 mM Tris pH 7.2, 150 mM NaCl, 0.1% SDS, 
0.5% sodium deoxycholate, 1% Triton-X100, 1X protease inhibitor cocktail, 1mM PMSF, 
10 mM sodium azide, 10 mM sodium ascorbate, 5 mM Trolox) on ice for 5 min, followed 
by shearing the lysate by passing 3 times through 27G needle. The lysate was snap-
frozen in liquid nitrogen and stored in -80 C until further steps.  
Affinity purification of biotinylated proteins 
 50 L of streptavidin bead slurry was washed 3 times with RIPA lysis buffer and 
cell lysate from ~7*106 cells was added. The beads were incubated in a rotator for 1 h at 
4 C and the lysate was separated from the beads. The procedure was repeated 2 more 
times with fresh aliquots of beads, to generate 3 fractions of biotinylated proteins. Each 
aliquot was washed 2 times in ice-cold RIPA buffer, one time with 2 M urea in 10 mM 
Tris pH 8.0 and 2 more times with RIPA buffer. The beads were then washed 5 times in 
100 mM ammonium bicarbonate pH 7.4 and stored in ammonium bicarbonate at 4 C 
until further processing. 
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Sample processing for mass spectrometry 
 The affinity-purified biotinylated proteins bound to the beads were reduced with 
DTT and alkylated with iodoacetamide as previously described (Schroeder et al., 2004). 
The beads were subjected to a 10 min trypsin digest (1:20 trypsin:protein ratio by mass) 
at room temperature in 2 M urea. The digest was quenched with glacial acetic acid and 
stored at -40 C for downstream applications. 
Mass spectrometry 
 5% of the sample was pressure-loaded onto 360 m outer diameter, 75 m inner 
diameter fused-silica microcapillary pre-column (Polymicro Technologies) packed with 6 
cm of irregular C18 resin (YMC, Kyoto, Japan) and washed with approximately 20 
column volumes of 0.1% v/v acetic acid. The pre-column was then connected to a 360 
m outer diameter, 50 m inner diameter fused-silica analytical column (Polymicro 
Technologies) packed with 6 cm of C18 resin, 5 m, 120 A (YMC, Kyoto, Japan) and 
equipped with a laser-pulled electrospray emitter tip (P-2000, Sutter Instruments) 
(Martin et al., 2000). 
 Nanoflow (60 nL/min) reverse-phase HPLC was used to elute the sample, and 
micro-electrospray ionization was used to ionize it. The Fourier transform hybrid mass 
spectrometers (LTQ-FTMS and LTQ-Orbitrap, Thero Scientific) were used for sample 
analysis. Mass spectrometers were equipped with either electron-transfer dissociation 
(ETD) or collisionally activated dissociation (CAD). The instrument method was 
employed in a data-dependent manner to select abundant precursor ions for 
fragmentation. Qual Browser software (Thermo Fisher Scientific) was used for data 
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analysis, and peptides were searched against human RefSeq database using OMSSA, 
assuming a maximum of 3 missed trypsin cleavage sites. 
6.3. Results 
 The exact cellular localization of RSK1 in epithelial cells is unknown. RSK1 has 
been suggested to transiently localize to the plasma membrane upon activation, and 
subsequently translocate to the nucleus (Richards et al., 2001). However, other groups 
have shown that RSK1 does not localize to the nucleus in MCF7 cells and in mouse 
brain tissue sections (Eisinger-Mathason et al., 2008, Heffron and Mandell, 2005). 
Given the lack of success in using RSK1-specific antibodies in immunofluorescence, 
and a diffuse pattern of RSK1 signal in fluorescently tagged overexpression 
experiments, we decided to perform sub-cellular fractionations. The outline of the 
protocol is presented in fig. 23A. We used a series of differential centrifugations of 
whole-cell lysates collected by homogenization in a high-density iso-osmotic buffer. 
Three membrane fractions, along with the cytosol, were collected. The heavy 
mitochondrial fraction contained most of the cellular mitochondria, as evidenced by the 
presence of mitochondrial markers MTCO2 and VDAC1 in the fraction (fig. 23B). Light 
mitochondria and microsomes contained EEA1 and catalase, the markers of 
endosomes and peroxisomes, respectively. Ran was used as a cytoplasmic protein 
marker, and was almost exclusively found in the cytosolic fraction, indicating that the 
membrane-bound tractions were not contaminated with cytosolic proteins. Interestingly, 
we detected RSK1 in all membrane-bound fractions, in addition to a cytosolic pool 
(fig. 23B). This distribution was in stark contrast to that of RSK2, which was exclusively 
found in the cytosol.  
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Figure 23. RSK1, and not RSK2, associates with intracellular membranes in normal 
and transformed breast epithelial cells. 
A) A flow-chart demonstrating the sub-cellular fractionation protocol used in the 
experiments. 
B) Sub-cellular fractionation of MCF7 cells demonstrates that RSK1 stably associates 
with intracellular membranes. 10*106 cells were fractionated according to protocol 
outlined in A), electrophoresed and immunoblotted.  
C) Sub-cellular fractionation of MCF10A cells demonstrates that RSK1 stably 
associates with intracellular membranes. 10*106 cells were fractionated according to 
protocol outlined in A), electrophoresed and immunoblotted. 
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 Given that each fraction was produced by further centrifugation of the 
supernatant from the previous step, and the pellets were washed to remove 
contaminations, we concluded that RSK1 was stably associated with membrane-bound 
compartments in the cells. One of these compartments could be mitochondria, as these 
organelles were heavily enriched in the heavy mitochondrial fraction. However, it is not 
the only compartment, as almost the third of the RSK1 signal was found in the 
microsomes, which do not contain mitochondria. RSK1 distribution does not follow 
closely any of the markers, suggesting that it does not associate with just one specific 
compartment. Another potential localization of RSK1 would be the endoplasmic 
reticulum (ER). The ER stain was not included in the fractionation analysis. A 
subpopulation of ER membranes is decorated by ribosomes, and RSK has been shown 
to associate with actively translating ribosomes (Angenstein et al., 1998). ER 
localization could explain apparent diffuse localization of the fluorescent signal in the 
overexpression experiments, since the cytosolic RSK1 would overlay the fine reticular 
pattern of the ER and prevent clear distinguishing of this localization. 
 In order to investigate if RSK1 association with the membranes is not limited to 
MCF7 cells, we performed analogous experiments in the MCF10A cell line. Consistent 
with the results obtained in MCF7 cells, RSK1 was distributed between all four fractions 
in the cells, and the staining pattern did not closely follow the distribution of 
mitochondria, microsomes or endosomes (fig. 23C). Therefore, we conclude that in 
epithelial cell lines a significant proportion of RSK1 is stably associated with intracellular 
membranes, and this distribution is not shared by RSK2. 
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Figure 24. RSK1-APEX is properly activated and localized, and functional in MCF7 
cells. 
A) RSK1-APEX is expressed and properly activated in MCF7 cells. Cells were serum-
starved overnight and either untreated or treated with 500 nM PMA in serum-
containing medium. The lysates were electrophoresed and immunoblotted. 
B) RSK1-APEX follows the sub-cellular distribution of the endogenous protein. MCF7 
cells expressing RSK1-APEX were fractionated according to the protocol in fig. 23A, 
electrophoresed and immunoblotted. 
C) RSK1-APEX is capable of biotinylation in intact cells. RSK1-APEX expressing MCF7 
cells were treated with or without 500 M biotin-phenol for 1 h and stimulated with 1 
mM hydrogen peroxide for 1 h. Whole-cell lysates were electrophoresed and 
biotinylations were detected using HRP-conjugated streptavidin. The nitrocellulose 
membrane was stained with Ponceau S prior to streptavidin binding to assess the 
total protein amounts. 
D) MCF7 cells contain endogenously biotinylated proteins, and RSK1-APEX 
biotinylates multiple proteins in intact cells. MCF7 cells expressing RSK1-APEX 
were treated with or without biotin-phenol for 16 h and stimulated with hydrogen 
peroxide for 15 min. Cells were fixed, immunostained, and imaged using 
fluorescence confocal microscopy. 
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 In order to identify the RSK1-specific interacting partners and phosphorylation 
targets, we decided to employ the APEX-mediated biotin labeling in intact cells (Rhee et 
al., 2013, Hung et al., 2014). We chose to perform the study using human estrogen 
receptor positive breast cancer cell line, MCF7. Our previous studies have shown that 
inhibition of RSK by the small molecule, SL0101, reduces proliferation in this cell line, 
while the non-transformed breast epithelial cell line, MCF10A, is not sensitive to RSK 
inhibition (Smith et al., 2005; chapters 3-5 and appendix). RSK1 was ectopically 
expressed as a fusion protein with the APEX peroxidase attached at the C-terminus. 
The construct was delivered using a lentiviral platform that allows integration of the 
cDNA of the overexpressed protein with the host genome (Wiznerowicz and Trono, 
2005). RSK1-APEX was expressed at a high level compared to the endogenous RSK1 
(fig. 24A). Stimulation with a potent mitogen, PMA, activates RSK, which is evidenced 
by the phosphorylation of RSK on multiple sites, including Thr359 and Ser363 (Roux et 
al., 2003). We serum-starved cells overnight to reduce the basal level of RSK activation, 
and stimulated cells with PMA for 20 minutes. As expected, we did not detect 
endogenous RSK phosphorylation at Thr359/Ser363 in unstimulated cells. PMA 
stimulation caused phosphorylation of RSK on Thr359/Ser363. RSK1-APEX was not 
phosphorylated in unstimulated cells, and a strong phosphorylation signal was detected 
in RSK1-APEX after PMA stimulation. These results show that RSK1-APEX is active 
and this activity is properly regulated in cells. For all subsequent experiments, in order 
to reduce the amount of overexpression of RSK1-APEX, we reduced the time between 
viral transduction and collection of the lysates. 
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 RSK1-APEX closely followed the distribution of endogenous protein in 
fractionation experiments (fig. 24B). Therefore, we concluded that in addition to proper 
activation, RSK1-APEX localizes to the appropriate compartments. It is also important 
to note that we were able to reduce the level of over-expression of RSK1-APEX to the 
amounts comparable to those of the endogenous protein. These results together 
indicate that RSK1-APEX is an appropriate construct to study the properties of the 
endogenous protein.  
 We assessed the activity of APEX in cells expressing the RSK1-APEX construct. 
Initially, the cells were treated with 500 M biotin-phenol for 1 hour, which is the 
incubation time reported in previous studies using HEK cells (Hung et al., 2014, Rhee et 
al., 2013). To ensure maximum signal we stimulated cells with hydrogen peroxide for 
1 hour. In cells not treated with biotin-phenol, we detected a number of endogenously 
biotinylated proteins (fig. 24C). These observations are consistent with the fact that 
mammalian cells express several enzymes that possess biotin as a prosthetic group in 
the active site, including pyruvate carboxylase, propionyl-CoA carboxylase and acetyl-
CoA carboxylase (Knowles, 1989). A dramatic increase in biotinylation signal was 
detected in cells expressing RSK1-APEX, confirming that the peroxidase is capable of 
catalyzing biotinylation of multiple proteins in intact cells (fig. 24C).  
 We assessed cellular biotinylations by immunofluorescence imaging. In order to 
detect the ectopically expressed RSK1-APEX we used a V5-tag that is encoded in the 
linker between RSK1 and APEX. The anti-V5 antibody allowed us to identify cells 
expressing RSK1-APEX and the intracellular localization of this protein. RSK1 was 
present in the cytoplasm and did not localize to the nucleus (fig. 24D), which is 
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consistent with previously reported inability of RSK1 to enter this cellular compartment 
(Eisinger-Mathason et al., 2008, Heffron and Mandell, 2005). Cytoplasmic stain of 
RSK1-APEX represented a diffuse pattern with no clear compartmentalization. We then 
used fluorescently labeled streptavidin to detect biotinylated proteins. Untreated cells 
displayed a distinct biotinylation staining pattern in a discrete cellular compartment, 
whereas the majority of cytoplasm and the nucleus were devoid of biotinylated proteins. 
These results are consistent with the fact that the majority of endogenously biotinylated 
proteins in mammalian cells reside in the mitochondria, where they participate in various 
metabolic processes (Coene et al., 2008). When cells were loaded with biotin-phenol 
and stimulated with hydrogen peroxide, extensive biotinylation was detected, both in the 
cytoplasm and in the nucleus (fig. 24D). Therefore, we conclude that the RSK1-APEX 
construct is active and capable of labeling multiple proteins in diverse cellular 
compartments in intact cells. Since we did not detect RSK1-APEX in the nucleus, the 
presence of biotinylation in this compartment most likely is due to nuclear translocation 
of proteins that became labeled in the cytoplasm by RSK1-APEX. 
 In order to optimize the labeling conditions of RSK1-APEX interacting partners, 
we tested several different treatment regimens. First, since biotin-phenol is an essential 
substrate for APEX, we investigated the optimum incubation time for efficient loading of 
this reagent to the cells. We have already seen that loading with biotin-phenol for one 
hour, followed by 1 hour of hydrogen peroxide stimulation, was sufficient to induce 
extensive biotinylation (fig. 24C). We tested the condition in which the pre-incubation 
with biotin-phenol was extended to 2 hours. In this condition as well, the cellular 
proteins were extensively biotinylated (fig. 25A).  
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Figure 25. Biotinylated proteins can be affinity-purified using streptavidin-magnetic 
beads. 
A) 16 h pre-incubation with biotin-phenol ensures maximum coverage of 
biotinylation pattern in MCF7 cells. RSK1-APEX expressing cells were loaded with 
biotin-phenol and stimulated with hydrogen peroxide for indicated times. Lysates were 
electrophoresed and probed with HRP-conjugated streptavidin. Prior to biotin detection, 
the membrane was stained with Ponceau S. 
B) 15 min stimulation with hydrogen peroxide is sufficient to induce maximum 
coverage of biotinylation pattern in MCF7 cells. RSK1-APEX expressing cells were 
loaded with biotin-phenol and stimulated with hydrogen peroxide for indicated times. 
Lysates were electrophoresed and probed with HRP-conjugated streptavidin. Prior to 
biotin detection, the membrane was stained with Ponceau S. 
C) Biotinylated proteins can be eluted off the beads using RapiGest or SDS boiling. 
RSK1-APEX expressing cells were loaded with biotin-phenol and stimulated with 
hydrogen peroxide. Biotinylated proteins were affinity-purified using streptavidin 
magnetic beads, followed by boiling the beads for 10 min with buffers containing 
indicated detergent. The samples were electrophoresed, stained with Ponceau S and 
probed with HRP-conjugated streptavidin.  
D) Streptavidin beads can be saturated with biotinylated proteins. RSK1-APEX 
expressing MCF7 cells were treated as in C) and indicated amounts of lysate were 
incubated with 10 L of streptavidin bead slurry. The beads were boiled with SDS, 
electrophoresed and probed with HRP-conjugated streptavidin. 
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 We were concerned that a prolonged incubation with hydrogen peroxide can 
affect the cellular signaling and change the interactome of RSK1, therefore we decided 
to shorten this treatment condition. When hydrogen peroxide was added to cells for 
30 min, it resulted in a decrease in the number and intensity of bands indicating protein 
biotinylations (fig. 25A). Extending biotin-phenol loading to 16 h prevented that 
decrease in biotinylation associated with shortened hydrogen peroxide stimulation, 
suggesting that biotin-phenol levels were the limiting factor in this set of experiments. In 
addition, we observed the appearance of new bands, and an increase in intensity of 
some other bands, when biotin-phenol was loaded for 16 hours (fig. 25A, black arrows). 
Therefore, it appears that this condition allowed for the most extensive detection of 
RSK1-APEX interacting proteins. We then proceeded to test shorter incubations with 
hydrogen peroxide, to minimize the cellular perturbations introduced by this oxidative 
insult. Shortening the hydrogen peroxide treatment to from 30 min to 15 min did not 
significantly reduce the number of detected bands (fig. 25B). However, when hydrogen 
peroxide was added for 5 minutes, a number of bands disappeared (fig. 25B, black 
arrows), and the overall staining intensity was decreased, suggesting that this short 
incubation was not sufficient to induce full labeling of the RSK1 interactome. Therefore, 
we identified labeling conditions that ensured sufficient cellular levels of the substrate 
for APEX, as well as the length of stimulation that induced sufficiently complex and 
intense labeling. 
 In order to separate the biotin-labeled proteins from the whole-cell lysate, we 
decided to employ streptavidin-conjugated magnetic beads. The biotin-streptavidin 
binding is one of the strongest non-covalent interactions found in nature (Green, 1990), 
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and in case of wild-type streptavidin can only be disrupted in extremely low pH, high 
temperature or shear stress (Laitinen et al., 2006, Stayton et al., 1999). Therefore, we 
chose to boil the beads in 4% SDS containing 2 mM free biotin, as well as in RapiGest, 
a detergent that can be used for downstream mass spectrometry applications, to elute 
the proteins off the beads for subsequent Western Blot analysis. We were able to 
efficiently bind biotinylated proteins and separate them from the rest of the lysate, as 
evidenced by the lack of biotinylations in the supernatant after the binding reaction 
(fig. 25C, lane 2). The majority of cellular proteins were still present in the supernatant, 
which was visualized by the Ponceau S stain of the membrane (fig. 25C, lower panel). 
We then tested the capacity of the beads to bind biotinylated proteins. 10 L of bead 
slurry was incubated with increasing amounts of the lysate from biotin-treated RSK1-
APEX expressing cells, corresponding to the indicated cell numbers (fig. 25D). We 
found that adding more lysate beyond ~4.7*105 cells did not further increase the amount 
of bound proteins, indicating that the beads were saturated. 
 Having identified the conditions for biotin labeling of RSK1-interacting proteins in 
intact cells, and the conditions for affinity-purifications of these proteins, we proceeded 
to perform a full-scale experiment, using ~7*106 cells. The affinity-purified proteins were 
subjected to on-bead trypsin digestion and subsequent LC/MS analysis, to identify the 
peptides. We have observed that untreated cells express endogenously biotinylated 
proteins, and that multiple proteins from untreated cells are pulled down by the 
streptavidin beads. Therefore, we included a negative control, in which control cells 
expressing RSK1-APEX were stimulated with hydrogen peroxide but not loaded with 
biotin-phenol. The beads from both conditions were subjected to the same processing 
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and analysis, and the resulting peptide lists were cross-referenced. We initially 
observed a large amount of streptavidin-derived peptides in the tryptic digests, therefore 
we chose to shorten the length of time trypsin is allowed to digest the peptides on the 
beads. As a result, we predicted longer peptides, with some trypsin-digest sites 
remaining uncleaved in the process. Protein mass spectrometry can utilize two methods 
to generate charged products of peptide fragmentation, the collision-activated 
dissociation (CAD) and electron transfer dissociation (ETD) (Li and Wysocki, 2012, 
Syka et al., 2004, Chalkley et al., 2010). The latter method is more amenable to 
fragmentation and sequencing of larger and more charged peptides (Chalkley et al., 
2010). Since we generated incomplete tryptic digests of the proteins on the beads, we 
utilized both methodologies to analyze the samples by mass spectrometry, and 
generated two separate peptide lists, one from each method. Therefore, we obtained 
four lists of peptide fragment spectra. 
 High-throughput proteomics generates thousands of peptide mass spectra 
(Washburn et al., 2001). Identification of these peptides requires extensive data 
analysis, and one of the methods commonly used is the Open Mass Spectrometry 
Search Algorithm (OMSSA) (Geer et al., 2004). This algorithm compares the 
experimental peptide mass spectra to those generated by in silico digestion of a protein 
sequence library and assigns the probability of the peptides to be derived from the 
proteins in that library. The protein hits are scored from the most to the least probable, 
based on various criteria, such as predicted abundance and homology to other proteins 
(Geer et al., 2004). We used human protein database based on the latest release of 
RefSeq to identify the potential proteins. We analyzed the same data against the 
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database of reverse protein sequences from RefSeq to predict the false discovery rate. 
We chose the 1% false discovery rate as a significance cutoff in the peptide lists. As a 
result, we generated four lists of potential protein hits. We then compared the lists of 
potential proteins from each fragmentation method separately, to subtract the proteins 
present in the negative control beads from the proteins present in the RSK1-APEX 
samples. Each method separately yielded 186 proteins present in the RSK1-APEX and 
not present in the negative control condition (fig. 26A). It is possible that a protein will be 
present in both conditions, but will be much more abundant in RSK1-APEX samples, 
compared to the control. In order to account for such possibility we re-assessed the lists 
of proteins present in both samples. We decided to include in further analysis those 
proteins that appeared at least 3-fold more abundant in the RSK1 sample, compared to 
the control, based on the total number of peptides identified in the sample. As a result, 
we added 23 and 17 proteins to the CAD and ETD lists, respectively. Therefore, we 
identified 209 and 203 potential RSK1-interacting proteins though either method of 
peptide analysis. We then compared these two groups to identify proteins found on both 
lists. As a result, we identified 54 protein candidates that were found through both CAD 
and ETD methods in the RSK1-APEX sample, and were >3-fold more abundant in this 
sample than in the control, as measured by the total number of peptides found 
(fig. 26A).  
 Since OMSSA is probability-based, it generates a list of potential proteins. These 
protein hits have to be manually validated to confirm correct identification of the proteins 
(Nesvizhskii et al., 2007). We manually assessed these protein hits and found that 29 of 
them represented true hits found in the RSK1-APEX samples and not in the negative 
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control samples. Further 8 proteins were found in both samples, but were >3-fold more 
abundant in the RSK1-APEX sample. Taken these results together, we identified 37 
potential RSK1-interacting partners (table 1). 
 In order to better understand the relationship between the identified proteins, we 
performed functional annotation analysis. This tool allows identifying the gene ontology 
clusters, or GO-terms, that are significantly enriched in the given list (Harris et al., 
2004). As a result, this method of data mining helps predicting what are the common 
features of the elements in the set. We found that the single most significantly enriched 
biological function in the list was generation of precursor metabolites and energy. Eight 
of the 37 proteins were annotated into this cluster (fig. 26B). In terms of cellular 
components, the most enriched GO-terms were parts of the mitochondrion and 
ribosome (fig. 26C). Similarly, the molecular function GO-terms contained such terms as 
the structural constituents of the ribosome and cytochrome C-oxidase. In addition the 
inorganic cation transmembrane transporter activity was significantly enriched in the 
protein list. Therefore, the functional annotation strongly suggested that RSK1 might be 
regulating such cellular processes as protein translation and production of energy, and 
could perform these functions through changes in electron transport chain activity and 
inorganic cation transport. 
 A second approach to analyzing the data was to perform the protein-protein 
interaction network analysis. We utilized the recently developed online tool that 
compiles known and predicted interactions between input proteins to generate a 
functional network (Szklarczyk et al., 2015). Among the 37 proteins we analyzed, we 
identified 4 putative clusters of interactions (fig. 27).  
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Table 1. RSK1-APEX-mediated biotinylation identified 37 potential novel RSK1-
interacting proteins. 
Proteins are sorted by decreasing abundance, as assessed by total number of identified 
peptides. 54 predicted protein hits were manually validated for presence of peptides in 
the control and RSK1-APEX samples. RefSeq accession # indicates protein identity 
predicted by OMSSA. # of validated peptide hits indicates total number of peptides 
corresponding to this protein found in the peptide spectra. Numbers in brackets indicate 
number of peptides belonging to this protein found in the negative control sample. Red 
indicates proteins containing putative RSK phosphorylation sites, RxRxxS/T, or RRxS/T, 
where R can also be K. Green indicates no consensus RSK phosphorylation sites.
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Figure 26. 37 potential RSK1-interacting proteins are enriched for constituents of 
ribosomes and mitochondrial membranes. 
A) Analysis of lists of potential proteins generated by OMSSA search from the peptide 
spectra of RSK-APEX and negative control samples identified 54 most likely 
interacting partners of RSK1. 
B) Biological function gene ontology analysis found a single significantly enriched 
cluster, the generation of precursor metabolites and energy, containing 8 proteins, in 
the list of 37 manually validated potential RSK1 interacting partners. Significance 
cut-off was set at Benjamini <0.05, which is the most stringent criterion in statistical 
analysis of functional annotation. 
C)  37 potential RSK1-iteracting partners are localized to mitochondrial and ER 
membranes, and to ribosomes. Cellular components and molecular functions gene 
ontology analysis several significantly enriched clusters in each category. 
Significance cut-off was set at Benjamini <0.05, and the bar graphs present the –
log(p) value for each cluster. 
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Figure 27. String network analysis identifies 4 putative functional clusters among 37 
proteins identified through mass spectrometry.  
Each sphere represents one protein from the list of potential RSK1-interacting partners. 
The thickness of the line connecting the spheres indicates the strength of connection 
between proteins, based on published and predicted physical and functional 
interactions. 
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 One cluster consisted of 5 large ribosomal subunit proteins, as well as RPN2, an 
essential component of ER-associated ribosomes (Crimaudo et al., 1987, Fu and 
Kreibich, 2000). The second cluster closely linked to the large-ribosomal subunit was a 
group of 3 proteins involved in ribosome biogenesis, NOP56, RSL1D1 and DDX54. The 
third cluster consisted of 6 proteins found in the mitochondrial electron transport chain. 
Finally, the forth cluster contained mitochondrial outer membrane proteins, VDAC1/2, 
HK1 and HKDC1, as well as an ER-membrane-bound protein CLN6. Taken these 
results together, the pathway analysis suggested that RSK1 may be involved in 
regulation of ribosome biogenesis, ER-associated ribosomes, and mitochondrial 
membrane components. These results are in agreement with the gene ontology 
analysis presented in fig. 26.  
 Since RSK1 is a kinase, we hypothesized that among those proteins we could 
identify the substrates for RSK-mediated phosphorylation. The consensus RSK-
phosphorylation motif is known, therefore we analyzed the protein sequences of all 37 
hits and identified those that contain this motif. Of 37 proteins, 25 contained at least one 
potential RSK phosphorylation site (table 1). Therefore, it appears that a large 
proportion of the identified proteins could be regulated by direct phosphorylation by 
RSK1.   
 Taken all the results together, we conclude that RSK1 stably associates with 
intracellular membranes and potentially interacts with a number of proteins involved in 
ribosome and mitochondrial synthesis and function. Association of RSK1 with 
ribosomes has previously been suggested (Angenstein et al., 1998). However, 
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association of RSK1 with mitochondrial membranes and the ribosome biogenesis 
machinery represents a novel finding.  
6.4. Discussion 
 We report the first use of APEX labeling to identify potential interacting partners 
of a protein kinase. We also report the first use of on-bead digestion of streptavidin 
affinity purified proteins in the APEX method. Previous reports have used in-gel 
digestion of proteins boiled off the beads with SDS. In previous studies APEX was fused 
to a mitochondrial localization signal to label all proteins found in this tight cellular 
compartment (Hung et al., 2014, Rhee et al., 2013). These studies were not designed to 
interrogate interacting partners of a particular protein, but rather enrich for all proteins 
found in a given cellular compartment. Incidentally, endogenously biotinylated proteins 
are known to almost exclusively localize to the mitochondria, and here we confirm this 
observation using fluorescently-labeled streptavidin for immunofluorescence (fig. 24D). 
As a result, the endogenously biotinylated proteins were expected to be identified in the 
procedure and did not confound the interpretation of the results. A new study using a 
specific APEX fusion protein has very recently been reported (Lam et al., 2015). 
However, this protein was not used for a high-throughput proteomics study.  
 We were able to identify RSK1-interactions with the ribosomal components, 
which is consistent with previous reports. In addition, we identify potential new 
associations of RSK1 with mitochondria and the endoplasmic reticulum. None of the 37 
proteins has ever been directly shown to interact with and be regulated by RSK1. Of 
those, two proteins, CLN6 and NOP56, were previously identified as potential RSK 
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substrates through another high-throughput proteomics study (Galan et al., 2014). In 
this study, RSK1 and RSK2 were either inhibited using BI-D1870, or silenced using 
siRNA, in HEK293 cell line and a melanoma cell line A375. The changes in protein 
phosphorylation were analyzed using SILAC, to identify proteins whose phosphorylation 
status changes upon loss of RSK1/2 expression or activity. Since both RSK1 and RSK2 
were silenced and inhibited together, the study did not reveal which isoform was 
responsible for the observed change in phosphorylation status. CLN6 and NOP56 were 
not experimentally validated in that study and their role in the context of RSK signaling 
remains unknown.   
 Further optimization of the high-throughput proteomics method described in this 
chapter should yield more extensive list of potential novel RSK1-interacting protein, 
beyond the 37 proteins we identify. One major area for improvement is reducing the 
number of non-specific protein hits. We have detected >500 potential proteins binding to 
the beads in cells not treated with biotin-phenol. Since OMSSA analysis is based on 
probabilities, this large number could be due to relative low abundances of peptides, 
lowering the dynamic range of the detection. In fact we did detect a very high 
abundance of streptavidin-derived peptides, compared to all the other peptides. We 
speculate that limiting the amount of time the beads are allowed to digest with trypsin 
could solve this issue. We offer two alternative strategies to obtain this goal. The first 
possibility is to perform a very brief trypsin digest on the beads, to liberate only the 
major peptides, followed by separation of these peptides from the beads and re-
digestion of the supernatant with trypsin to further cleave proteins into fragments 
compatible with downstream mass spectrometry analysis. The second option is to boil 
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the proteins off the beads using the mass spectrometry-compatible detergent RapiGest. 
This detergent can be decomposed by lowering pH of the solution, which generates the 
water-soluble denatured protein fraction and a separate hydrophobic phase that can be 
easily separated. Such denatured proteins in mass spectrometry-competent buffer can 
then be processed by trypsin and subjected to further analysis. 
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Chapter 7 
RSK regulation of cancer bioenergetics 
 
Summary 
 The RSK family of Ser/Thr protein kinases consists of four members that share 
very high sequence homology and are products of separate genes. RSKs are activated 
by the extracellular signal regulated kinase ERK1/2 in response to various stimuli, 
including growth factors, cytokines and neurotransmitters. In addition to known functions 
in promoting survival, proliferation and motility, RSK has been suggested to influence 
cellular metabolism. RSK was shown to phosphorylate proteins involved in energy 
homeostasis, such as an mTORC1 component Raptor, kinase Lkb1 and mitochondrial 
protein Bad. However, the significance of these interactions in the context of 
metabolism has not been reported. We previously found that breast cancer cells rely on 
RSK for proliferation, while non-transformed cells do not. Global changes in cellular 
metabolism are one of the hallmarks of cancer. We hypothesized that the reliance of 
RSK on proliferation could be associated with the differences in cellular metabolism. We 
found that RSK inhibition caused a reduction in mitochondrial oxidative phosphorylation, 
and this effect was specific to transformed cells. Therefore, we hypothesize that 
inhibition of RSK offers a therapeutic strategy to target metabolic transformation in 
breast cancer. 
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7.1. Introduction 
Changes in cellular metabolism have long been recognized as one of the 
hallmarks of cellular transformation (Hanahan and Weinberg, 2011). Early studies have 
shown that cancer cells derive a significant fraction of their cellular ATP from glycolysis 
even in the presence of oxygen, a phenomenon known as Warburg effect (Hsu and 
Sabatini, 2008). However, the Warburg effect does not indicate that cancer cells no 
longer rely on their mitochondria for survival. It is thought that the decrease in 
mitochondrial ATP synthesis is caused by depletion of metabolic intermediates from the 
mitochondria. These metabolites are utilized in the anabolic processes to fuel rapid 
proliferation (Hanahan and Weinberg, 2011). This phenomenon of metabolic 
transformation has been proposed to constitute novel therapeutic target in cancer 
treatment (Tennant et al., 2010). 
RSK is a family of four Ser/Thr protein kinases activated by the extracellular 
signal regulated kinases 1/2 (ERK1/2) (Carriere et al., 2008b). RSK has been 
extensively studied in the context of pro-survival and pro-growth signaling in a number 
of cancers, as well as in normal cell homeostasis (Pasic et al., 2011, Romeo et al., 
2012, Anjum and Blenis, 2008). Of the four RSK isoforms, only a RSK2 knock-out 
mouse has been reported in the literature (Laugel-Haushalter et al., 2014). This knock-
out displayed a number of defects in metabolism, including lipodystrophy, insulin 
resistance and increased glycogen synthesis (El-Haschimi et al., 2003, Dufresne et al., 
2001). However, the exact mechanism of RSK2-mediated regulation of organismal 
metabolism has not been elucidated. RSK has been shown to phosphorylate many 
proteins with known functions in regulating cellular metabolism. For example, RSK was 
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reported to phosphorylate Lkb1 on residue Ser341 (Sapkota et al., 2001). However, the 
physiological significance of this phosphorylation in the context of cellular metabolism 
was not assessed. Later studies revealed that Ser341 phosphorylation of Lkb1 did not 
affect its ability to interact with the plasma membrane or phosphorylate its downstream 
target involved in regulation of metabolism, AMPK (Fogarty and Hardie, 2009, Houde et 
al., 2014). In addition to Lkb1, RSK was shown to phosphorylate GSK and mTOR 
component Raptor (Carriere et al., 2008a, Sutherland et al., 1993). However, in none of 
these studies the changes of metabolism in response to RSK perturbation were 
explored. Therefore, it remains unknown what is the role of RSK in regulating cellular 
metabolism. 
We have developed the first potent, selective inhibitor of RSK, SL0101 (Smith et 
al., 2005). This inhibitor is remarkably specific for its target (Sapkota et al., 2007), and 
therefore has been proposed as a promising lead compound for developing RSK 
inhibitor suitable for in vivo studies (chapters 2-5 and appendix). Based on the evidence 
in the literature that RSK could regulate metabolism, we set out to characterize the 
effects of inhibiting this kinase on the metabolism of both non-transformed and 
transformed cell lines. We have previously found that the human estrogen receptor-
positive breast cancer cell line, MCF7, was sensitive to RSK inhibition, while a non-
transformed human breast epithelial cell line, MCF10A, was not. Therefore, we 
hypothesized that RSK could differentially regulate cellular metabolism in transformed 
vs. non-transformed cells. 
We have found that RSK inhibition caused a reduction in mitochondrial oxygen 
consumption in breast cancer cell lines. Consistent with the differences in the effects of 
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SL0101 on proliferation of normal and breast cancer cell lines, we found that in non-
transformed cells RSK inhibition did not decrease oxygen consumption. We observed 
decreases in mitochondrial superoxide generation, membrane potential and calcium 
levels in MCF7 cells, consistent with a defect in mitochondrial respiration. Our results 
provide the first evidence of the differential role of RSK in regulating cellular metabolism 
in transformed cells. We hypothesize that inhibiting RSK with SL0101 and its analogs 
could offer therapeutic strategy to specifically target metabolic alterations in cancer. 
7.2. Materials and methods 
Reagents and antibodies 
 Mitochondrial stress test kits were purchased from Seahorse Bioscience (North 
Billerica, MA). BI-D1870 was purchased from Enzo Life Sciences (Farmingdale NY). 
SL0101 and its enantiomer were synthesized by George O’Doherty (Northeastern 
University, Boston, MA). 200 mM glutamine and 100 mM pyruvate solutions, as well as 
glucose and ionomycin were purchased from Sigma (St. Louis, MO). MitoSox Red, 
TMRM, Rhod-2 and fibronectin from human plasma were purchased from Life 
Technologies (Carlsbad, CA).  
Cell culture and treatments 
 MCF7, MCF10A and T47D cell lines were cultured according to the instructions 
from the American Type Culture Collection. For live-imaging experiments, cells were 
passaged and seeded at 50,000 cells onto 2-well borosilicate glass LabTek slides 
(Fisher, Rochester, NY). 2 days later, the treatments were commenced. For MitoSox 
Red imaging, cells were washed 3 times with phosphate-buffered saline (PBS) and 
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vehicle or 100 M SL0101 were loaded in serum-free medium for 2 hours. The medium 
was changed for inhibitor- or vehicle-containing medium with 5 M MitoSox Red and 
incubated for 10 minutes. Cells were then washed and fresh serum-free medium with or 
without inhibitor was added. Cells were imaged by confocal microscopy immediately 
after the removal of MitoSox Red from the medium. 
 For TMRM imaging, cells were washed 3 times with PBS and incubated with 
DMSO or 100 M SL0101 in serum-free medium without glucose for 2 hours. 1.5 h into 
the incubation with the inhibitor, TMRM was added at the final concentration of 20 nM. 2 
hours into the inhibitor treatment, cells were imaged using confocal microscopy. 
 For Rhod-2 imaging, cells were washed 3 times with PBS, and 5 M Rhod-2 in 
serum-free medium without glucose was added for 50 min. Rhod-2-containing medium 
was removed and fresh serum-free glucose-free medium with or without 100 M 
SL0101 was added. 2 hours later, cells were imaged using confocal microscopy. For 
ionomycin treatment, cells were treated as described above, and ionomycin was added 
at final concentration of 20 ng/mL. 10 minutes later, cells were imaged using confocal 
microscopy. 
Mitochondrial stress tests 
 Mitochondrial stress tests were performed according to manufacturer’s protocol. 
Briefly, cells were passaged and seeded onto 12-well or 96-well seahorse assay plates 
(Seahorse Bioscience, North Billerica, MA). 96-well plates were coated with 80 L/well 
of 5 g/mL human fibronectin in PBS prior to cell seeding. Cells were seeded at 30,000  
or 16,000 cells/well in a 12-well and 96-well plate, respectively, which was confirmed to 
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be within the linear range of the basal respiration rate for each cell line. For 12-well 
plates, cells were collected with trypsin and seeded in full growth medium with serum, 
and 16 hours later medium was changed for unbuffered base medium (pH 7.4) with 
glucose, glutamine and pyruvate, and with or without the inhibitors. The measurements 
of oxygen consumption were conducted 2 hours later on Seahorse Xf24 analyzer. For 
96-well plates, cells were collected with 10 mM EDTA in PBS and seeded in unbuffered 
serum-free medium with indicated nutrients. 16 h later, DMSO or 100 M SL0101 were 
added in the medium with appropriate nutrients. 1 hour later, the measurements of 
oxygen consumption rate wee commenced using Seahorse Xf96e analyzer. 
7.3. Results 
 In order to investigate whether RSK is involved in regulation of cellular 
metabolism, we undertook the effort to characterize the changes in cellular respiration in 
response to RSK inhibition. To investigate the role of RSK in regulating mitochondrial 
oxidative phosphorylation the estrogen receptor positive breast cancer cell line, MCF7, 
was treated with a series of mitochondrial inhibitors and changes in oxygen 
consumption rate were measured in response to these inhibitors (Brand and Nicholls, 
2011). First, to determine basal respiration, the basal oxygen consumption rate was 
measured in cells incubated in DMEM medium containing glucose, pyruvate and 
glutamine (fig. 28A). The presence of all three basic nutrients was intended to ensure 
that the mitochondria operated at the optimum capacity. In the next step oligomycin was 
added to the medium to inhibit ATP synthase. Blocking the activity of the ATP synthase 
by oligomycin treatment caused a decrease in oxygen consumption.  
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 The difference between the initial oxygen consumption and the levels of oxygen 
consumption induced by oligomycin represented oxygen consumption associated with 
mitochondrial ATP synthesis. The addition of a mitochondrial uncoupler FCCP allowed 
the electron transport chain to operate at its maximum capacity independent of the 
activity of the ATP synthase. As a result, an increase in the oxygen consumption was 
observed. This increase represented the maximum respiratory capacity. Addition of the 
combination of rotenone and antimycin A, the inhibitors of electron transport chain 
complexes I and III, respectively, completely blocked electron transport chain, which 
resulted in an almost complete abrogation of oxygen consumption. The remaining rate 
of oxygen consumption was therefore associated with non-mitochondrial oxygen 
consumption. Initial OCR represented basal respiration rate, while OCR following FCCP 
addition defined the maximum respiration.  
Inhibition of RSK by SL0101 caused a 30% reduction in both basal and maximal 
respiration in MCF7 cells (fig. 28B). In addition, proton leak was increased upon SL0101 
treatment. Proton leak can occur through two general mechanisms. First, electrons can 
pass across the mitochondrial membranes through the protein channels, such as 
uncoupling proteins (UCP) or the adenine nucleotide translocase (ANT) (Jastroch et al., 
2010, Busiello et al., 2015). Alternatively, protons can be carried directly through the 
mitochondrial membranes, as in the case of the protonophore FCCP (Jastroch et al., 
2010). To test whether SL0101 acts as a mitochondrial protonophore, we used an 
enantiomer of SL0101 (ent-SL0101, fig. 28C). This compound has the same chemical 
structure as SL0101, but due to a reverse chirality on the anomeric carbon it is 
biologically inactive (chapter 5).  
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Figure 28. Inhibition of RSK decreases mitochondrial oxidative phosphorylation in 
breast cancer cell lines, but not in a non-transformed cell line. 
A) Schematic representation of the mitochondrial stress test assay.  
B) SL0101 decreases basal and maximal OCR by 30% in the breast cancer cell line 
MCF7. Combined mean ±SD, N=2 in ≥ quadruplicate, normalized to control basal 
respiration. * p<0.01 Student’s t-test 
C) Chemical structures of SL0101, ent-SL0101 and cyclitol compound 1  
D) Ent-SL0101 does not affect OCR in the breast cancer cell line MCF7. Combined 
mean ±SD, N=2 in ≥ quadruplicate, normalized to control basal respiration. * p<0.01 
Student’s t-test compared to the control 
E)  cyclitol-SL0101 [1] decreases basal and maximal OCR in MCF7 cell line by 30%, 
consistent with the effects of SL0101. Representative graph of N=2, mean ±SD in 12 
replicates. * p<0.01 (SL0101) in Student’s t-test compared to the control; ^ p<0.01 
([1]) in Student’s t-test compared to the control 
F) BI-D1870 decreases basal and maximal OCR by 30% in the breast cancer cell line 
MCF7. Combined mean ±SD, N=2 in ≥ quadruplicate, normalized to control basal 
respiration. * p<0.01 Student’s t-test 
G)  SL0101 decreases basal and maximal OCR by 30% in the breast cancer cell line 
T47D. Combined mean ±SD, N=2 in ≥ quadruplicate, normalized to control basal 
respiration. * p<0.01 Student’s t-test 
H) SL0101 does not affect OCR in the non-transformed breast epithelial cell line 
MCF10A. Combined mean ±SD, N=2 in ≥ quadruplicate, normalized to control basal 
respiration. * p<0.01 Student’s t-test compared to the control 
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 We observed no decrease in oxygen consumption in cells treated with ent-
SL0101 (fig. 28D). Therefore, we conclude that SL0101 does not act as a protonophore. 
A hexose sugar ring is a structural component of both SL0101 and its enantiomer. It is 
conceivable that these two chemicals could interfere with sugar uptake or utilization in 
cells independent of their ability to affect RSK activity. To address this possibility we 
tested a SL0101 derivative in which the rhamnose ring was replaced with a 
corresponding cyclitol ring (compound [1] in fig. 28C). This compound is a potent 
inhibitor of RSK both in vitro and in cell-based assays (chapter 5). Cyclitol-derivative of 
SL0101 reduced mitochondrial oxygen consumption in MCF7 cells to the same extent 
as its parent compound (fig. 28E). Consistent with the effects of SL0101, cyclitol-
SL0101 also caused an increase in proton leak. Taken these results together, we 
conclude that inhibition of RSK caused decreases in basal and maximal OCR, and an 
increase in proton leak. Since SL0101 is not a protonophore, RSK inhibition could 
induce an increase in proton leak through the action of mitochondrial ion channels.  
To further support the role of RSK signaling in the regulation of mitochondrial 
oxygen consumption, a structurally unrelated inhibitor of RSK, BI-D1870, was used. 
Treatment of MCF7 cells with this compound caused a 30% reduction in both basal and 
maximal respiration (fig. 28F), which is consistent with the effects of SL0101. However, 
BI-D1870 did not increase proton leak. It is important to note that BI-D1870 and SL0101 
have different selectivities against RSK isoforms. BI-D1870 inhibits all four isoforms of 
RSK, while SL0101 is selective for RSK1/2 (chapter 2). Therefore, it is possible that the 
biological effects of one of these compounds would not be fully recapitulated by the 
other inhibitor. SL0101 and BI-D1870 both caused a reduction in basal and maximal 
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oxygen consumption, indicating that RSK1/2 stimulates these two respiratory rates. It is 
possible that RSK1/2 is a negative regulator of proton leak, while RSK3/4 counteracts 
this action of RSK1/2. In such case, inhibition of RSK1/2 would trigger RSK3/4 
dependent increase in proton leak. However, BI-D1870 would block the ability of 
RSK3/4 to enhance proton leak upon RSK1/2 inhibition.  
We tested the effects of SL0101 in another ER-positive breast cancer cell line, 
T47D. Consistent with the results obtained in MCF7 cells, treatment of T47D cells with 
SL0101 reduced both basal and maximal oxygen consumption rates by 30% (fig. 28G). 
In addition, proton leak was also increased in these cells upon SL0101 treatment. 
These results indicated that the role of RSK in regulating mitochondrial function is not 
unique to MCF7 cells. 
We have previously observed that RSK inhibition reduced proliferation of MCF7 
cells, but a non-transformed breast epithelial cell line, MCF10A, was not sensitive to a 
loss of RSK activity (Smith et al., 2005; chapters 3-5 and appendix). We hypothesized 
that the differential response of cancer vs. non-transformed cell lines could, at least in 
part, be due to a differential effect of RSK inhibition on mitochondrial oxidative 
phosphorylation. In order to address this hypothesis we performed a mitochondria 
stress test in MCF10A cells treated with SL0101. RSK inhibition did not reduce basal 
and maximal oxygen consumption MCF10A cell line (fig. 28H), which is consistent with 
the lack of inhibition of proliferation in this cell line upon RSK inhibition. Intriguingly, 
SL0101 treatment caused a significant increase in proton leak in MCF10A cells. 
However, SL0101 does not reduce proliferation of this cell line. Proton leak results in a 
decrease in the efficiency of ATP synthesis in the mitochondria (Jastroch et al., 2010). 
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However, ATP can be produced by other metabolic processes, such as glycolysis 
(Jastroch et al., 2010, Fernie et al., 2004). Therefore, although proton leak seems to be 
commonly increased upon RSK inhibition, the biological significance of this effect 
remains unknown. 
Taken together, these data demonstrate that in breast cancer cell lines RSK 
promotes mitochondrial respiration. However, RSK signaling is not involved in 
regulating oxidative phosphorylation in non-transformed breast cells. We have 
discovered that SL0101 is an isoform-specific inhibitor of RSK1/2, as it does not inhibit 
RSK3 and RSK4 (chapter 2). Here, we observed the same reduction in mitochondrial 
oxygen consumption induced by both SL0101 and another RSK inhibitor, BI-D1870, in 
breast cancer cell lines. Therefore, the observed effects on basal and maximal 
mitochondrial respiration were due to inhibition of RSK1/2, and did not involve RSK3 
and RSK4.  These results uncovered a novel function of RSK1/2 in regulating cancer 
cell metabolism. This discovery opens a new possibility of targeting breast cancer by 
specific inhibition of cancer bioenergetics. It remains to be determined which of the two 
isoforms of RSK1/2 is responsible for the observed mitochondrial phenotypes. 
The experiments described above were conducted in the presence of glucose, 
glutamine and pyruvate. All 3 of these substrates enter the tricarboxylic acid (TCA) 
cycle in the mitochondria (Fernie et al., 2004). We sought to determine whether 
inhibition of RSK1/2 resulted in a decrease in utilization of one of the nutrients to a 
greater extend than the others. First, we treated cells with full medium, or basal medium 
with glutamine alone (fig. 29A). In control cells, glutamine alone induced the same basal 
OCR as the full medium, but maximal OCR was reduced, compared to the full medium. 
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In the presence of pyruvate alone, basal OCR was increased by 60%, compared to full 
medium, as was equal to the maximal OCR in this condition (fig. 29B). Glucose alone 
maintained basal OCR levels comparable to those of the full medium, but was not 
sufficient to increase the maximal OCR above the basal levels (fig. 29C). In all 3 
conditions, SL0101 suppressed basal OCR in the presence of individual substrate by 
20%, compared to the full medium control. In addition, pyruvate-stimulated increase in 
basal OCR above the levels in full medium was blocked by SL0101 (fig. 29B). IN the 
presence of SL0101, each substrate alone was unable to bring the maximal OCR above 
the basal levels in this condition. The presence of all 3 substrates in combination with 
SL0101 was only sufficient to raise the maximal OCR to the basal levels in the full 
medium control. In summary, SL0101 inhibited utilization of all 3 substrates, and the 
biggest decrease in basal OCR was in the presence of pyruvate alone. Therefore, 
inhibition of RSK caused a decrease in the utilization of all 3 substrates individually, and 
adding back all those substrates was not sufficient to rescue the maximal OCR levels. 
We sought to determine if the decrease in oxidative phosphorylation seen upon loss 
of RSK1 and RSK2 activity was sufficient to trigger a biologically relevant change in 
cellular metabolism. Mitochondrial respiration is coupled to ATP synthesis through the 
proton gradient generated by the electron transport chain (ETC) in the inner 
mitochondrial membrane (Dimroth et al., 2003, Dimroth et al., 2000). ETC is a 
supercomplex composed of four complexes transporting electrons from NADH and 
succinate onto molecular oxygen, with a simultaneous exclusion of protons from the 
mitochondrial matrix. A small amount of electrons carried by complexes I and III can 
prematurely leak to molecular oxygen to generate superoxide, a main mitochondrial 
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reactive oxygen species. Therefore, superoxide is a by-product of mitochondrial 
respiration (Drose and Brandt, 2012). Since loss of RSK activity caused a decrease in 
oxygen mitochondrial respiration, we hypothesized that the amount of mitochondrial 
superoxide generated by cells was changed. To test this possibility, a mitochondria-
localized fluorescent superoxide sensor MitoSox Red was used. This indicator is rapidly 
and selectively targeted to mitochondria in live cells, where is specifically reacts with 
superoxide, but not other reactive oxygen species. The chemical modification caused by 
superoxide activates red fluorescence, which can be measured by confocal microscopy. 
Consistent with the role of RSK in stimulating oxygen consumption by mitochondria, 
SL0101 treatment in MCF7 cells caused an 80% reduction in MitoSox Red fluorescence 
intensity (fig. 30A).  
 Maximal OCR rate defines a condition in which the ETC can operate at its 
maximum capacity (Brand and Nicholls, 2011). RSK1/2 inhibition caused a decrease in 
this level, suggesting that loss of RSK1/2 activity reduced the function of the ETC. Since 
ETC generates the proton gradient across the mitochondrial membrane, we 
hypothesized that SL0101 treatment caused a decrease this membrane potential. In 
order to measure the changes in mitochondrial proton gradient we employed a 
fluorescent indicator, tetramethylrhodamine methyl ester (TMRM). This fluorescent dye 
accumulates in the mitochondria in a process dependent on the mitochondrial 
membrane potential. We performed the experiment is MCF7 cells treated with SL0101 
and loaded with 20 nM TMRM. 
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Figure 29. RSK inhibition reduces oxidative phosphorylation in the presence of each of 
the substrates. 
A) SL0101 reduces basal and maximal OCR in MCF7 cells both in the presence of 
glutamine alone, and all 3 nutrients. Representative experiment of n=2 in 12 
replicates, mean±SD.  
B) SL0101 reduces basal and maximal OCR in MCF7 cells both in the presence of 
pyruvate alone, and all 3 nutrients. Representative experiment of n=2 in 12 
replicates, mean±SD.  
C) SL0101 reduces basal and maximal OCR in MCF7 cells both in the presence of 
glucose alone, and all 3 nutrients. Representative experiment of n=2 in 12 replicates, 
mean±SD.  
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 RSK inhibition caused a ~70% decline in TMRM fluorescence intensity, 
compared to the DMSO vehicle control, suggesting a decrease in the mitochondrial 
membrane potential upon the loss of RSK activity (fig. 30B). These observations further 
support the role of RSK in maintaining the activity of the ETC in MCF7 cells. It is 
possible that SL0101 interfered with the ability of TMRM to enter and be accumulated in 
cells. The experimental setup we used did not test for this possibility. Therefore, the 
results of the TMRM imaging need to be interpreted with caution. 
 Mitochondrial oxidative phosphorylation is coupled to the ability of the 
mitochondria to maintain a concentration gradient of the calcium ions across the 
mitochondrial inner membrane (Williams et al., 2013). Calcium ion concentration is kept 
very low in the cytosol, while the endoplasmic reticulum and mitochondria provide a 
major storage site for these ions. When mitochondria become depolarized, they release 
stored calcium ions to the cytoplasm, which can trigger various cellular processes, 
including apoptosis (Smaili et al., 2000). Therefore, the ability of the mitochondria to 
maintain calcium stores is linked to the mitochondrial membrane potential and the 
activity of the electron transport chain. We hypothesized that the decrease in 
mitochondrial ETC activity and membrane potential upon loss of RSK activity could 
result in a decrease in the calcium ion concentration in the mitochondrial matrix. In order 
to test this hypothesis we used Rhod-2, a fluorescent calcium indicator. This rhodamine 
dye derivative accumulates in the mitochondria where upon calcium ion binding it 
becomes fluorescent. Therefore, it can be used to measure the concentration of this 
metal ion in mitochondria. SL0101 caused a 90% decrease in fluorescence intensity of 
Rhod-2 (fig. 30C).  
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Figure 30. RSK inhibition decreases superoxide levels, membrane potential and 
calcium levels in the mitochondria in transformed cells. 
A) RSK inhibition decreases mitochondrial superoxide levels in MCF7 cells. Cells were 
treated for 2 hours with or without SL0101, and MitoSox Red was loaded for 10 min 
and imaged by live confocal microscopy. Combined normalized fluorescence 
intensity per cell, N=3, Student’s t-test. 
B) RSK inhibition decreases mitochondrial membrane potential levels in MCF7 cells. 
Cells were treated for 2 hours with or without SL0101, and TMRM was loaded for 30 
min and imaged by live confocal microscopy. Combined normalized fluorescence 
intensity per cell, N=3, Student’s t-test. 
C) RSK inhibition decreases mitochondrial calcium levels in MCF7 cells. Cells were 
loaded for 50 min with Rhod-2 and treated for 2 hours with or without SL0101. Cells 
were imaged by live confocal microscopy. Combined normalized fluorescence 
intensity per cell, N=3, Student’s t-test. 
D) RSK inhibition does not affect mitochondrial calcium levels in MCF10A cells. Cells 
were loaded for 50 min with Rhod-2 and treated for 2 hours with or without SL0101. 
Cells were imaged by live confocal microscopy. Combined normalized fluorescence 
intensity per cell, N=2, Student’s t-test. 
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 To prove that the loss of Rhod-2 fluorescence upon SL0101 treatment was due 
to a decrease in mitochondrial calcium ions, and not due to the drug interfering with the 
fluorophores, cells were treated with the calcium ionophore, ionomycin. Ionomycin 
treatment caused a rapid increase in Rhod-2 fluorescence in both DMSO and SL0101 
treated cells, providing evidence that Rhod-2 dye was able to respond to the increase in 
mitochondrial calcium ion concentration. The results indicate that RSK inhibition by 
SL0101 causes a decrease in mitochondrial calcium ion levels. These observations 
provide further support for the role of RSK in stimulating the activity of the electron 
transport chain. 
 We have found that RSK activity was dispensable for the regulation of oxidative 
phosphorylation in non-transformed cell line, MCF10A. To further support this 
hypothesis we measured the mitochondrial calcium levels in MCF10A cells treated with 
SL0101. Consistent with the observation that RSK inhibition in this cell line did not affect 
mitochondrial oxygen consumption, SL0101 treatment did not affect the mitochondrial 
calcium levels in these cells (fig. 30D). These results provided further evidence for a 
divergent role of RSK signaling in regulating mitochondrial respiration between breast 
cancer and non-transformed breast epithelial cell lines. 
7.4. Discussion 
 The specific role of RSK1 and RSK2 in regulating caner bioenergetics remains to 
be described. Based on our results there are several potential processes whose 
perturbations could lead to observed phenotypes. One possibility is that RSK1/2 
regulates the activity of the ETC complexes. Interestingly, our results of the RSK1 
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interactome analysis suggested that this kinase might interact with several components 
of the ETC complexes: complex I (NDUFB4), complex III (UQCRH) and complex IV 
(COX5B, COX6A) (chapter 6). An alternative mechanism could involve regulation of the 
activity of the TCA cycle. In this case, SL0101 treatment would lead to a reduction in the 
production of NADH and succinate, which constitute the substrates for the ETC. As a 
result, oxygen consumption and the proton transfer across the mitochondrial membrane 
would decline. Hence, the mitochondrial membrane potential would decrease, which in 
turn would result in the decrease in mitochondrial calcium levels.  
 The regulation of the TCA cycle could involve RSK phosphorylating and thereby 
changing the activity of the metabolic enzymes involved in the cycle. This mechanism 
would have to involve RSK translocating into the mitochondrial matrix, as this is the site 
where the TCA cycle enzymes reside in. Conversely, RSK could phosphorylate a 
regulator of the activity of the TCA cycle enzyme that can translocate between 
cytoplasm and the mitochondrial matrix. Interestingly, it has become increasingly 
appreciated that transformation involves changes in both expression and activities of 
multiple metabolic enzymes, including those involved in the TCA cycle (Desideri et al., 
2015). For example, it has recently been shown that alteration in the enzyme 
mitochondrial aconitase 2 (ACO2) could contribute to tumorigenesis in renal cancer 
(Ternette et al., 2013). Therefore, the ability of RSK to affect the activities of the ETC 
complexes remains a possibility that should be further explored. 
 As mentioned above, we observed a decrease in mitochondrial calcium levels in 
MCF7 cells upon RSK inhibition. This decrease could be a consequence of a decline in 
the activity of the ETC complex. However, mitochondrial calcium level has long been 
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recognized a critical regulator of the activity of the TCA cycle (Williamson and Cooper, 
1980). The activities of multiple TCA cycle enzymes dramatically decrease upon a 
decline in calcium ion concentration. Therefore, in addition to being a consequence of a 
loss in mitochondrial membrane polarization, a drop in mitochondrial calcium could be a 
source of a decrease in mitochondrial function. Calcium is transported into mitochondria 
through the mitochondrial calcium uniporter MCU (Baughman et al., 2011). It has been 
shown that the activity of this ion channel can be regulated by other proteins, such as 
MICU1 (Perocchi et al., 2010) and MCUR1 (Mallilankaraman et al., 2012a, 
Mallilankaraman et al., 2012b). It is possible that RSK could regulate mitochondrial 
respiration though the changes in the activity of the mitochondrial calcium uniporter, 
either directly or through the MCU-regulating proteins. Interestingly, we have indentified 
potential interactions of RSK1 with proteins involved in ion homeostasis in the 
mitochondria and endoplasmic reticulum, including VDAC1 and VDAC2, ATP2A2, 
SLC25A13 and SLC25A3 (chapter 6).  
 In conclusion, we have discovered a novel role of RSK1 and RSK2 in regulating 
bioenergetics in breast cancer. This role is specific to transformed epithelial cells, as 
mitochondrial oxidative phosphorylation in the MCF10A cell line does not depend on 
RSK signaling. These observations uncover an exciting new opportunity to selectively 
target growth and survival of cancer cells versus normal epithelium.  
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Chapter 8 
General discussion 
 
 The ability to sense the changes in the environment and to adapt to these 
alterations is one of the fundamental properties of living systems. One of the major 
groups of proteins involved in these processes is the family of extracellular signal 
regulated kinases (ERK). The function of this particular family of proteins is to integrate 
the various mitogenic signals into a specific biological response of the cell, such as 
increased cellular proliferation, survival and differentiation. These end goals are 
achieved by the modulation of the downstream effectors of ERK with specialized 
functions. The RSK family of kinases has been recognized as one of the major 
downstream effectors of ERK. Many molecular functions of RSK have been described 
to date, and disregulation of some of these functions has also been demonstrated to 
contribute to various pathologies, including cancer. Therefore, there is an ongoing 
interest to better understand how RSK kinases execute the specific biological tasks 
dictated by mitogenic signals, and whether these functions represent potential targets 
for the therapeutic intervention in various pathologies driven by inappropriate ERK 
signaling. 
 RSK signaling downstream of the ERK family of kinases is complicated by the 
existence of four functionally non-redundant, yet structurally very similar isoforms. Of 
those, only RSK2 has been knocked out in the genetically engineered mouse model. 
Therefore, our full understanding of the complex biology of RSK is limited by the 
226 
 
relatively scarce in vivo data for individual RSK functions. Taken all these factors 
together, there is a need to develop small molecule inhibitors of RSK that could be used 
to study the biological functions of this family of kinases in vivo, both in the context of 
normal homeostasis and in the various disease states. It s also increasingly appreciated 
that in order to better understand the in vivo functions of RSK, the tools to study the 
biology of the individual isoforms of RSK have to be developed. 
 Driven by the need to establish such methods to study specific functions of RSK 
in vivo, in particular in the context of breast cancer, we undertook the efforts to better 
characterize the previously reported small molecule inhibitor of RSK, SL0101. The 
section 8.1 of this dissertation summarizes the findings and demonstrate how these 
results allow us to rationalize a novel SL0101 analog with superior properties in vivo. 
Here, we also report a previously overlooked selectivity of SL0101 for RSK1/2 isoforms, 
which distinguishes this compound from other published small molecule inhibitors of 
RSK kinases. 
 Among the plethora of biological affects that have been proposed to be regulated 
by RSK, the cellular energy homeostasis has remained a relatively understudied 
function of this family of kinases. Although several potential mechanisms of RSK 
regulation of these processes have been postulated, the biological consequence of RSK 
inhibition on cellular energy homeostasis has remained unexplored. Driven by this 
paucity of experimental data, and previous unpublished observations from our 
laboratory, we set out to investigate the effects of RSK1/2 inhibition on cellular energy 
homeostasis. We show for the first time that RSK1/2 are involved in stimulation of the 
cellular energy production specifically in the mitochondria, and that this mechanism 
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appears to be confined to transformed cell lines. The results of these studies are 
summarized in section 8.2 of this dissertation. 
8.1. SL0101 analogs as potential therapeutic agents to inhibit RSK1/2 in vivo 
8.1.1. Conclusions of chapters 2-5: SL0101 is a prototypical member of a family of 
isoform-specific allosteric inhibitors of RSK1/2 
 RSK family of kinases constitutes well-established downstream effectors of the 
mitogenic ERK signaling. Multiple studies have characterized the role of these kinases 
in regulating cellular proliferation, survival and motility. Consistent with the importance 
of these proteins in stimulating these cellular processes, RSK kinases have been found 
to be often misregulated in a variety of cancers. As a result, there has been an ongoing 
effort to identify new inhibitors of RSK. Several compounds have previously been 
described as RSK inhibitors, and some of these molecules have proven very useful in 
mechanistic studies of RSK in tissue culture systems. However, all these molecules 
suffer from limited applicability in vivo. As a result, many of the described functions of 
RSK characterized in cell-based assays are yet to be translated to clinically relevant 
in vivo observations.  
 Here, we investigated the properties of one RSK inhibitor, the natural compound 
SL0101. Previous studies have described remarkable kinase selectivity of SL0101 for 
RSK, and the basis of this selectivity has not been very well understood. The crystal 
structure of RSK bound to SL0101 suggested a very unusual mode of inhibition of the 
enzyme employed by the compound, indicating the potential that SL0101 is an allosteric 
inhibitor of RSK. We provide the in vitro enzyme kinetics data in support of this model 
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(chapter 2). Our studies indicate that SL0101 acts as a non-competitive inhibitor of 
RSK, and this mode of inhibition likely involves stabilization of the unique conformation 
of the kinase that has been suggested by the crystallography studies. Additionally, we 
discover unexpected selectivity of SL0101 for RSK1/2, which differentiates this 
compound from other previously characterized RSK inhibitors, including BI-D1870.  
 Selectivity of small molecule kinase inhibitors is often a major concern in 
developing new ways of targeting specific kinases (Vieth et al., 2004, Knight and 
Shokat, 2005). Small molecules that inhibit the active state of the kinase tend to be able 
to bind in a similar fashion to multiple targets, hence displaying a relatively poor 
selectivity profile (Knight and Shokat, 2005). On the other hand, inhibitors that target 
conformations different than the active fold of the kinase are typically much more 
selective for their target. SL0101 is a glycosylated form of flavonoid kaempferol, 
kaempferol no-specifically binds to active conformations of multiple kinases (Calderon-
Montano et al., 2011). Consequently, SL0101 was assumed to be an ATP-competitive 
inhibitor of the active state of RSK kinases. This assumption stayed in contrast to the 
remarkable selectivity of SL0101 for other kinases, suggesting that the binding 
properties of SL0101 could be different than anticipated. Together with the previous X-
ray crystallography studies, our current results offer an explanation to this discrepancy.  
 Unique characteristics of SL0101 as a highly selective allosteric inhibitor of 
RSK1/2 have encouraged us to investigate the possibility of improving its poor in vivo 
properties. Our goal was to identify a derivative compound with superior in vitro affinity 
for the target, as well as greatly extended stability in cell-based assays, and with 
preserved selectivity for the target. To this end, we characterized three chemical 
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alterations to the SL0101 molecule that significantly improved one or more of these 
properties of the parent compound. The C6’’-n-propyl modification conferred a fifty-fold 
increase in the in vitro affinity of SL0101 for RSK2, while preserving its selectivity for the 
target kinases (chapter 3). We discovered that replacing the rhamnose sugar 
constituent within the SL0101 molecule with a corresponding cyclitol resulted in the 
greatest increase in its ability to reduce proliferation of the breast cancer cell line, MCF-
7 (chapter 5). However, this modification also negatively affected the selectivity profile 
of SL0101. Finally, we identified the carbamate modification to the acetyl groups within 
the sugar ring of SL0101 that preserved its in vitro affinity for RSK2, as well as the 
selectivity profile in cell-based assays (appendix 1).  
 Despite the loss of selectivity for RSK exhibited by the some analogs of SL0101 
(chapters 4 and 5), these compounds help define the biological space that can be 
occupied by RSK inhibitors. These inhibitors help us understand what modifications can 
be accommodated by the features of the target kinase. We can use this information to 
combine the modifications that confer desired properties to the analog into one 
molecule. For example, we anticipated that the cyclitol analog of SL0101 would be more 
stable in vivo, since it modifies the chemical character of the bond linking the sugar and 
kaempferol parts of the molecule (chapter 5). However, this modification caused a 
decrease in selectivity of the analog for RSK. At the same time, the analog was a much 
more potent inhibitor of MCF7 cell proliferation, compared to the parent compound. The 
shift in cell-based IC50 could suggest an increase in bioavailability of the inhibitor. On 
the other hand, the increased sensitivity to the inhibitor could be due to its off-target 
effects, inhibiting other pathways essential for the growth and survival of this cell line. 
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Combining the cyclitol modification of SL0101 with the modification that greatly 
improved the affinity of SL0101 for RSK could potentially overcome that loss of inhibitor 
selectivity. We are now in the advanced stages of validating such compound and indeed 
have seen a restoration of the kinase selectivity of the cyclitol analog (unpublished 
data). We have also seen an increase in stability of the compound in cell-based assays, 
consistent with the predicted stabilization of the molecule by the cyclitol modification. 
However, we did not know whether the two modifications together would act as we 
predicted until the new analog was tested. 
 The fact that, unlike BI-D1870, SL0101 does not inhibit RSK3/4 has important 
implications for the use of these compounds in mechanistic studies of the biological 
functions of the RSK family of kinases. It is now becoming increasingly appreciated that 
individual RSK isoforms may perform divergent functions. Therefore, inhibiting a subset 
of the members of this family may have different biological effects than reducing the 
activity of all four isoforms. Such differences could represent the functions of RSK3/4, 
as these two kinases are affected by BI-D1870, and not by SL0101. Indeed, 
inconsistencies between the biological effects of BI-D1870 and SL0101 have previously 
been reported (Chen and Mackintosh, 2009, Roffe et al., 2015).  
8.1.2. Emerging questions from chapter 2: allosteric inhibition of RSK1/2 
 Our results strongly suggest that the ability of SL0101 to bind to and inhibit the 
NTKD of RSK1/2 is influenced by the CTKD of these proteins. The notion that the 
activity of the NTKD is regulated by the C-terminal segments of the protein is also 
supported by two previous observations. First, the phosphorylation of the conserved 
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residue Ser 227 in the activation loop is not sufficient for a full activation of the RSK2 
NTKD. In addition to this activating phosphorylation, the hydrophobic motif from within 
the linker between the two kinase domains of RSK has to interact with the active site of 
the NTKD (Frodin et al., 2002). Second, our crystal structure of SL0101 bound to the 
NTKD of RSK2 showed that the two acetate residues within the sugar ring of SL0101 
were not involved in inhibitor binding to the kinase (Utepbergenov et al., 2012). 
However, these two acetates appear to be crucial for SL0101 affinity for full-length 
RSK2 in vitro (chapters 3-5). 
 Taken all these observations together, we argue that the changes in RSK NTKD 
kinase activity in response to SL0101 binding represent a complex mechanism involving 
multiple parts of the polypeptide chain, in addition to the kinase domain itself. 
Interestingly, while the N- and C-terminal kinase domains of all RSK isoforms are ~90% 
identical, the linker between the kinase domains and the C- and N-terminal extensions 
are much more divergent (Carriere et al., 2008b). Therefore, the isoform-selectivity of 
SL0101 for RSK1/2 and not RSK3/4 can potentially be dictated by the C-terminal part of 
these kinases. This possibility could be tested by assessing the ability of SL0101 to 
inhibit the isolated NTKDs of RSK3 and RSK4. If the isolated kinase domains are 
inhibited by SL0101, the features of the kinases conferring the isoform-selectivity of 
SL0101must be contained in the sequences outside these domains.  
 The understanding of the mechanisms governing kinase activity comes from 
extensive studies of the cAMP-dependent protein kinase (PKA) that spans the last two 
decades (Taylor et al., 2013). The example of PKA shows that regulatory domains 
within the kinase itself, as well as other proteins, can allosterically modulate the activity 
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of the kinase (Taylor et al., 2012). Our studies of SL0101 binding to and inhibition of 
RSK1 and RSK2 now suggest a similar complexity of regulation of RSK kinase activity. 
In addition to a known function in the phosphorylation and activation cascade of RSK, 
the C-terminal part of this kinase can also act as an allosteric modulator of the NTKD 
activity. This allosteric regulation could be conserved between RSK1 and RSK2, and 
not RSK3 and RSK4, explaining the lack of inhibition of the latter two kinases with 
SL0101. Importantly, unlike other isoforms, RSK4 appears to be constitutively active 
even in the absence of the mitogen stimulation, and the mechanism of this activation 
remains elusive (Dummler et al., 2005). Therefore, there is evidence of a differential 
regulation of kinase activity between the RSK isoforms. 
 Our full understanding of the complex regulation of RSK activity is limited by the 
lack of success in solving the structures of the full-length enzyme. Multiple attempts to 
crystallize both RSK kinase domains together have proven unsuccessful. So far, only 
the structures of the isolated CTKD and NTKD of RSK1 and RSK2 are known 
(Malakhova et al., 2009, Utepbergenov et al., 2012, Ikuta et al., 2007, Malakhova et al., 
2008, Alexa et al., 2015). Therefore, it remains unknown how all the parts of the kinase 
could affect the overall activity of the enzyme. However, the results of our studies 
highlight the importance of fully elucidating this mechanism. With the advancement in 
the area of structural biology beyond crystallography, such studies are becoming 
possible. For example, the differences in the interactions of the NTKD and the CTKD 
between the active and inactive states of RSK isoforms, as well as between the ATP-
bound and SL0101-bound kinases, could be investigated using small angle X-ray 
scattering (Vestergaard and Sayers, 2014, Hennig and Sattler, 2014). Cryo-electron 
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microscopy could also offer a method of investigating the changes in RSK protein 
conformation between different active and inhibited states (Cheng, 2015). Interrogating 
the structures of the full-length proteins could help us better understand the complex 
regulation of RSK kinase activity, as well as effects of small-molecule inhibitors.  
 The ability of cancer cells to leave the primary tumor mass and colonize distant 
sites, called metastasis, is its most deadly feature (Sethi and Kang, 2011), accounting 
for more than 90% of cancer-related mortality (Hanahan and Weinberg, 2011, Chaffer 
and Weinberg, 2011, Steeg, 2006). As summarized in chapter 1, RSK has been shown 
to regulate a variety of processes involved in cancer cell metastasis, in addition to 
survival and growth of primary tumors. Therefore, RSK has been proposed as a very 
promising new target for inhibition of metastasis (Sulzmaier and Ramos, 2013). The 
therapeutic potential of small-molecule inhibition of RSK to block metastasis has 
recently been demonstrated in vivo for the first time. In this study, RSK inhibitor fmk 
decreased metastatic potential of the mouse xenograft of human head and neck 
squamous cell carcinoma (HNSCC) (Li et al., 2013). In vitro studies of RSK inhibitors, 
as well as RSK knock-down experiments in cell lines and in xenograft models suggest 
that the function of RSK as a promoter of metastasis is not limited to HNSCC, but can 
be a common feature of many types of cancers, especially those driven by hyperactive 
Ras/MAPK pathway. The unpublished results from our laboratory also indicate the role 
of RSK1 and RSK2 in promoting metastasis in the xenograft model of aggressive breast 
cancer. Therefore, developing RSK inhibitors offers a great promise for new therapies 
targeting the metastatic cascade. 
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 Based on the structure-activity relationship studies described in chapters 3-5, we 
hypothesize that the cyclitol-C6’-n-propyl analog of SL0101 could be a superior inhibitor 
of RSK in vivo. The future work will require full validation of this compound in vivo. A 
preliminary study in an experimental model of breast cancer metastasis in mouse we 
have recently completed suggests that indeed the new analog is capable of eliciting 
desired effects on RSK in vivo (unpublished data). The design of this inhibitor would not 
have been possible without characterizing the individual modifications of SL0101 in the 
studies descried in chapters 3-5. 
 Since RSK appears to be a major effector of ERK signaling, the potential benefits 
of using RSK inhibitors in cancer therapy could be extended to tumors driven by 
hyperactive Ras-MAPK axis. Melanoma is an excellent example of a disease is driven 
by inappropriate signaling mediated by this pathway (Homet and Ribas, 2014). At least 
70% of all melanomas are driven by defined activating mutations in the pathway (Gray-
Schopfer et al., 2007). Due to the dependency of a large fraction of melanomas on the 
activating mutation in BRAF, these tumors have been successfully targeted by small-
molecule inhibitors of this kinase (Chapman et al., 2011, Hauschild et al., 2012). 
However, recent results suggest that both de novo and acquired resistance to mutant 
BRAF inhibitors in melanoma is frequently associated with re-activation of the MAPK 
pathway through various mechanisms (Fedorenko et al., 2015, Lito et al., 2013). 
Interestingly, RSK is frequently activated in melanomas (Old et al., 2009). Therefore, 
RSK inhibition could offer an attractive target in melanomas, particularly as a 
combination treatment with mutant BRAF inhibitors.  
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 It is very important to highlight that the four RSK isoforms may have non-
overlapping, and even opposing functions. There is ample evidence that RSK2 acts as 
a mediator of tumor-promoting signaling in multiple cancers (chapter 1). In addition to 
promoting survival and proliferation, it also participates in the pro-motile and pro-
invasive cellular program in these cancers. The literature concerning RSK1 functions in 
promoting cell invasiveness almost unanimously characterizes it as a positive regulator 
of motility. The exception is one publication, in which silencing of RSK1 in lung cancer 
cell lines decreased motility and invasiveness (Lara et al., 2011). This study also 
indicated that the protein expression of RSK1 is decreased in non-small cell lung cancer 
(NSCLC) metastases, compared to the primary tumor samples from the same patients. 
Therefore, it is possible that the role of RSK1 in conferring invasive phenotype may be 
cell-type specific.  
 Contrary to RSK1 and RSK2, RSK3 and RSK4 have been suggested to serve a 
putative tumor suppressor function. For example, RSK3 was found to be down-
regulated in ovarian cancer, and re-expression of RSK3 in ovarian cancer cell lines led 
to cell cycle arrest and apoptosis (Bignone et al., 2007). The role of RSK3 in promoting 
cancer cell motility and invasiveness has never been investigated. RSK4 has been 
shown to be decreased in colon and renal tumors, and low expression of RSK4 was 
correlated with poor outcome in colorectal tumors (Lopez-Vicente et al., 2009, Cai et al., 
2014). RSK4 was shown to be a negative regulator of invasiveness in an aggressive 
breast cancer cell line (Thakur et al., 2008). However, RSK3 and RSK4 were also 
suggested to drive resistance to PI3K inhibitors in a breast cancer cell line (Serra et al., 
2013). In addition, existence of multiple splice variants of RSK4 has complicated the 
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interpretation of the studies investigating expression of this protein in cancer samples 
(Sun et al., 2013). Therefore, our current knowledge of the functions of these two RSK 
isoforms is not sufficient to make predictions on their roles in cancer etiology. Potentially 
divergent functions of RSK isoforms in regulating cancer metastasis highlight the 
importance of developing isoform-selective inhibitors of this family of kinases. SL0101 
and its derivatives offer such possibility for the first time. 
8.2. RSK1/2 regulation of cancer cell bioenergetics 
8.2.1. Conclusions of chapters 6 and 7: RSK1/2 regulate energy homeostasis in 
transformed epithelial cell lines 
 Previous studies of phenotypes observed in RSK2 knock-out mice, as well as 
phosphorylation targets of RSK in cell lines, have implicated the potential roles of 
RSK1/2 in regulating cellular energy homeostasis. However, the exact mechanisms of 
RSK1/2 involvement in cellular energy balance have never been elucidated. 
Understanding the exact functions of RSK1 and RSK2 has is complicated by the paucity 
of definitive studies characterizing the isoform-specific functions of these proteins. 
Therefore, we set out to establish a systematic approach to investigate the interacting 
partners and phosphorylation targets of individual RSK isoforms. 
 In order to better understand the biological functions of RSK1, we developed a 
high throughput proteomics method to discover new interacting partners of this protein 
in intact cells. We set out to modify the method based on APEX peroxidase-mediated 
labeling of transient and stable interacting partners in intact cells, which has recently 
been described (Rhee et al., 2013, Hung et al., 2014). The novelty in our approach was 
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two-fold. First, nobody has published using this technique to investigate the interacting 
partners of a specific protein. Second, the previous studies using this method have 
relied on in-gel digestion of electrophoretically separated proteins enriched by the 
labeling. We decided to perform digestion of the labeled proteins on the beads. We 
identified 37 potential RSK1-binding proteins with known functions in regulating protein 
synthesis, as well as in mitochondrial energy homeostasis (chapter 6). Even in such a 
short list we found two proteins that have previously been reported in another 
proteomics study of RSK targets, NOP56 and CLN6. Importantly, that study used a very 
different method of identifying potential new RSK targets (Galan et al., 2014).  
 Our results of the proteomics study provide additional piece of evidence 
suggesting a potential role of RSK proteins in regulating cellular energy homeostasis. 
Therefore, we investigated the involvement of RSK1/2 in maintaining mitochondrial 
function. We found that RSK1/2 inhibition significantly decreased mitochondrial 
oxidative phosphorylation, and this reduction was associated with decreases in several 
markers of mitochondrial fitness (chapter 7). Intriguingly, oxidative phosphorylation in 
non-transformed breast epithelial cell line, MCF-10A, was insensitive to RSK1/2 
inhibition. These observations add to the repertoire of cellular functions of RSK1/2 that 
contribute to a well-documented preferential dependence of transformed cells on RSK 
for their survival. 
 Decades of extensive studies in various mammalian systems have established 
that cellular energy demand is matched by ATP production, such that at steady state 
the cellular ATP levels remain constant (Wieser and Krumschnabel, 2001, Buttgereit 
and Brand, 1995, Schmidt et al., 1991). The three main energy consumption processes 
238 
 
in mammalian cells are protein synthesis, sodium/potassium antiport and calcium 
transport, with protein synthesis accounting for between 20-50% of total ATP 
consumption, depending on cell type (Rolfe and Brown, 1997, Wieser and 
Krumschnabel, 2001). In addition to these processes involved in basic cellular 
homeostasis, actin dynamics associated with migration was found to constitute a major 
pathway of energy consumption (Desai et al., 2013). Importantly, RSK signaling has 
well-established roles in potentiating all these processes (fig. 31). As a result, activation 
of RSK puts increased stress on cellular energy balance. Therefore, it is conceivable 
that RSK could act to stimulate cellular energy production to meet this increased 
demand. Several kinases integrating signals to regulate both protein expression and 
energy production have previously been identified. Among those are such enzymes as 
PDK1, which is involved in activation cascades of multiple pro-survival kinases, 
including RSK, as well as phosphorylation and regulation of activity of pyruvate 
dehydrogenase, a critical enzyme involved in glucose metabolism (Cairns et al., 2011). 
In addition, kinase complex mTOR was shown to regulate amino acid metabolism and 
rates of protein synthesis in response to nutrient availability (Mayer and Grummt, 2006, 
Jewell et al., 2013, Jewell and Guan, 2013). 
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Figure 31. RSK regulates both energy production and consumption in breast cancer 
cells. 
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 To summarize, the findings that RSK1 could regulate both protein translation at 
ribosomes and energy metabolism in mitochondria in breast cancer cells point to a 
possibility that RSK1 is a critical mediator of cellular resource management. RSK1 could 
act to integrate cellular signaling downstream of growth factors to coordinate energy 
production and consumption. Targeting RSK could offer a possibility to induce cancer 
cell death through the disruption of the bioenergetic balance of these cells. This 
mechanism adds to the repertoire of known functions of RSK in regulating proliferation, 
survival and motility of cancer cells, further reinforcing the potential of targeting these 
kinases in the treatment of cancer. 
9.2.2. Emerging questions from chapters 6 and 7: Regulation of cancer 
bioenergetics by RSK1/2 
 We found a striking difference in the distribution of RSK1 and RSK2 between the 
cytoplasmic compartments. RSK1 appeared to be associated with intracellular 
membranes in a stable fashion. Since its localization is so different from that of RSK2, it 
is conceivable that these two kinases would phosphorylate different targets. In addition, 
RSK1 does not posses any known features that would allow it to stably bind to the lipid 
bilayers, therefore we expected it would be anchored to the membranes through 
interactions with other proteins.  
 Although the method we developed still requires further optimization, it has 
already yielded very interesting results. The main problem that still needs to be resolved 
is a relatively low dynamic range of the method, giving a long list of potential proteins 
with relatively low confidence in the detection of each of these proteins. We are 
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confident, however, that with the improvements in the processing of affinity-purified 
proteins samples we can increase the dynamic range of the assay. 
 We will pursue further optimization of the labeling approach to interrogating the 
RSK1-interactome in intact cells. The results of the high-throughput proteomics will be 
analyzed using a variety of bioinformatics tools, to identify functional clusters and nodes 
connecting these clusters. These nodes will represent the most promising potential 
targets of RSK1 regulation. The validation of the hits will encompass a variety of 
biochemical and cell biology approaches, including assessment of total protein and 
phosphorylation levels upon RSK1 knock-down or inhibition, as well as 
immunoprecipitations and investigations of sub-cellular distribution.  
 The mechanism by which RSK inhibitors could elicit the decrease in 
mitochondrial metabolism remains unknown. However, the proteomics approach 
described in chapter 7 offers a method to identify this mechanism. In view of the 
preliminary findings that RSK1 can potentially interact with mitochondrial proteins 
involved in oxidative phosphorylation, the identification of the mechanism becomes a 
real possibility. When applied to non-transformed cells, this method could also help 
explain the differential ability of RSK to regulate oxidative phosphorylation specifically in 
transformed cells.  
 In addition to mitochondria, endoplasmic reticulum provides a major cellular 
reservoir of calcium ions, and the two sites dynamically communicate with each other to 
maintain cellular homeostasis of these ions (Kaufman and Malhotra, 2014, Naon and 
Scorrano, 2014). Interestingly, ER proteins were identified in our initial screen of 
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potential RSK1-interacting partners (chapter 7). Therefore, RSK1 could regulate the 
function of both compartments. Such possibility should be further investigated. For 
example, the ER-mitochondria contact sites could be imaged using super-resolution 
microscopy or electron microscopy. 
 It is important to note that this cell line displays high spare respiratory capacity, 
compared to breast cancer cell lines MCF-7 and T47D (fig. 32). This respiratory reserve 
is thought to represent the flexibility of cells to changes in energy demand (Fern, 2003). 
Lower respiratory capacity in breast cancer cell lines suggests that these cells are 
experiencing high energy demand, and are forced to operate close to the upper limit of 
a possible energy output. Inhibition of RSK would prevent cells from accessing this 
spare capacity, lowering energy production below the critical threshold required to 
sustain proliferation. In MCF-10A cells, however, the basal energy demand is low 
enough that the spare capacity does not have to be employed, and RSK inhibition does 
not affect the basal oxygen consumption rate. Consistent with the role of the respiratory 
reserve in cell proliferation and survival, reduced spare respiratory capacity has been 
shown to correlate with increased susceptibility to death induced by various types of 
stress in multiple cell types (Sriskanthadevan et al., 2015, Nickens et al., 2013, Choi et 
al., 2009, Zhu et al., 2012). 
 The changes in mitochondrial metabolism should be further investigated in the 
context of multiple cell lines. The studies should encompass measurements of 
enzymatic activities of mitochondrial ETC complexes. Changes in cellular distribution of 
the calcium stores should also be investigated. The studies conducted so far included 
small-molecule inhibition of RSK. The individual roles of RSK1 and RSK2 in this context 
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have to be further investigated. Each isoform should be knocked down individually, and 
a double knock-down should be performed. The mitochondrial phenotypes, such as 
membrane polarization, superoxide production and calcium levels should then be 
assessed. The knock-down studies should be accompanied by re-expression of RSK1 
and RSK2, to evaluate the specificity of the knock-down short hairpins.  
Studies of RSK1/2 function in regulating oxidative phosphorylation in various cell types 
could help us understand whether the functions of RSK in regulating mitochondria is a 
unique feature of transformed cells, or is it shared by other cell types, particularly those 
with high energy demand, like muscle cells and neurons. In addition to ATP synthesis, 
proton gradient established by oxidative phosphorylation is used for heat generation by 
brown and beige adipose tissue (Wu et al., 2015). Interestingly, lipodystrophy has been 
reported in RSK2 knock-out mice, suggesting a role of this protein in the normal function 
of this tissue (El-Haschimi et al., 2003). Therefore, the studies of RSK in these cell 
types are warranted. 
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Appendix 
Analogs of the RSK inhibitor SL0101: Optimization of in vitro biological stability 
Adapted from: 
Hilinski, M.H., Mrozowski, R.M., Clark, D.E., Lannigan, D.A. (2012) Analogs of the RSK 
inhibitor SL0101: Optimization of in vitro biological stability. Bioorg. Med. Chem. Lett. 
22: 3244-3247 
 
Summary 
 The Ser/Thr protein kinase, RSK, is important in the etiology of tumor 
progression including invasion and motility. The natural product kaempferol-3-O-(3”,4”-
di-O-acetyl--L-rhamnopyranoside), called SL0101, is a highly specific RSK inhibitor. 
Acylation of the rhamnose moiety is necessary for high affinity binding and selectivity. 
However, the acetyl groups can be cleaved by esterases, which accounts for the poor 
in vitro biological stability of SL0101. To address this problem a series of analogs 
containing acetyl group replacements were synthesized and their in vitro stability 
evaluated. Monosubstituted carbamate analogs of SL0101 showed improved in vitro 
biological stability while maintaining specificity for RSK. These results should facilitate 
the development of RSK inhibitors derived from SL0101 as anticancer agents. 
246 
 
A.1. Materials and Methods 
Kinase Assays 
 Glutathione-S-transferase (GST)-fusion protein (1 g) containing the ER-Ser167 
sequence- RLASTND was adsorbed in the wells of LumiNunc 96-well polystyrene 
plates (MaxiSorp surface treatment). The wells were blocked with sterile 3% tryptone in 
phosphate-buffered saline. Kinase (5 nM) in 50 L of kinase buffer (5 mM -
glycerophosphate, pH 7.4, 25 mM HEPES, pH 7.4, 1.5 mM DTT, 30 mM MgCl2, 0.15 M 
NaCl) was dispensed into each well. 25 µL of the compound at the indicated 
concentrations or vehicle was added and reactions were initiated by the addition of 25 
L of ATP to a final ATP concentration of 10 M. Reactions were terminated after 120 
min by addition of 75 L of 500 mM EDTA, pH 7.5. All assays measured the initial 
velocity of reaction. After extensive washing of wells, a polyclonal phosphospecific anti-
ER-pSer167 antibody and HRP-conjugated anti-rabbit antibody (211-035-109, Jackson 
ImmunoResearch Laboratories, West Grove, Pennsylvania) were used to detect serine 
phosphorylation of the substrate. HRP activity was measured using Western Lightning 
Chemiluminescence Reagent (NEL102, PerkinElmer Life Sciences) according to the 
manufacturer’s protocol. Maximum and minimum activity is the relative luminescence 
detected in the presence of vehicle and 500 mM EDTA, respectively. His-tagged active 
RSK was expressed in Sf9 cells and purified using NiNTA resin (Qiagen, Valencia, 
California). Baculovirus was prepared using the Bac-to-Bac baculovirus expression 
system (Invitrogen, Carlsbad, California). Maximum responses and the concentrations 
at half the inhibitory response (IC50) were determined by performing a best-fit analysis of 
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the data (GraphPad Prism). 
Cell Culture 
 For proliferation and stability studies cells were seeded at 2000 cells per well in 
96-well tissue culture plates in the appropriate medium as described by American Type 
Culture Collection. After 24 h, the medium was replaced with medium containing 
compound or vehicle as indicated. Cell viability was measured 48 h later (proliferation 
studies) or 48 h, 96 h, and 144 h later (stability studies) using CellTiter-GloTM assay 
reagent (Promega, Madison, Wisconsin) according to the manufacturer’s protocol. 
Maximum responses and the concentrations of half the effective response (EC50) were 
determined by performing a best-fit analysis of the data (GraphPad Prism). For 
specificity studies, cells were seeded at 1 x 105 cells/60 mm dish. After 24 h incubated 
with compound or vehicle for 2 h, 48 h, or 96 h. Cells were lysed with boiling SDS-
sample buffer without dithiothreitol (DTT). The lysates were normalized for total protein, 
and DTT was added to an aliquot, which was electrophoresed and immunoblotted. 
Antibodies used on cell lysates included anti-eEF2 (2332) and anti-Cyclin D1 (2926) 
from Cell Signaling Technologies. 
Chemistry 
 Unless otherwise noted, reagents and solvents were of reagent grade and used 
without further purification. Anhydrous tetrahydrofuran and N,N-dimethylformamide 
were purchased from Sigma-Aldrich. All reactions involving air- or moisture-sensitive 
reagents or intermediates were performed under a nitrogen atmosphere. Flash 
chromatography was performed using Fisher 70 – 230 mesh silica gel. Analytical TLC 
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was performed using 0.25 mm Merck KGaA silica gel 60 plates that were visualized by 
irradiation (254 nm) or by staining with Hanessian’s stain (CAM). 1H and 13C NMR 
spectra were obtained using 300 and 500 MHz Varian instruments. Chemical shifts are 
reported in parts per million (ppm ) referenced to the residual 1H resonance of the 
solvent (CDCl3, 7.26 ppm; acetone-d6 2.09 ppm). 13C spectra were referenced to the 
residual 13C resonance of the solvent (CDCl3, 77.3 ppm; acetone-d6 29.9 ppm). 
Splitting patterns are designated as follows: s, singlet; br, broad; d, doublet; dd, doublet 
of doublets; t, triplet; q, quartet; m, multiplet. High-resolution mass spectra were 
obtained from the Michigan State University-NIH Mass Spectrometry Facility. 
A.2. Results 
 The members of the p90 ribosomal S6 kinase (RSK) family of Ser/Thr protein 
kinases have been shown to play a role in a number of different cancers as key drivers 
of proliferation and metastasis (Eisinger-Mathason et al., 2010, Doehn et al., 2009, 
Smolen et al., 2010, Cho et al., 2007, Clark et al., 2005, Kang et al., 2007a, Kang et al., 
2010, Kang et al., 2009). These discoveries have been enabled in part by our report of 
the identification and isolation of the RSK inhibitor SL0101 (1, fig. A1) (Smith et al., 
2005). SL0101 is a flavonoid glycoside (kaempferol 3-O-(3”,4”-di-O-acetyl- -L-
rhamnopyranoside)) isolated from Forsteronia refracta, a variety of dogbane found in 
the South American rainforest. SL0101 is highly specific for RSK, inhibiting RSK1/2 but 
not unrelated kinases nor the closely related kinases MSK1 and p70S6K1 (Doehn et al., 
2009, Smith et al., 2005, Bain et al., 2007). SL0101 inhibits the proliferation of breast 
and prostate cancer lines but not their normal counterparts even though it inhibits RSK 
activity in all the lines (Eisinger-Mathason et al., 2010, Clark et al., 2005, Smith et al., 
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2005). Thus it appears that some cancer cells have become addicted to RSK, which 
suggests that RSK may be a potential new target for cancer therapeutics. SL0101, 
owing to its exquisite specificity, is a compelling lead compound from which to begin the 
process of identifying drug-like RSK inhibitors.  
 We and others have reported the total synthesis and biological evaluation of 
SL0101 and a number of analogs, with the ultimate goal of developing an anticancer 
drug that targets RSK (Maloney and Hecht, 2005, Smith et al., 2006, Smith et al., 2007, 
Shan and O'Doherty, 2006, Shan and O'Doherty, 2010). These analogs have provided 
key information about the SAR of both the aglycone and carbohydrate portions of the 
natural product. In the course of this work we discovered that the 3” and 4” acetyl 
groups of the carbohydrate are critical for potency and specificity for RSK (Smith et al., 
2007). TriOH-SL0101 (2), lacking these acetyl groups, is 12-fold less potent for 
inhibition of RSK in vitro and does not inhibit the growth of cancer cell lines, likely due to 
poor membrane permeability (Smith et al., 2007). These results indicate that SL0101 is 
not a suitable candidate for in vivo evaluation, as hydrolysis of the acetates by 
esterases would generate a less potent inhibitor. 
 An analog that replaces these acetates with ethyl ethers (3) inhibits RSK with 
potency roughly equivalent to SL0101 (Smith et al., 2007). We previously determined 
that the specificity of SL0101 and its analogs for RSK could be evaluated by their 
preferential ability to inhibit the growth of the human breast cancer line, MCF7, 
compared to the normal human breast line, MCF-10A (Smith et al., 2006). 
Unexpectedly, we observed that the ethyl ether analog 3 inhibited both lines to a similar 
extent, which indicates that it has a decreased specificity for RSK (Smith et al., 2007).  
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Figure A1*. The RSK inhibitor SL0101 and two previously reported analogs. 
*Figure contributed by Michael Hilinski.
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Figure A2*. Synthesis of a bis-ketone analog of SL0101.  
*Figure contributed by Michael Hilinski. 
253 
 
254 
 
Figure A3*. General scheme for the preparation of carbamate analogs of SL0101..  
*Figure contributed by Michael Hilinski. 
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Figure A4*. Evaluation of in vitro and cell-based efficacy and stability of SL0101 
analogs. 
A) Potency of analogs in in vitro kinase and MCF7 cell-based assays. IC50 is 
concentration needed for 50% inhibition; the 95% CI is shown in parentheses; n=3 in 
triplicate. * p<0.05. PS; partially soluble. 
B) In vitro determination of analog stability. The inhibitor (100 M) was added to MCF7 
cells at time 0 and percentage of growth determined for the indicated time points. 
(n= 3 in quadruplicate, #p ≤ 0.05 at 48 h when compared to vehicle at 48 h, *p ≤ 0.05 
when compared to 48 h treatment with the same analog). 
C) Persistence of RSK inhibition. MCF7 cells were treated with SL0101 or the more 
stable analogs 11 and 12 (100 M). At the indicated time in hours (h) the cells were 
lysed and the lysates immunoblotted. Each analog was analyzed on a single 
membrane with SL0101. White space indicates sections of the membrane that were 
cropped to remove unnecessary lanes 
D) Inhibition of growth of MCF-10A versus MCF7 cells by SL0101 and select analogs. 
The inhibitor concentration was 50 M. (n = 3 in quadruplicate, *p ≤ 0.05 when 
compared to vehicle). 
  
*Panels B,C,D contributed by David Clark. 
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 These results demonstrate that the acetates are a key modulator of specificity 
and thus a more carefully considered approach is necessary to identify suitable 
replacements. Accordingly, we have focused our efforts on identifying analogs bearing 
replacements for the acetates that confer greater biological stability without decreasing 
potency or specificity for RSK. Herein we present our approach, which has led to the 
identification of SL0101 analogs that are both specific for RSK and more biologically 
stable in vitro than the parent compound. 
 The only structural difference between the diethyl analog 3 and the diacetyl 
parent compound is the replacement of two methylenes with two carbonyl groups. It is 
surprising that such a seemingly small structural feature can regulate specificity for 
RSK. To recover this specificity, in the design of new analogs we sought to better mimic 
the acetates and particularly the acetate carbonyls, sterically and electronically, in a way 
that would confer a greater resistance to metabolism by esterases. In one approach we 
investigated the dependence of potency and specificity on the relative position of the 
carbonyl group. To this end we prepared an analog 9 in which the acetates are replaced 
by alkoxyacetones (fig. A2), moving the carbonyl group one carbon further from the 
carbohydrate ring and replacing the labile ester bond with an ether bond. The desired 
functionality could be installed at a late stage in the synthesis of the analog. Alkylation 
of known diol 6 (Smith et al., 2007) with propargyl bromide provided bis-alkyne 7, which 
after mercury-catalyzed hydration provided bis-ketone 8. Removal of the benzyl ether 
protecting groups by hydrogenolysis using Pearlman’s catalyst provided the completed 
analog 9.  
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 In a second approach we retained the acetate carbonyl in the correct position but 
in a more biologically stable form in a series of analogs in which we replaced the 
acetates with bioisosteric mono- or disubstituted carbamates. Late-stage installation of 
the carbamate was desirable for maximum synthetic efficiency. Thus, carbamoylation of 
diol 6 with the appropriate isocyanate or diaklycarbamoyl chloride followed by 
hydrogenolysis of the benzyl ethers provided mono- or dialkylated carbamates 10–15 
(fig. A3).  
 The ability of all new analogs to inhibit RSK activity was determined in an in vitro 
kinase assay and compared with the parent compound 1 (fig. A4A). The ketone analog 
9 was twofold more potent than 1 at inhibiting RSK2. Analogs 11, 13, and 14 were as 
potent as SL0101 (1), and analogs 10, 12, and 15 were slightly (two to threefold) less 
potent. Overall, we found that the ability of an analog to inhibit RSK was not greatly 
influenced by the structure of the acetate replacement, which is consistent with previous 
observations.  
 We also determined the ability of all new analogs to inhibit MCF7 cell proliferation 
(fig. A4A). The ketone analog 9 was again the most potent of the new analogs. The 
three monosubstituted carbamates, analogs 10-12, were similarly potent to the parent 
compound, with a trend toward improved potency with increasing lipophilicity of the 
carbamate substituent, presumably due to improved membrane permeability. In the 
disubstituted carbamate series, the dimethyl analog 13 and 1-pyrrolidinyl carbamate 
analog 14 exhibited poor solubility in cell culture media and therefore their ability to 
inhibit cell growth was not determined. The morpholino bis-carbamate 15 showed 
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improved solubility but was unable to inhibit cell proliferation despite its ability to inhibit 
RSK in the in vitro kinase assay, most likely due to poor membrane permeability. 
 Analogs that inhibited MCF7 cell proliferation were evaluated along with 1 for 
their stability in a MCF7 cell-based assay. The inhibitor was added when the cells were 
plated and proliferation analyzed at various time points to determine the persistence of 
the inhibitory effect. SL0101 (1) was able to inhibit MCF7 proliferation for 48 h 
(fig. A4B). However, at longer time points the cells began to proliferate indicating that 
SL0101 was no longer effective, which we hypothesize is due to degradation of the 
inhibitor by esterases to the inactive triol 2. Treatment of cells with either the bis-ketone 
analog 9 or the ethyl carbamate analog 10 did not result in sustained growth inhibition, 
indicating poor in vitro stability of these analogs. As the 3” and 4” substituents of analog 
9 are non-hydrolyzable, its poor stability was initially surprising. However, MCF7 cells 
express aldo-keto reductases (AKRs), well known to be Phase I metabolizing enzymes 
for a variety of drugs bearing carbonyl groups (Ruiz et al., 2011, Jin and Penning, 
2007). Thus an alternative metabolic pathway is available to analog 9 whereby one or 
both ketones could be reduced by AKRs to secondary alcohols, leading either directly to 
a less potent RSK inhibitor or indirectly as the secondary alcohols could be further 
metabolized by conjugation (Jin and Penning, 2007). 
 Encouragingly, the more lipophilic monosubstitued carbamate analogs 11 and 12 
demonstrated improved in vitro stability, as cells treated with these compounds did not 
proliferate over the full time course (fig. A4B). We further examined the stability of 
analogs 11 and 12 by determining whether cyclin D1 levels were inhibited (fig. A4C). 
Previously, we found that SL0101 inhibits proliferation in breast cancer cell lines by 
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inducing a cell cycle block in G1, which is due to RSK regulation of cyclin D1 levels 
(Eisinger-Mathason et al., 2010, Eisinger-Mathason et al., 2008). In agreement with the 
MCF7 stability results we observed that SL0101 decreased the levels of cyclin D1 at 48 
h compared to the control, but that cyclin D1 levels began to increase at later time 
points, indicating degradation of the inhibitor. However, cyclin D1 levels remained low in 
cells treated with 11 or 12, indicating persistent inhibition of RSK and therefore 
improved biological stability of the carbamate analogs over the parent compound. 
Taken together, these results indicate that analogs 11 and 12 have improved stability 
over SL0101 (1). 
 We then investigated whether our strategy of reintroducing the carbonyl group 
improved the specificity of 11 and 12 relative to the diethyl analog 3 (Smith et al., 2007). 
We have previously shown that the specificity of an analog for RSK can be evaluated by 
determining its antiproliferative activity in both MCF-10A and MCF7 cells, with the most 
specific analogs showing no inhibition of MCF-10A but substantial inhibition of MCF7 
proliferation, due to the differential dependence of the growth of these cell lines on RSK 
(Smith et al., 2005, Smith et al., 2006). We have also previously shown that while 
SL0101 does not inhibit the growth of MCF-10A cells up to a concentration of 100 M, 
the diethyl analog 3 significantly inhibits the growth of MCF-10A cells, indicating 
reduced specificity for RSK (Smith et al., 2007). We found that analogs 11 and 12, like 
SL0101 (1), significantly inhibited the growth of MCF7 cells but did not significantly 
inhibit the growth MCF-10A cells (fig. A4D). These results suggest that analogs 11 and 
12, like SL0101 (1), specifically inhibit RSK (Doehn et al., 2009, Smith et al., 2005, Bain 
et al., 2007). The only significant differences in biological activity between the two 
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compounds are slightly improved potencies for 11 versus 12 in both the kinase and 
MCF7 cell proliferation assays. As these small differences are unlikely to be 
physiologically important, either carbamate modification should render an analog 
suitable for in vivo evaluation. 
 In summary, the C3” and C4” acetates on the carbohydrate moiety of SL0101 are 
required for both potent and specific inhibition of RSK but we predict that they would be 
metabolized rapidly by esterases in vivo, a fact which is supported by the poor biological 
stability of the natural product in vitro. Thus, SL0101 is not suitable for in vivo evaluation 
and analogs with improved stability are needed. The number of suitable replacements 
for these acetates that would confer greater biological stability is surprisingly limited as 
a simple change from acetyl to ethyl leads to a reduction in specificity for RSK. As a 
solution to this problem, bioisosteric replacement of the acetates by carbamates 
provided analogs that are more biologically stable than SL0101 in vitro and are as 
specific as SL0101 for RSK. These modifications along with others aimed at further 
improving the stability and potency of SL0101 analogs are currently being investigated 
in our laboratory with the goal of identifying a RSK inhibitor that could be advanced to 
preclinical testing. 
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